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Abstract 
Since the advent of the acellular pertussis vaccine, safety testing has been carried out using the 
Histamine Sensitisation Assay (HIST assay). This assay is crude in nature and involves large 
numbers of mice to ensure statistically relevant output. In this work, a permeability assay is 
described that is a viable alternative to the HIST assay. Human Umbilical Vein Endothelial Cells 
(HUVECs) in co-culture with peripheral blood mononuclear cells (PBMCs) were used in a 
permeability assay to distinguish a preparation of DTaP5-IPV-Hib vaccine spiked with pertussis 
toxin (PTx) from a second control preparation. Using this assay, permeability of the HUVEC 
monolayer was determined to be a reliable indicator of PTx activity. TNF-α secretion was 
quantified to determine if there was a correlation with permeability, however, it was highly 
variable between blood donors. Therefore, it was likely that the permeability was the result of 
direct interaction between PTx and the HUVECs. Tight junctional (TJ) dysregulation as 
demonstrated by immunostaining the TJ complex and measuring the transendothelial electrical 
resistance (TEER) was investigated as the primary cause of PTx-induced permeability. 
Subsequent investigation into gap junction functionality corroborated this as a reduction in 
connexin functionality was observed which can be partially explained by TJ dysfunction, 
however, PTx was also shown to impair connexin 43 deposition at the plasma membrane, 
demonstrating that TJ expression could be used as alternative and/or combination assay. 
Additionally, Fluorescence Lifetime Imaging (FLIM) was carried out to directly image PTx activity 
within the HUVECs, by imaging endogenous NADH fluorescence. PTx activity was shown to be 
associated with a small increase in protein-bound NADH and since FLIM is non-destructive this 
allowed other experiments to be carried out on the same generation of HUVECs. In conclusion, 
the permeability assay described here is capable of detecting PTx in vaccine preparations at 
concentrations below the required threshold of 4 IU/ml PTx. 
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1.1 Introduction 
Bordetella pertussis is the aetiological agent of whooping cough, which presents in three distinct 
stages known as the catarrhal stage, the paroxysmal stage and the convalescent stage. The 
catarrhal stage can be characterised by cold-like symptoms including a runny or blocked nose 
and petechia in the throat (Kline et al., 2013). The secondary paroxysmal stage is associated with 
a distinctive ‘whoop’ in young children as the infection takes hold; this is what gives the 
condition its name. Together these symptoms can last for several weeks (6-10) (Kline et al., 
2013). The infection then begins the convalescent stage which is characterised by a reduction in 
severity of the symptoms before recovery (Kline et al., 2013). However, there can be serious 
complications that can occur during B. pertussis infection including death (Heninger et al., 1996). 
As a result, there has been a concerted effort to produce a safe, efficacious vaccine ever since 
B. pertussis was isolated and confirmed as the causative agent of whooping cough in 1906 by 
Bordet and Gengou (Cherry., 1996). The first successful pertussis vaccines were developed in 
the mid-to-late 1920s and continued into the 1930s, these consisted of a crude preparation of 
heat inactivated whole cell B. pertussis (wP) (Cherry., 1996). Despite progress in the 1920s, the 
wP vaccine commercial production did not begin until 1934 and the vaccine was not routinely 
adopted until 1957 (Amirthalingam et al., 2013). 
While the positive effect of the introduction of an effective vaccine cannot be disputed, there 
are serious side-effects that are associated with wP vaccines. These range from more mild 
symptoms such as, redness around the injection site (Gustafsson et al., 1996) to severe 
symptoms such as febrile seizure (Olin et al., 1997). It should be noted that severe symptoms 
like seizures are extremely rare; however, they are frequent enough to be for an elevated risk 
of febrile seizure to be detected (Barlow et al., 2001. RR=5.70, 95% CI: 1.98-16.42). This is what 
has driven the development of acellular pertussis vaccines (aP). These vaccines include only 
those antigens considered to be most important in the generation of a protective immune 
response (Storsaeter et al; 1998). This means that reactogenic components of the wP vaccine, 
such as lipopolysaccharide - which is extremely reactogenic and can be very damaging, are 
omitted from the final vaccine formulation. The result is a vaccine which exhibits a much lower 
rate of serious side-effects that remains satisfactorily immunogenic (Storsaeter et al; 1998). 
While this is a positive step, the mechanisms behind such rare occurrences like seizure are poorly 
understood, however it has been previously suggested that pertussis toxin (PTx) can increase 
the permeability of the blood brain barrier (BBB). Although, it has been postulated that 
neurological adverse events exhibited in some children are due to increased sensitisation of the 
endothelial component of the BBB to vasoactive amines (Lithicum et al; 1982). This increased 
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sensitivity results in increased permeability of the BBB as molecules such as ICAM-1 and VCAM-
1 are expressed on the cell surface (Su et al., 2001). One of the main hurdles in understanding 
the mechanism of these adverse effects is the lack of a suitable model, be it in vivo or in vitro. 
The study of the pathogenesis of B. pertussis and its derivative vaccines is difficult as the 
pathogen is host-adapted to humans (Parkhill et al; 2003), meaning that only limited animal 
models are available for the human disease. Currently, in vivo assays for assessing activity are 
available, such as the histamine-sensitisation test (HIST). This is a murine model which can be 
used to determine the level of activity of PTx or pertussis toxoid (PTd) (Gomez et al., 2007) and 
is not suitable for the study of how PTx or its derivatives act in human cells. A model does exist 
for the human BBB, which would allow the interactions of aP vaccine antigens to be investigated 
for their ability to cause destabilisation of this barrier. This model was originally developed to 
study the neurological symptoms of AIDS (Eugenin et al., 2006). However, it would not be 
difficult to adapt it to study the effects of different components of aP on the integrity and 
permeability of the BBB. This model and how it may be modified will be discussed later. Given 
the importance of the BBB and the association of pertussis vaccines and reduced BBB integrity, 
it is imperative that the mechanisms behind this are understood. There has already been some 
work on this and genetic conditions such as, Dravet’s syndrome, which is a mutation of a sodium 
channel, may be a risk factor for seizure following vaccination (Novy et al: 2010). Although, 
Dravet’s syndrome has been identified as a risk factor for seizure after receipt of aP, it is rare 
and does not account for all of those afflicted with seizure following vaccination (Novy et al: 
2010). Clearly there are subtler interactions between the vaccine, the immune system and the 
BBB which result in some individuals suffering from seizures as a result of vaccination. 
Several epidemiological studies have noted that the risks of severe side effects like seizures are 
rare which means many are not powered sufficiently to detect a significant difference between 
the incidence of seizure following wP vaccination and aP vaccination (Omer et al., 2009). The 
rarity of the seizures following vaccination means a very large sample size, in the order of 
hundreds of thousands (Zangwill et al., 2008) is required which makes it very difficult to calculate 
the true risk of seizure following vaccination. Without confirmation of a biological mechanism 
behind febrile seizure induced by vaccination, it is very difficult to prove aP is a risk factor for 
febrile seizure using epidemiological data alone. Thus, it is vital that this subject is researched 
more thoroughly. 
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1.2 The Pathogenesis of Bordetella pertussis 
Before beginning to try to understand how pertussis vaccines function, it is important to 
understand how B. pertussis causes disease and how the immune system attempts to combat 
invasion. There are four main phases of infection by B. pertussis, in which the bacterium utilises 
a wide range of virulence factors to facilitate their survival within the host. Following 
transmission, the first phase of colonisation that is undertaken is preparation for adhesion. The 
niche that this organism inhabits is relatively hostile and the pathogen employs a number of 
virulence factors to overcome the host defences (Cotter et al., 1998). The first obstacle to B. 
pertussis is the mucocilliary escalator which ensures that most potential pathogens are removed 
from the trachea and bronchi and moved into the oesophagus where they are later destroyed 
in the stomach (Fliegauf et al., 2013). To combat this, B. pertussis releases the virulence factors 
tracheal cytotoxin (TCT) and lipo-oligosaccharides (LOS) (see Table 1 for a list of the main 
virulence factors involved in invasion). Together; TCT and LOS stimulate IL-1α production which 
leads to the production of reactive nitrogen compounds resulting in the loss of cilia from the 
tracheal surface (Heiss et al., 1993). This disrupts the mucocilliary escalator and allows the 
bacteria to adhere to the remaining cilia using filamentous haemagglutinin (FHA) (Smith et al., 
2001). During adhesion, the virulence factors FHA, fimbriae (fim) and pertactin (prn) adhere to 
the cilia of the tracheal endothelial cells (Smith et al 2001), resulting in changes in protein 
expression in those cells. For example, FHA induces expression of intercellular adhesion 
molecule-1 (ICAM-1) which the bacteria exploit to cement itself on the tracheal wall (Ishibashi 
et al., 2002). 
After the immune system begins to mount a response against the invading bacteria, the bacteria 
begin expressing adenylate cyclase toxin (ACT); the primary function of ACT is to kill 
macrophages (Gueirard et al., 1998). ACT induces cell death by rapidly increasing cAMP within 
the cell which induces the cell to undergo apoptosis (Khelef et al., 1993). Furthermore, ACT has 
been shown to enhance expression of Il-10 which dampens the Th1 immune response and 
providing time for the bacteria to colonise the host (Ross et al., 2004). B. pertussis is also capable 
of forming biofilms. Little is known about the role of the biofilm phenotype with regard to 
infection, however, it may play a role in asymptomatic carriage of the bacteria in the 
nasopharynx (Conover et al., 2010).  Recent research has identified Bps, a polysaccharide that 
promotes adherence in the nasopharynx but not in the lungs, which has been shown to be 
necessary for the formation of biofilms in the nose (Conover et al., 2010). This suggests that 
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while B. pertussis is capable of forming biofilms, they are not required for virulence, they are 
instead utilised as a means of carriage. 
 
Table 1:  The virulence factors involved in the colonisation and invasion 
phases of infection with B. pertussis1 
Virulence Factor Function 
Tracheal Cytotoxin Kills ciliated cells 
Lipo-oligo saccharide Kills ciliated cells 
Filamentous 
Haemagglutinin 
Adhesion and Th1 suppression 
Fimbriae Adhesion 
Pertactin Adhesion, resistance to neutrophil 
mediated clearance 
Adenylate Cyclase 
Toxin 
Kills epithelial cells and 
macrophages 
Pertussis Toxin Ribosylates G-proteins, inhibits 
signal transduction 
1This is not an exhaustive list 
 
1.2.1 The Virulence Factors of Bordetella pertussis 
The virulence factors listed above in table 1 are the most important virulence factors possessed 
by B. pertussis, in terms of its ability to cause disease in humans. TCT, important in the initial 
phase of infection, is a peptidoglycan fragment which has been shown in vitro to inhibit DNA 
synthesis and cause the death of ciliated cells (Heiss et al., 1994). Such is their importance to the 
virulence of B. pertussis; TCT, PTx and dermonecrotic toxin have been proposed as candidates 
for knock-out in a live attenuated B. pertussis vaccine strain that would be delivered to the naso-
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pharyngeal mucosa (Fedele et al., 2011). LOS carries out a similar function and acts 
synergistically with TCT to induce death of ciliated cells, LOS is also sufficient to trigger TLR4 and 
induce its downstream effects (Fedele et al., 2008).  
Another important virulence factor for the virulence of B. pertussis is pertactin (prn). Prn is 
involved in the adhesion of B. pertussis to its target, however; recent evidence suggests that prn 
may not be as important as previously thought. There may be a growing trend for infectious and 
virulent prn deficient strains of B. pertussis outside of the UK (Otsuka et al., 2012). This indicates 
that prn is not essential for the bacterium’s adherence to the trachea and that the other 
mediators of adhesion are able to compensate effectively for its loss. Although, this may be 
deleterious for the bacteria’s resistance to clearance by neutrophils (Inatsuka et al., 2010), its 
loss may enhance the bacteria’s ability to evade the adaptive immune response raised against 
it. This phenomenon has also been seen in France where strains lacking prn and PTx have been 
isolated (Bouchez et al., 2009). There has also been an increased heterogeneity in the PFGE 
profiles of B. pertussis since the introduction of pertussis vaccines in Poland (Mosiej et al., 2011) 
and in France (Hegerle et al., 2012). This is an interesting development as it indicates that 
vaccines have become a selective pressure on the bacteria (Octavia et al., 2011), in much the 
same way that antibiotics are.  
Further virulence factors important for B. pertussis include ACT, which is delivered to the cell in 
outer membrane vesicles (OMV) (Donato et al., 2012). ACT intoxicates the cell with cAMP and 
this kills epithelial cells by non-apoptotic pathways and arrests the cell cycle in macrophages, 
hampering the ability of this cell type to fight the infection (Gray et al., 2011). This delays the 
clearance of the bacteria as macrophages are the main cell type employed in the actual 
destruction of the bacteria. Despite this, the bacteria will not ultimately be able to prevent 
macrophage mediated clearance in the majority of cases. 
 
1.2.2 The Mechanism of Action of Pertussis Toxin and its Role in the aP Vaccine 
Pertussis toxin is an AB5 type toxin. This means it is a protein oligomer made up of six different 
domains, S1, S2, S3, two identical S4 domains and an S5 domain (Stein et al., 1994). The S1 
domain is the A subunit, which is the toxigenic part of the protein, the other domains are B 
subunits (Stein et al., 1994). The B subunits form a pentamer responsible for binding to the host 
target cell, this action allows the A subunit to be translocated across the plasma membrane by 
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retrograde transport (Figure 1.1) (Millen et al., 2013). The A subunit is an ADP-ribosyl transferase 
which acts upon a membrane associated G-protein (Figure 1.2). 
The B subunits are responsible for the binding of PTx to its appropriate target. It does this 
through the use of lectin-like binding characteristics. After the B-pentamer has contacted the 
appropriate glycan (Neu5AcGal in the case of PTx) (Millen et al., 2010), the A-subunit is then 
able moves through the pore created in the middle of the B-pentamer and receptor mediated 
endocytosis of the A-subunit is triggered (el Baya et al., 1997). The A-subunit is trafficked to the 
Golgi apparatus before reaching the endoplasmic reticulum. Once inside the endoplasmic 
reticulum, the A-subunit is translocated into the cytoplasm by Sec61 (Paton et al., 2006). 
Thereafter, the toxin is able to move to PTx-sensitive G-proteins where it ADP-ribosylates them. 
The B-pentamer is also able to activate T cell receptors (TCR) (Millen et al., 2013). This toxin 
mediated activation of the TCR results in reduced sensitivity of CXCR4, a chemokine ligand 
important in the migration of T cells (Schneider et al., 2009) and therefore temporarily 
attenuates the T cell response to infection.  
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Figure 1.1: Retrograde transport of PTx. 1. Contact between the B-pentamer 
of PTx and its cellular receptor, the glycan Neu5AcGal, induces the A-subunit 
to move through the pore in the centre of the B-subunits as well as clatharin 
accumulation at the plasma membrane, 2. The A-subunit is endocytosed into 
a clatharin coated vesicle and transported to the Golgi apparatus, 3. The Golgi 
apparatus transports the A-subunit to the endoplasmic reticulum, 4. The A-
subunit moves to the membrane transporter protein Sec-61, 5. The A-subunit 
is then translocated into the cytoplasm by Sec-61 where it is then free to carry 
out its biological function. 
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Once the toxin A subunit is inside the cytoplasm of the cell, it ribosylates G-proteins which causes 
them to become inactivated and they cannot decouple from their sensory domains. The 
ribosylation of the G-protein prevents dissociation of the trimeric signalling complex by 
ribosylating a cysteine residue four amino acids from the carboxy-terminus of the protein (West 
et al., 1985). It has subsequently been shown that Gα-protein chimeras where the cysteine 
residue near the C-terminus has been deleted are resistant to PTx mediated ribosylation (Joshi 
et al., 1998). Although the exact mechanism by which PTx binds its substrate is as yet unknown 
as the N-terminus is thought to play a role also (Osawa et al., 1990).  Although, it is known that 
inhibition of Gαi1 and Gαi3 by PTx leads to over-sensitivity of the vascular endothelium to 
vasoactive amines (Diehl et al., 2014). 
 
 
Figure 1.2: The mechanism of action of PTx. The B subunits initially make 
contact with the cell which initiates retrograde transport of the A subunit. 
Once inside the cell, the A subunit ribosylates a membrane associated G-
protein preventing it from uncoupling from its sensory domain.  
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The G-proteins that are inhibited by PTx are the first step in several signal transduction pathways 
which perform a wide variety of functions, including; control of the formation of the zona 
occludens (Denker et al., 1998), thus the action of pertussis toxin may destabilise the tight 
junctions between the cells. As the Gα family of G-proteins that pertussis toxin acts upon are 
expressed in many cell types, it has been developed into a test for the detection of these G-
proteins in all tissues of the body (Katada et al., 2012) and it is conceivable the effects of 
intoxication with PTx may be seen in every tissue (Mangmool et al., 2011). This means it is 
reasonable to hypothesise that residual toxicity may be, in part, responsible for the breakdown 
of the BBB, assuming that there is some residual toxicity associated with PTd. Although, there is 
evidence that an increase of cAMP, mediated by cholera toxin, does not significantly affect the 
integrity of tight junction expressing epithelial cells as it was expected to (Denker., 1998), the 
same is not necessarily true of other bacterial toxins, such as PTx, that increase cAMP 
concentrations. It has been discovered that the correct levels of cAMP in human umbilical vein 
endothelial cells (HUVEC) plays a critical role in the stability of tight junctions in this cell type, 
although it has no direct action on zona occludens proteins (Beese et al., 2010). Instead it 
modulates the action of protein kinase A (Beese et al., 2010), which is an important regulator of 
tight junction formation. The tight junction integrity was analysed using antibodies conjugated 
to a fluorophore and laser scanning confocal microscopy in this study. 
Nicotinamide adenine dinucleotide (NADH) is a vital co-factor for the ADP-ribosylation of G-
proteins by PTx, this means that measuring the levels of free NADH versus NADH associated with 
protein NAD(P)H may give an indication of the activity of PTx in the cell. Due to the structure of 
NADH it is possible to induce it to auto-fluoresce with the appropriate excitation wavelength 
light (Niesner et al., 2004); this can be done using two-photon scanning fluorescence 
microscopy. The emission spectra of NADH and NAD(P)H are different so it is possible to 
distinguish the ratio of NADH to NAD(P)H (Niesner et al., 2004); this can be done using either a 
single or two-photon scanning fluorescence microscopy. As the action of PTx is dependent on 
NADH as a co-factor, changes in the ratio of NADH to NAD(P)H may give an indication of PTx 
activity within the cell. Under normal circumstances, the greatest concentration of NADH and 
NAD(P)H is around the mitochondria (Niesner et al., 2004) as these are the metabolic centres of 
the cell. This technique is useful for analysing conditions which affect the metabolic status of 
the cell, conditions like PTx intoxication.  This has been shown to be effective previously when 
this technique was applied to visualise NADH and FAD activity in malignant tumour cells 
(Provenzano et al., 2008). The use of new techniques in confocal microscopy allow much more 
in depth study of the dynamics of pertussis toxin in the cell and by extension, the dynamics of 
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aP vaccine components, particularly with regard to understanding how the vaccine interacts 
with the BBB. 
Therefore, the action of pertussis toxin; whilst appearing to be a relatively simple biochemical 
interaction may have significant downstream effects within an infected cell. However, there is 
little data on what these effects are, therefore, it is only possible to hypothesise at this time. 
Given that pertussis toxin sensitive G-proteins are widespread in the human physiology, the 
effects of PTx could potentially be widespread also. cAMP levels are manipulated by PTx and 
cAMP is known to be an important factor in the regulation of protein kinase A and the Rac family 
of GTPases, which are directly involved in tight junction formation (Oldenburger et al., 2012 & 
Braga et al., 1997). Understanding this could give rise to a better understanding of the 
pathogenesis of B. pertussis on the whole, especially with regard to the aP vaccine where loss of 
integrity of tight junctions can particularly dangerous. 
 
1.3 Immune response to B. pertussis and bacterial immunomodulatory 
strategies 
To combat infection by B. pertussis, it is important that the innate and adaptive divisions of the 
immune system are properly stimulated so that the most appropriate response to infection may 
be elicited. During initial infection, B. pertussis may be phagocytosed by macrophages or 
dendritic cells (DCs) as the innate immune system attempts to combat the infection. These cell 
types digest the bacteria and present fragments called pathogen associated molecular patterns 
(PAMPs) to T helper cells. T helper cells then stimulate an appropriate response from the 
adaptive immune system i.e. a cellular or a humoral response is initiated. In the case of B. 
pertussis, the response that is generated by the immune response is a Th1/Th17 cellular response 
as opposed to an antibody dependent humoral response; demonstrated in a mouse model and 
in ex vivo monocyte derived dendritic cells respectively (Dunne et al., 2015 and Fedele et al., 
2010). An over view of this is given in Figure 1.3. 
In the initial stages of infection, DCs recognise pathogens through the use of pathogen 
recognition receptors (PRRs) and then present these to T cells using major-histocompatibility 
complex (MHC) (Watts et al., 2010). The receptors include toll-like receptors (TLRs), endogenous 
NOD-like receptors and MAPK sensors (Watts et al., 2010). TLRs are known to be vital for the 
recognition of antigens by DCs, there are several types of TLR with TLR4 and TLR5 among the 
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most important TLRs for recognising bacterial pathogens as they recognise LPS and flagellin 
respectively. When stimulated, these receptors up-regulate Human Leukocyte Antigen (HLA), 
this enables the DC to present antigens to T cells.  
Once an antigen has been presented to a naïve T cell, the T cell differentiates (Goenka et al., 
2011) into either a Th1 or Th2 cell; this determines whether or not the immune response will be 
cell mediated or antibody mediated. B. pertussis elicits a mixed Th1/Th2 response. The cytokines 
that are involved in the Th1 response include IFN-γ and Il-2 (Cope et al., 2011); other cytokines 
such as Il-4, Il-5 and Il-10 are notable by their absence and are associated with a Th2 response 
(Han et al., 2010). Furthermore, the maturation of populations of Th1 cells has been correlated 
with the clearance of B. pertussis (Mills et al., 1993) and more recently in mice Th17 cells have 
been demonstrated to play a vital role in the protective immunity against B. pertussis (Ross et 
al., 2013). Among the functions of B. pertussis’ virulence factors include induction of secretion 
of Th2 type cytokines, this serves to dampen the Th1 immune response and occurs in the early 
stages of infection as B. pertussis establishes colonies (Mahon et al., 1997). The cytokines of the 
Th1 response activate macrophages which are the primary mechanism by which B. pertussis is 
cleared. While the importance of Th1 cannot be understated, it is also believed that the humoral 
response has a role to play also. Antibodies have been shown to aid in the clearance of the 
bacteria, although their role is not as important as Th1 (Mills et al., 1998). FHA of B. pertussis has 
been shown to skew the immune response by inducing transcription of Il-10 (McGuirk et al., 
2000 & 2002), Il-10 induced Treg1 cells may allow a subset of Th2 cells mature and compensate 
for bacterial suppression of Th1.  
The Th1 response has long been thought to be the pivotal factor in clearance of B. pertussis. This 
is unusual as the Th1 response is more closely associated with the activation of cytotoxic CD8+ T 
cells and the clearance of intracellular pathogens. Their presence during infection by a pathogen 
that is for the most part remains extracellular is confusing, although, they are able to induce 
macrophages to migrate to the site of infection (Martinez et al., 2008).  The study of Th17 cells 
in a baboon model shed more light on the behaviour of the adaptive immune response towards 
pertussis and it is now clear that Th1 is not the only facet of the adaptive immune system that is 
necessary for the clearance of B. pertussis (Warfel et al., 2013). In the case of B. pertussis, the 
Th17 response is induced through recognition of ACT by the inflammasome (Dunne et al., 2010). 
The primary effector of the Th17 is Il-17, this cytokine is a potent activator of macrophages and 
induces them to secrete Il-1β and TNF-α (Jovanovic et al., 1998) and leads to a sustained pro-
inflammatory response which is conducive to the clearance of the bacteria. Furthermore, Il-17 
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has also been shown to down-regulate occludin, this has been linked to loss of BBB integrity in 
mice (Huppert et al; 2010). 
B. pertussis has evolved several mechanisms by which it is able to evade or dampen the immune 
response to its presence. Perhaps the most valuable virulence factors that the bacterium 
possesses in this regard are FHA and ACT. FHA has been shown to induce cytokines that suppress 
the Th1 response such as Il-10 (Mattoo et al., 2005); this causes the differentiation activation of 
Treg1 cells (Heo et al., 2010) and the subsequent suppression of Th1 cells. However, it does not 
suppress the classic Th1 cytokines such as Il-12 and IFN-γ, meaning that the signals associated 
with the Th1 response are still present. Additionally, FHA appears to inhibit secretion of Il-17 
from macrophages themselves and in the same study it was hypothesised that FHA acts 
synergistically with ACT to inhibit IL-23 also (Henderson et al., 2012), this cytokine is critical to 
the differentiation of Th17 cells from naïve T cells. B. pertussis also possesses ACT which blunts 
the macrophages ability to clear B. pertussis. It does this by intoxicating macrophages with 
cAMP, which decreases their ability to adhere and present antigens (Martin et al., 2011). This 
means that the macrophages are less effective at clearing the bacteria. 
Therefore, the immune system favours a Th1/Th17 response for clearing infections by B. pertussis 
and this is of particular importance during the latter stages of infection, however the Th2 
response that is also seen should not be underestimated during the early stages. It could be 
argued, however, that the Th17 response is more important than Th1 as the latter is associated 
with the clearance of intracellular pathogens like viruses and the former is a more potent 
activator of macrophages. Macrophages being the principle cell type involved in the actual 
destruction of the bacteria. Therefore, B. pertussis has evolved mechanisms to suppress these 
responses. Principally, these include the actions of FHA and ACT which act synergistically to 
dampen the Th1 response by inducing Il-10 secretion, attenuate macrophages and dampen the 
adaptive immune response. However, further evidence that the interaction between B. pertussis 
and the immune system is not fully understood emerged when it was demonstrated that ACT 
was crucial in the activation of the inflammasome, which subsequently activates antigen specific 
Th17 cells via the action of Il-1β (Dunne et al., 2010). Further strategies used by the host to clear 
bacterial infections include the complement system. One strategy employed by Gram negative 
bacteria to combat complement mediated killing is expression of LPS with long O-polysaccharide 
repeats to prevent effective membrane attack complex formation (Doorduijn et al., 2016). B. 
pertussis lacks LPS with long O-polysaccharide repeats (Caroff et al., 2000) and instead recruits 
the complement regulatory protein C1 esterase inhibitor (C1inh), by expressing the Bvg-
regulated autotransporter Vag8 which binds C1inh at the cell surface (Marr et al., 2011). 
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Furthermore, FHA has been shown to bind the complement inhibitor C4BP to aid complement 
evasion, although ΔFHA mutants are still capable of recruiting C4BP (Fernandez et al., 1998), 
highlighting redundancy of function between several bacterial proteins. It is also important to 
consider that genes encoding for several of the bacterial virulence factors including PTx, FHA, 
fim and Vag8 are under the control of the BvgAS two-component regulatory system (Cotter and 
Jones., 2003, Finn and Amsbaugh., 1998). The BvgAS system ensures that virulence factors are 
expressed appropriately and ensures those virulence factors work in concert to aid the bacterial 
colonisation of the host. 
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Figure 1.3: The relationship between dendritic cells, T-cells and macrophages 
during infection by B. pertussis. The immune system tries to instigate a 
Th1/Th17 response; however, in the early stages of infection, the bacteria use 
the virulence factors FHA and ACT to activate Treg1 cells. This is done by 
inducing secretion of Il-10 by dormant regulatory T cells and inhibiting 
transcription of Il-12 in DCs. This suppresses the Th1 response and allows the 
bacteria to persist. Another effect of ACT is premature apoptosis in 
macrophages; this compounds the dampening of the Th1 response as 
macrophages that are attempting to clear the infection to undergo premature 
apoptosis.  
Il-1 
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1.4 Pertussis Whole-Cell Vaccine 
Prior to the introduction of the pertussis whole cell vaccine (wP), Bordetella pertussis was 
considered to be one of the greatest threats to the health of children in Britain. Early production 
of wP vaccines began in the 1930s, however it was not until 1957 that these were adopted as 
part of a vaccination program (Amirthalingam et al., 2013). Prior to 1957 there were significant 
numbers of pertussis notifications in England and Wales, introduction of the wP vaccine 
precipitated a reduction in the number of notifications.  
 
 
 
 
While the wP vaccine is undoubtedly very effective at providing protective immunity from 
pertussis, it is also associated with a high degree of reactogenicity. These can range from mild, 
more common events such as redness and swelling around the site of injection to rare but severe 
adverse events like hypotonic episodes and convulsions and are more commonly as associated 
with the wP vaccine as opposed to the available aP alternatives (Gustafsson et al., 1996). 
Publicity surrounding these rare adverse events in the 1970s (Baker., 2003) led to reduced 
uptake of the wP vaccine and subsequent increases in pertussis notifications (Figure 1.4) until 
vaccine coverage recovered and pertussis notifications dropped. Encephalopathy has been 
associated with wP vaccination for many decades and in 1978 the first data from the National 
Childhood Encephalopathy Study (NCES) was published by Miller and Ross. This study made 
several suggestions as to why an association between encephalopathy and pertussis vaccination 
exists, mainly that the chances of coincidental encephalopathy and pertussis vaccination were 
high due to the median ages of the children admitted to hospital suffering encephalopathy. 
Furthermore, two-thirds of the children that recovered from encephalopathy had a history of 
Figure 1.4: Pertussis notifications between 1940 and 2012 in England and 
Wales and percentage vaccine coverage of pertussis vaccines in the period 
1970-2012.  Adapted from Amirthalingam et al., 2013. 
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disease characterised by high fever which could, under the correct circumstances, trigger 
convulsions that are not related to the wP vaccine. The study concluded that after a year of 
study these was no clear association between wP vaccination and brain injury. The NCES has 
been invoked the courts during the legal controversy surrounding long term brain injury and 
pertussis vaccination where it was proven, in a legal sense, that pertussis vaccination was not 
likely to result in childhood encephalopathy and long term brain injury (Baker., 2003). Further 
scrutiny of the NCES concluded that selection bias may have led to an overestimation of the 
association of wP vaccination and encephalopathy but that pertussis vaccination related cases 
could not be absolutely ruled out (Marcuse and Wentz., 1990). Additional study and discussion 
has largely concluded that a causal relationship between wP vaccines and brain injury is not as 
straightforward as was previously thought (Cherry., 1990, Cowan., 1993 and Howson and 
Feinberg., 1992). These reviews discussed the possibility that wP vaccine induced neurological 
damage could occur but concluded that there was insufficient evidence to establish causality. 
Despite the lack of causality between wP vaccination and long term brain injury, ultimately, the 
rate at which severe side effects was perceived as being too high in many countries and the 
decline in wP uptake led to the development of aP vaccine. The aP vaccine induced a robust Th2 
type immune response and was significantly less reactogenic as the rate of severe side-effects 
was reduced to insignificant levels. Therefore, developed countries have withdrawn use of the 
wP vaccine in favour of the aP vaccine. 
 
1.5 Acellular pertussis vaccine 
Since the introduction of the wP vaccine, there was a rapid decline in the number of cases of 
pertussis. However, the whole cell pertussis vaccine is associated with many adverse effects, the 
most severe of which is seizure, which can potentially lead to death although rates of seizure 
and death are extremely low as was found in a large cohort study conducted in Denmark (Sun 
et al., 2012). aP vaccine was introduced as an alternative to wP, without the serious side effects 
like seizure (Chang et al., 2013). Although the prevalence of vaccine-associated seizure has been 
significantly reduced by the introduction of the aP vaccine, there is still a small incidence of 
seizure following vaccination (Chang et al., 2013). The link between seizure and aP vaccine has 
been difficult to prove as many epidemiological studies are not powered to detect this 
relationship and are geared towards some of the more common but less severe adverse effects. 
The mechanism behind seizures induced by the wP vaccine is unknown, but it is most likely due 
to the number of highly reactive elements, like LPS, or improperly detoxified virulence factors 
like PTx that remain in the final vaccine formulation (Dias et al., 2013). These virulence factors 
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are theoretically capable of causing seizure and it has been postulated that they disrupt the BBB 
and allow inflammatory mediators and peripheral blood mononuclear cells (PBMCs) across into 
the brain. In the aP vaccine, these highly reactive elements of the bacteria are removed and the 
virulence factors that are used in the final vaccine formulation are carefully detoxified where 
necessary. Even after this is done, there are still some cases of seizure after vaccination with aP; 
Rosenthal et al., 1996 reported 0.5 seizures per 100,000 vaccine doses given (versus 1.7 per 
100,000 for the wP vaccine.  
 
1.5.1 The Resurgence of B. pertussis  
Despite the success of the whole cell vaccine, lingering concerns over vaccine safety ultimately 
led to its replacement with an acellular vaccine in the primary vaccine schedule that was 
associated with far lower rates of adverse events (Greco et al., 1996). Whilst the acellular vaccine 
is associated with fewer adverse events and elicits a robust antibody response against B. 
pertussis, serious question over the vaccines suitability have been raised in the face of the re-
emergence of B. pertussis. 
Since the introduction of the acellular pertussis vaccine as a primary vaccine, rates of adverse 
events have reduced however concerns have been raised over the vaccine’s efficacy with regard 
to longevity of immunity. Waning immunity has been observed in children in the United States 
who have received 5 doses of the DTaP (Diphtheria, Tetanus and acellular pertussis) vaccine and 
were never primed with the DTwP vaccine (Tartof et al., 2013). In this study, 224 378 children in 
Minnesota were observed for a period of 6 years and the relative risk of pertussis infection was 
monitored. It was found that the relative risk of acquiring pertussis following the 5th DTaP dose 
increased to 8.9 (CI: 6.0-13.0) from 1.9 (CI: 1.3-2.9) six years after receipt of the final DTaP 
vaccination. Klein et al., 2014 noted similar trends with regard to the DTaP vaccine and Koepke 
et al., 2014 in Wisconsin, USA showed that pertussis incidence has increased if dTap is used as a 
booster, concluding that waning immunity to B. pertussis may be becoming a serious problem. 
Furthermore, Witt et al., 2013 showed that children receiving DTaP only vaccinations were at 
increased risk of contracting pertussis versus those that had received at least one dose of DTwP 
(RR 8.57 times higher when acellular vaccines is received versus whole-cell). Each of these 
studies postulates that the observed rise in pertussis cases is due to waning immunity of reduced 
vaccine effectiveness, but none of them are mechanistic studies and do not go into the 
underlying reasons why these trends were observed. Investigations into the humoral immune 
response to acellular pertussis vaccines have shown that antibody levels of 20 EU/ml IgG against 
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PTx in children (6-7 years of age) 5 years after initial vaccination (Carollo et al., 2014) can be 
achieved. The authors note that 20 EU/ml anti-PTx IgG is assumed to be protective but that this 
has not been confirmed. The epidemiological evidence discussed suggests it may be inadequate, 
however, Witt et al., 2012 proposed that vaccine scheduling and not the acellular pertussis 
vaccine itself may be inadequate following observations made during an outbreak in California. 
To combat deficiencies in the vaccination schedule, maternal vaccination with the Tdap vaccine 
has been undertaken. In theory, immunising the mother should passively immunise the foetus 
with protective antibodies against pertussis. The efficacy of maternal vaccination appears to be 
high as studies show that prevalence of pertussis in new-borns has reduced in England in the 
space of a year between 2013 and 2014 since the introduction of maternal vaccination with 
DTaP-IPV in 2012 (Amirthalingam et al., 2014). Further evidence supporting maternal 
immunisation against pertussis was obtained by Munoz et al., 2014, where it was found that 
maternal anti-pertussis antibodies were circulating in infants and did not interfere with 
responses to further vaccination. This suggests that maternal immunisation with Tdap is 
effective with regard to reducing pertussis prevalence in very young infants. However, it does 
not address the issue of aP vaccines inducing a different kind of immunity when compared to 
the wP vaccine.  
The type of immune response generated by the aP vaccine must be considered also. This is 
important as the aP vaccine induces a Th2 type humoral immune response as opposed to a 
Th1/Th17 cell mediated response induced by the wP vaccine that is more akin to the response 
seen following natural infection. A longitudinal study in children aged between 7 and 48 months 
(4 years) showed that cell-mediated immune (CMI) responses to acellular vaccines were possible 
initially. However, 20% and 37% of responders against PTd and FHA showed a negative response 
after 48 months, suggesting that that memory T cells are not mature enough in the early stages 
of life (Ausiello et al., 1999) and therefore, waning immunity against pertussis could be expected 
very young children. Interestingly, some children that were CMI negative at 7 months had 
acquired a CMI response to pertussis antigens by 48 months. This apparent discrepancy is likely 
due to the acquisition of a B. pertussis infection that remained asymptomatic. Concerns 
regarding the acellular vaccine’s ability to elicit robust immunity have been underlined by the 
pertussis baboon model. The immune responses generated by acellular vaccination have been 
characterised as having robust antibody responses adequate for prevention of disease but not 
carriage of the bacteria. A naïve baboon was infected with B. pertussis acquired from a 
vaccinated individual (Warfel et al., 2013 & 2014), showing that it is possible that reservoirs of 
B. pertussis may exist within a vaccinated population and that these vaccinated but infected 
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individuals may transmit the bacteria to vulnerable individuals. Therefore, it is likely that 
resurgence of B. pertussis is due in part to stimulation of humoral immunity as opposed to 
cellular immunity, faster waning of that immunity and inadequate protection against 
colonisation.  
Since the introduction of aP vaccines, B. pertussis strains that have mutations in Prn and the ptxP 
promoter have emerged. Some of these strains are Prn deficient (Lam et al., 2014 & Martin et 
al., 2015) and may explain some pertussis outbreaks but it has not been determined if such 
strains are widespread enough to explain overall trend of pertussis re-emergence. Other strains 
that possess a mutated form of Prn, prn2, have been identified (Octavia et al., 2012). Currently, 
prn2 are more circulate more commonly that prn1 strains (Lin et al., 2006 and Shuel et al., 2013) 
and have a selective advantage with regard to aP vaccine pressure as vaccine strains express 
prn1 (He et al., 2003). Besides Prn mutations, several isolates have been identified which 
produce more PTx and that these strains have also begun to become more prevalent in recent 
years leading to an association with pertussis resurgence in the Netherlands (Mooi et al., 2009). 
In these strains, several single nucleotide polymorphisms (SNPs) in the ptxP promoter have been 
observed and linked to the ptxP3 allele (van Gent et al., 2012). Strains possessing ptxP3 are 
becoming more common that those possessing ptxP1. This promoter mutation is significant 
because Mooi et al., 2009 were able to provide evidence that ptxP3 was associated with increase 
virulence and King et al., 2013 demonstrated that ptxP3 mutants colonised the lungs and trachea 
of mice more efficiently. Therefore, the re-emergence of pertussis is likely due to the 
deficiencies of the acellular vaccine with regard to longevity of immunity and its inability induce 
a sterilising immune response, however, mutation of key virulence factors and evolution of new 
strains should also be considered. 
 
1.5.2 Detoxifying Pertussis Toxin 
Pertussis toxin forms the basis of all licenced aP vaccines today. The vaccine always consists of 
toxoided pertussis toxin as a base and various other antigens and adjuvants are added (Olin et 
al., 1997). There are two accepted methods of toxoiding pertussis toxin and its other virulence 
factors used in commercially available vaccines, either by chemical or genetic means. Each has 
advantages over the other. Chemical deactivation of B. pertussis’ virulence factors leaves the 
possibility that the B-subunit may not be completely cross-linked, meaning that there may be 
residual toxicity (Donnelly et al., 2001). This is of particular concern with regard to PTx, but is 
less of a concern with other virulence factors included in the vaccine that are important in 
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adherence and are not inherently toxic themselves, such as FHA. This problem is, in theory, 
solved by genetically detoxifying PTx. This means that the DNA encoding the domain that is 
responsible for the toxic effect i.e. the active site of the A subunit, is removed and a non-toxic, 
immunogenic toxoid is produced instead.  
Chemical detoxification of PTx is essentially random and relies on the chemicals used, normally 
formaldehyde or glutaraldehyde cross-linking the B subunit of the toxin to such an extent that 
it can no longer bind to its carbohydrate target. As crosslinking is random, the toxin is exposed 
to these chemicals for a significant length of time to ensure that it is sufficiently detoxified, this 
may however reduce immunogenicity. Although it has been previously found that 
glutaraldehyde is unable to inactivate the ADP-ribosyl transferase activity of PTx due to the lack 
of appropriate residues in the active site for it to cross-link (Oh et al., 2013). This means that it 
is definitely possible that there may still be some ribosylating activity seen in PTd that has been 
toxoided using glutaraldehyde. It has also been shown that chemical detoxification with 
hydrogen peroxide does not denature epitopes to the same extent as glutaraldehyde and 
formaldehyde (Heron et al., 1999); furthermore, this method results in a well-tolerated vaccine 
(Thierry-Carstensen et al., 2013). Hydrogen peroxide deactivated PTd may be a better 
alternative to glutaraldehyde or formaldehyde detoxified PTd because the epitopes of the toxin 
are not damaged to the same extent (Sutherland et al., 2011). It has been shown that protective 
antibodies against PTx are more effective when generated during natural infection, the 
formaldehyde treated PTd had altered domains that were not as well recognised by the immune 
system as native PTx (Sutherland et al., 2011). This problem should be eliminated by detoxifying 
PTx by genetic methods. This would ensure that the catalytic active site of the A subunit was 
properly deactivated and that all the protective epitopes remain intact. Any adverse effect 
resulting from the use of genetically detoxified PTd would surely then be the result of over-
reaction by the immune system as the toxicity of PTx would no longer be a factor. 
 
1.5.3 Genetically Inactivating Pertussis Toxin 
Inactivation of PTx is undertaken to minimise any adverse events in pertussis containing vaccines 
that may be caused by the enzymatic activity of the toxin. In current pertussis-containing 
vaccines, the toxoid is produced by treating PTx with formaldehyde, glutaraldehyde or hydrogen 
peroxide (Heron et al., 1999 and Thierry-Carstensen et al., 2013). Chemical treatment of the PTx 
molecule does as intended with regard the toxin’s enzymatic activity, however, these 
treatments also compromise epitopes that are important for generating a protective immune 
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response (Sutherland et al., 2011). For this reason, a genetically toxoided PTd molecule was 
proposed as a potential vaccine candidate. In this method of toxoiding, the amino acid residues 
responsible for ADP-ribosyltransferase activity were identified and site-directed mutagenesis 
was performed to attenuate PTx activity (Pizza 1988). Mutants generated in this study were 
taken forward and it was determined which amino acid substitutions were the most promising 
as vaccine candidates. These candidates consisted three single substitution mutations and two 
double substitution mutations: PTx-9K, Arg-9 to Lys; PTx-13L, Arg13 to Leu; PTx-129G, Glu-129 
to Gly; PTx-9K/129G Arg-9 to Lys and Glu-129 to Gly and PTx-13L/129G, Arg13 to Leu and Glu129 
to Gly (Pizza et al., 1989). Each of these mutants possessed no ADP-ribosyltransferase activity 
and each was recognised by monoclonal antibodies, indicating successful epitope preservation. 
Further immunogenicity studies demonstrated that PTx-9K/129G was both mitogenic and 
capable of raising high levels of toxin neutralising antibodies in guinea pigs (Nencioni et al., 
1990). These findings, were further reinforced in a human study where high anti-PTx antibody 
titres, complemented by a cellular immune response, were observed after vaccination with PTx-
9K/129G (Podda et al., 1990). A further phase one trial of the PTx-9K/129G toxoid mutant in 
combination with FHA and Prn, showed that this test vaccine formulation did not result in 
adverse reactions any more severe than redness around the injection site. Furthermore, the 
vaccine induced high titres of anti-PT, FHA and Prn antibodies combined with a cellular immune 
response directed against each of the three antigens (Podda et al., 1991). The immunogenicity 
of genetically attenuated toxoids combined with minimal associated adverse events has led to 
arguments that chemically toxoided antigens should be replaced with genetically toxoided 
equivalents (Robbins et al., 2005). Therefore, genetically toxoided PTd is superior to chemically 
toxoided PTd in terms of immunogenicity and reactogenicity; however, given the cost of bringing 
a genetically inactivated PTd vaccine to market it is unlikely that chemical toxoiding will be 
replaced in the near future. 
 
1.5.4 Neurological Adverse Events Associated with Acellular Pertussis Vaccines  
Final vaccine formulations always contain non-antigenic chemicals such as aluminium salts 
which are the most common adjuvants used in vaccines in the UK or alternatively oil in water 
emulsions among others (Rappuoli et al., 2011). It is unlikely that these are the cause the severe 
neurological side-effects that are sometimes observed after aP vaccination as these are used in 
many commercial vaccines that are not associated with neurological side-effects. Furthermore, 
there may be residual chemicals such as glutaraldehyde or formaldehyde, both of which are 
used to detoxify pertussis toxin (Olin et al., 1997). It is possible that these vaccine additives and 
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residual chemicals may be causing or exacerbating weakness in the BBB caused by the antigenic 
components of the vaccine. The toxic effects of glutaraldehyde and formaldehyde are well 
documented (Zeiger et al., 2005 & Pandey et al., 2000). However, it is difficult to know for certain 
if it is the antigens in the vaccine, additives like adjuvants or residual toxic effect of the chemicals 
used to detoxify PTx that cause disruption to the BBB as there are few studies that have 
investigated this mainly due to the lack of a suitable model. Indeed, pertussis vaccine has been 
hit badly by public perception that the more severe side effects happen more regularly than 
statistics suggest (Omer et al., 2009). This does leave unvaccinated children nearly six times 
(RR=5.9, 95% CI: 4.2-8.2) (Feikin et al., 2000) more likely to contract pertussis, highlighting the 
protective effect that the vaccine confers.  
The vaccine itself is not the only factor that should be considered when analysing the rate of 
febrile seizure, the condition of the recipient of the vaccine recipient should also be taken into 
account. Underlying conditions such as Dravet’s disease can make an individual more 
susceptible to severe reaction (Verbeek et al., 2015). However, it is possible that other 
unidentified genetic factors that predispose individuals to febrile seizure in response to the 
vaccine. Despite this evidence, several studies have found that there is no increased risk of 
seizure following immunisation with DTaP vaccine (Huang et al., 2010, Carlsson et al., 1998 & 
Rorke-Adams et al., 2011). However, many studies are not powered to detect significance in the 
occurrence of febrile seizure with relation to vaccination as they do not set out with this in mind 
and so it is difficult to draw conclusions about the risk of seizure following vaccination. The lack 
of a suitable model, in vitro or in vivo, for investigating the possible mechanisms behind the 
neurological side effects of aP vaccination has compounded the problem, as there is no 
biological basis for the assumption of risk between the aP vaccine and febrile seizure, although 
some hypotheses do exist. 
Despite ambiguity with regard to the epidemiological evidence for serious neurological events 
following acellular pertussis vaccination, case reports of serious adverse events associated with 
vaccination are reported. These include several cases of neurological adverse events leading to 
death in infants post vaccination with acellular pertussis (Zinka et al., 2005). The authors note 
that no definitive connection can be drawn between the deaths and vaccination from these 
cases but, that histological material all were shown to have experienced an “anaphylactic 
reaction developed after the vaccination” (Zinka et al., 2005) that was delayed somewhat post-
vaccination. The veracity of the findings of in this study have been questioned on the basis that 
there are several factors that were not taken into account during the epidemiological analysis 
of behind possible vaccine related Sudden Infant Death (SID) (von Kries et al., 2006). 
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Furthermore, the pathology used to describe hexavalent vaccine induced encephalopathy was 
also called into question as the analysis contained a number of contradictions and according to 
this criticism, was likely of a poor standard and not of any value (Maurer., 2006 and Schmit et 
al., 2006). Additionally, Zinka et al., 2005 use a mouse model to compare the pathology they 
report, however this model involved injecting purified PTx and BSA into the mouse to induce 
SID-like syndrome and cannot be compared to SID following injection with a vaccine (Maurer., 
2006). 
 
1.5.5 Current methods of detecting pertussis toxin activity  
There are several methods by which the activity of pertussis toxin may be assessed and the most 
common method currently used is the HIST sensitisation assay. This assay involves the use of 
high number so of laboratory mice and the assay raises several ethical concerns. Briefly, mice 
are given a dose of vaccine or dose of PTx before being challenged five days post vaccination 
with histamine. The mice that received a dose of PTx experience anaphylactic shock, a drop in 
body temperature, general distress and death. The chief concerns surrounding the HIST assay 
relates to the experimental outcomes of the assay. Ethically, anaphylactic shock and death are 
not considered acceptable outcomes due to the distress that this causes the animal (Gomez et 
al., 2006).  Furthermore, large variation within the assay means that large groups of animals 
must be used to ensure that the results are statistically robust. Therefore, this assay is not 
appropriate from an ethical point of view as it causes distress to the animals and a large number 
of animals are necessary. The HIST assay requires binding, translocation and enzymatic activity 
of PTx to occur before any effects are seen. Ideally any replacement assay would also require all 
of these processes to determine that toxoiding is adequate. 
Mainly due to the concerns over the ethics of the HIST assay and the lack of understood 
mechanism, alternative assays have been put forward as replacements. These include the CHO 
cell assay and a high performance liquid chromatography (HPLC) based biochemical method 
with a concurrent B-subunit binding assay. The Chinese Hamster Ovary (CHO) cell assay has been 
widely mooted as a replacement assay for the HIST assay. CHO cells are cultured in a 96-well 
plate and a vaccine preparation is overlaid. Depending on the concentration of PTx in the 
preparation, the CHO cells become round to a varying degree (Gillenius et al., 1985). This assay 
takes into account binding, translocation and enzymatic activity when assessing PTx 
concentration, however the one of several disadvantages of the CHO assay is its semi-
quantitative nature. The degree of cell rounding is highly subjective and depends on the 
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technician’s opinion. This means that the results may differ depending on the individual 
performing the assay, efforts have been made to minimise this as a source of error by 
performing the assay alongside a reference preparation of known PTx concentration (Corbel et 
al., 2008). Furthermore, the alum adjuvant present in vaccines is known to be cytotoxic for CHO 
cells and would need to be removed before the assay is carried out. Steps are being taken to 
achieve this such as desorption of the alum antigen by incubating the vaccine preparation in 
citrate buffer (Isbrucker et al., 2010). Therefore, there are several problems associated with the 
CHO cell assay some like the requirement for adjuvant desorption may be overcome in future, 
however the fundamental problem is the subjective nature of the assay that is more difficult to 
account for.  
The subjective nature of the CHO cell assay means it is not ideal for testing pertussis-containing 
vaccines; therefore, other methods have been developed such as an HPLC-based method and 
carbohydrate-binding assay. The high performance liquid chromatography approach uses a 
fluorescently labelled Gα peptide to detect pertussis toxin activity as the PTx-modified Gα 
peptide elutes from the column faster than the unmodified form (Yuen et al., 2002). This method 
is highly sensitive and is excellent for detecting A-subunit activity, but does not address the 
binding capacity of the B-subunit that would be expected to be impaired following toxoiding. 
For this reason, this assay alone would be unsuitable as a regulatory assay. Therefore, a 
carbohydrate binding assay was later developed to take into account the binding of the PTd B-
subunit (Yuen et al., 2012). Here, bovine fetuin (Fet) or asialofetuin (AsFet) is used to coat a 96-
well plate and the capacity of PTd to bind to Fet/AsFet is determined using a HRP conjugated 
anti-PTx antibody. This combined with the HPLC based method accounts for both the enzymatic 
activity of PTx and the binding capacity of the toxin’s B-subunit. Together these assays may work 
well as a regulatory assay as toxoiding would be expected to compromise B-subunit 
carbohydrate binding. However, the problem that remains that they do not account for the 
efficiency of translocation, as only binding and enzymatic activity are accounted for. In the HIST 
assay, binding, translocation and enzyme activity are all required before an effect can be seen 
and the ideal replacement assay would also require all three events. Presented in this thesis, is 
an in vitro co-culture model based on a blood brain barrier model proposed in 2006 by Eugenin 
et al., which was initially used to assess the impact of inflammatory mediators on the BBB (Figure 
1.5). The assay developed here is not subjective like the CHO cell assay, it takes into account 
binding, translocation and enzymatic activity of PTx, unlike the HPLC/carbohydrate binding 
assays and no animals are required making it a suitable replacement for the HIST assay. 
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This method of model the distinct advantage of utilising only human derived cells, it takes into 
account binding translocation and toxin activity and it is not subjective. Furthermore, this assay 
could be developed into a quantitative assay capable of reliably detecting a range of PTx 
concentrations. Additionally, this model is readily adaptable and has the potential to be used to 
model a number of conditions linked to the integrity of the BBB. This includes the molecular 
mechanisms behind the interaction of the BBB and pertussis vaccine components as well as how 
the aP vaccine affects the integrity of the BBB.  
 
Figure 1.5: The in vitro model of the blood brain barrier proposed by Eugenin 
et al., 2006. Endothelial cells are grown on a permeable gelatin membrane 
until they form an impermeable barrier. Astrocytes are added to the other 
side and this induces the endothelial cells to express markers associated 
with endothelial cells of the BBB. This can then be placed in a test chamber 
and PBMCs are added. The permeability of the endothelium can be 
quantified by measuring the number of PBMCs that are able to cross the 
barrier. This was done by FACs analysis. 
Astrocyte 
Endothelial Cell 
PBMC 
Gelatin Membrane 
FACs 
Test chamber 
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1.6 Project aims 
The current safety test for pertussis-containing vaccines is the histamine sensitisation assay 
(HIST assay), it is an in vivo assay that requires large numbers of mice, is expensive and causes a 
high degree of suffering of the test mice. As a result of these shortcomings, the HIST assay has 
been deemed unacceptable; however, it cannot be replaced until a suitable alternative has been 
developed. Several attempts have been made, the CHO cell assay and enzyme linked HPLC are 
among the more successful, but these are still far from perfect. The CHO cell assay is semi-
quantitative and enzyme-linked HPLC only quantifies A subunit activity and not binding capacity 
of the B pentamer which is assayed in a separate test, neither assays for translocation. This 
research project seeks to build upon previous in vitro models used to investigate membrane 
permeability to establish new protocols for safety testing pertussis-containing vaccine products. 
The purpose of this assay was to develop a cell-based assay that may be used as an alternative 
to the HIST assay for detecting PTx in paediatric vaccines. The assay developed here is a co-
culture assay in which PTx induced permeability of Human Umbilical Vein Endothelial Cell 
(HUVEC) monolayers was measured and TNF-α secretion by PBMCs was investigated as a 
potential biomarker for PTx activity. The assay must be objective and it must take into account 
the three processes of binding, translocation and enzymatic activity involved in the action of 
PTx. Furthermore, the mechanisms by which PTx induces permeability in HUVEC monolayers 
was investigated using a number of functional microscopical techniques, including FRAP FLIM 
and fluorescent immunostaining to determine PTx activity within the HUVEC cells and what the 
effects of this activity has upon different junctional complexes of the HUVECs.   
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2.1 Introduction 
 
Pertussis toxin forms the basis of all licenced aP vaccines today. The vaccine always consists of 
toxoided pertussis toxin (PTd) as a base and various other antigens and adjuvants are added 
(Olin et al., 1998). There are two accepted methods of toxoiding pertussis toxin and its other 
virulence factors used in commercially available vaccines, either by chemical or genetic means. 
Each has advantages over the other. Chemical deactivation of B. pertussis’ virulence factors 
leaves the possibility that the active site may not be completely denatured, meaning that there 
may be residual toxicity (Donnelly et al., 2001), provided that the B pentamer retains its ability 
to bind to target cell. Residual toxicity is, in theory, solved by genetically detoxifying PTx.  
Chemical detoxification of PTx is essentially random and relies on the chemicals used, normally 
formaldehyde or glutaraldehyde denaturing the B subunit. The B subunit is pentameric and is 
responsible for binding to target cells and initiating retrograde transport of the A subunit across 
the plasma membrane, denaturation by chemical means prevents this from occurring. 
Denaturation is achieved by exposing the toxin to formaldehyde and glutaraldehyde for a 
significant length of time to ensure that it is sufficiently detoxified, although immunogenicity is 
reduced by this process (Di Tommasso et al., 1997). It should also be noted that glutaraldehyde 
is unable to inactivate the ADP-ribosyl transferase activity of PTx because of the lack of lysine 
residues in the active site for it to cross-link (Oh et al., 2013). This means that the toxoid still 
possesses ribosylating activity when only glutaraldehyde is used. It has also been shown that 
chemical detoxification with hydrogen peroxide does not denature epitopes to the same extent 
as glutaraldehyde and formaldehyde (Heron et al., 1999); furthermore, this method results in a 
well-tolerated vaccine (Thierry-Carstensen et al., 2013). Hydrogen peroxide deactivated PTd 
may be a better alternative to glutaraldehyde or formaldehyde detoxified PTd because the 
epitopes of the toxin are not damaged to the same extent (Sutherland et al., 2011), in terms of 
safety and immunogenicity.  
Genetic toxoiding is achieved by introducing substitution mutations in the active site of the A 
subunit, neutralising its activity resulting in an immunogenic toxoid comprising the A-subunit 
and an uncross-linked B-subunit. This should avoid the problem of residual toxicity. Additionally, 
it has been shown that protective antibodies against PTx are more effective when generated 
during natural infection. Formaldehyde treatment alters epitopes on the PTd molecule meaning 
it is not as well recognised by the immune system (Sutherland et al., 2011). The unaltered 
epitopes of a genetically toxoided PTd would solve this problem and this was demonstrated in a 
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study comparing antibody responses to chemically and genetically toxoided PTd (DiTommaso et 
al., 1997).  
There are several methods by which the activity of pertussis toxin may be assessed, perhaps the 
most common that are currently used are the HIST sensitisation assay and the CHO-cell assay. 
The HIST assay is currently the gold standard for safety testing pertussis containing vaccines. The 
assay itself is a lethal endpoint assay, the number of mice that are killed in response to histamine 
injection following PTx injection is used to determine if levels of residual toxicity are too high. It 
is very difficult to standardise because of its high variability (Xing et al., 2012) and requires large 
groups of animals to be used. Furthermore, histamine sensitisation by PTx in mice was first 
described in 1948 (Parfentjev & Goodline., 1948) and yet the mechanism behind it has remained 
undefined. These issues raise significant ethical questions relating to the continued use of this 
assay and as a result there have been some attempts to develop assays to allow us to move to 
in vitro alternatives. Possible candidates include the CHO cell assay which is highly subjective 
and is at best only semi-quantitative. Previously, two assays based on high performance liquid 
chromatography have been developed to determine the PTd molecules affinity for 
carbohydrates (Yuen et al., 2002 & 2010). Furthermore, there has also been another in vivo 
murine model developed using transgenic mice to study the effect of PTx induced inflammation 
in the brain (Schellenberg et al., 2012), however this has only been used in the context of 
research only.  
The purpose of this project is to design a human cell-based assay that is able to detect unsafe 
levels of pertussis toxin in final fill preparations of pertussis containing vaccines. The cell types 
utilised are Human Umbilical Vein Endothelial Cells (HUVEC), which were used to form the basis 
of a permeability assay (Figure 2.1), and Peripheral Blood Mononuclear Cells (PBMC). The 
mechanism of pertussis toxin induced permeability in endothelial cells will also be investigated 
and the PBMC element provides data on the immune interactions with endothelial cells when 
intoxicated with PTx and also makes the assay more representative of the physiological 
environment HUVECs are found in. Permeability assays have been used previously for 
investigating mechanisms of permeability of endothelial cells in response to various stimuli 
(Miyazaki et al., 2017 & Saker et al., 2014). Cytokine analysis was focussed on TNF-α secretion 
as this is a mediator of the proinflammatory response. 
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2.1.1 Objectives 
The main aim of this project is to develop a human cell-based (HUVEC) assay, with a clearly 
defined mechanism, that is a suitable as a candidate to replace in vivo pertussis vaccine safety 
testing. In the assay presented in this chapter, the hypothesis is that PTx induces permeability 
in endothelial cells by perturbing their ability to maintain tight junctional complexes. To 
investigate this hypothesis a permeability assay was designed to demonstrate permeability and 
immunostaining and transendothelial electrical resistance (TEER) was used to investigate tight 
junction functionality. Furthermore, reversion to toxicity or residual toxicity of PTx has been 
mooted as a potential cause of adverse events in pertussis-containing vaccines, even after 
treatment with 1% w/v formaldehyde pertussis toxin activity can be detected (Fowler et al., 
2003). 
  
Figure 2.1: The principle of the cell-based permeability used in the present 
study. Cells are cultivated in transwell inserts (Corning), before being 
treated with toxin (1). FITC dextran is then introduced (2) and the 
permeability resulting from the toxin treatment is quantified by measuring 
the dextran concentration in the lower chamber. 
Endothelial 
Cell 
Transwell 
membrane/insert 
1. PTx 
2. FITC-Dextran 
Fluorometric 
analysis 
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2.2 Materials and Methods 
2.2.1 Permeability assay development 
Human Umbilical Vein Endothelial Cells (HUVEC) were originally purchased from TCS Biologicals, 
Botolph Claydon, UK (product code: ZHC-2101) and maintained at NIBSC by Dr Jane Robinson, 
who gifted a cell bank to be used for this project. Stocks of HUVEC were maintained in T75 flasks 
using EGM-2 (Lonza, Slough, UK) for routine culture. For seeding and assaying cells in 
experiments a variety of media formulations were used (Table 2). Periodic Mycoplasma sp. 
testing was carried out by qPCR to ensure the cell cultures were not infected. 
The cells were seeded at three different densities: high = 5.5x103 cells/cm2 followed by two 10-
fold serial dilutions of this suspension to obtain medium = 5.5x102 and low = 5.5x101 cells/cm2 
(seeding densities were based on the manufacturer’s recommendations) cell seeding 
concentrations.  Some wells were also pre-coated with 10μg/cm2 fibronectin (Corning, NYC, 
USA) to aid the attachment of the cells to the transwell membrane, this was carried out 
according to the manufacturer’s instructions. 50μl of these suspensions were seeded on to a 24 
well HTS transwell plate (Corning, NYC, USA) made of polystyrene with 0.4μm pores. The 
membranes had been soaked in media for one hour prior to seeding. The volumes of media 
added to the upper and lower chamber were recommended by the manufacturer. Following 
seeding, the plates were incubated for 24 hours at 37°C with 5% CO2. A previous study had 
shown that this incubation time is enough for PTx to internalise and act upon the cells (Tan et 
al., 2013). The cells were cultured and assayed in the same media, initially EBM-2 with 2% or 5% 
FCS and subsequently only EBM-2 with 2% FCS. 50μl was added to the upper transwell chamber, 
resulting in a 1:1 dilution with the existing media. The monolayers were assayed using FITC 
dextran (10kDa, sigma) where the final concentration of dextran in the upper chamber of each 
well was 40μg/ml. The plates were then incubated for 4 hours before sampling. The plates were 
sampled following incubation by removing 50μl from the lower chambers of the transwell 
system and using a fluorescent plate reader to obtain the relative fluorescence intensities 
(Ex/Em: 480/520). These were normalised by comparing to the values obtained from a standard 
curve. 
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2.2.2 Detecting DTaP5-IPV-Hib Induced Permeability 
Cells were seeded in 2% FCS EBM-2 in transwell inserts on a 24 well HTS transwell plate and the 
transwell membranes had been coated with 10μg/cm2 fibronectin, the HUVECs were seeded at 
a cell concentration of 5.5 x 103 cells/cm2. Post seeding, the plates were incubated for 48 hours 
before treatment (Table 3). PBMCs were simultaneously added to some of the transwells; the 
isolation of these cells is described below, under “PBMC isolation”. The co-cultures were then 
incubated for 24 hours to allow the toxin to take effect. The final incubation period where 
treatments and dextran are added was extended to 24 hours in one experiment. Finally, the 
incubation period post seeding was shortened to 24 hours to allow a longer incubation with 
toxin. Phase contrast microscopy was used to determine that 25ng/ml PTx was an appropriate 
dose. The effects of 100, 50, 25, 12.5 and 6.25 ng/ml PTx upon HUVEC monolayers cultured in 
35mm petri-dishes. 25ng/ml was chosen because it was not enough to destroy the monolayer, 
but it was sufficient to induce morphological changes that could indicate distress.  All of the 
above were carried out in duplicate. Live/dead staining was also carried out using NucBlue 
nuclear stain (Life Technologies) and propidium iodide (Life Technologies, OR, USA) to confirm 
that the cells were still alive post treatment and to assess the distribution of the cells upon the 
transwell membrane. 
Table 2: Final concentrations of components of DTaP5-IPV-Hib treatments.  
Antigen Concentration1 
Diphtheria toxoid 30Lf/ml2 
Tetanus toxoid 40Lf/ml 
Pertussis toxoid3  20μg/ml 
Filamentous haemagglutinin 20ug/ml 
Pertactin 3ug/ml 
Fimbriae 2 & 3 5ug/ml 
Inactivated polio virus type 1, 2 & 3 40, 8, 23 units/ml 
Haemophilus influenzae type B 
polyribosylribitol phosphate 
10ug/ml 
1Concentrations were based on PEDIACEL© manufactured by Sanofi Pasteur 
 2Lf/ml – flocculation units/ml  
      3Toxoid prepared outside NIBSC using formaldehyde 
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A 50μl sample was taken from the lower well of the transwell system and the supernatant was 
removed from the upper chamber and frozen for determining TNF-α concentration by ELISA 
(described in Chapter 3) at a later time (TNF-α ELISA originally published by Findlay et al., 2010). 
The removed supernatant was replaced with modified EBM-2 containing 40μg/ml 10kDa FITC 
dextran was overlaid and incubated for a further 4 hours. Sampling was performed as previously 
described and samples were read using a fluorescent plate reader, also as previously described. 
 
2.2.3 PBMC Isolation 
PBMCs were then isolated from fresh whole blood donated by NIBSC staff. To be eligible to 
donate, donors must consider themselves healthy, i.e. free of infection for at least two weeks, 
they must not have taken anti-inflammatory drugs for 4 days before blood is withdrawn and 
they must not be pregnant. Gender is not considered when blood is taken. Whole blood was 
layered on to Histopaque 1077 (Sigma) and centrifuged at 340 x g for 45 minutes at 22°C. The 
PBMCs were removed and transferred to a new centrifuge tube and washed twice in PBS before 
being re-suspended in assay medium and left to rest in the incubator for 30 minutes before 
counting (trypan blue exclusion method). The cell concentration was adjusted so that 1x105 
PBMCs were added per well in a 96 well plate. Existing media was removed from the wells and 
either PBMC suspension or fresh media for HUVEC only wells was added to the appropriate wells 
according to the plate layout. 
 
2.2.4 Transendothelial resistance measurements 
HUVEC cells were cultured according to the method detailed above, with the exception that for 
the purpose of TEER measurement they were cultured in 6 well transwell inserts. These 
monolayers were treated with 25ng/ml PTx or 25ng/ml PTd or were left untreated and 
incubated for 24 hours. The inserts were removed from the plate and placed in the electrode 
cup linked to an EVOM voltohmmeter (both World Precise Instruments, Sarasota, FL, USA) and 
resistance measurements were taken. Due to constraints on the number of wells the treatments 
were done in duplicate and one reading was taken from each well. The final data set is collated 
data from 3 experiments. 
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2.2.5 Immunostaining and Confocal Imaging 
HUVEC cells were cultured on glass coverslips (No. 1.5) and allowed to reach confluence before 
being treated with PTx or PTd. After treatment, the cells were fixed with 4% paraformaldehyde, 
permeabilised with 0.3% Triton X-100 in PBS and stained with mouse anti human ZO-1 
monoclonal antibodies conjugated to Alexa Fluor 594 (Life technologies, 239914, Eugene, OR, 
USA). These antibodies were incubated for 2 hours at room temperature. The cells were then 
stained with Hoechst 33342/33258 and mounted to a microscope slide using Citifluor AF1 
(Citifluor, Hatfield, PA, USA) anti-fadant mounting media. The coverslips were glued in place 
using nail varnish.  
The slides were imaged using a Leica SP8 confocal microscope (Leica GmbH, Wetzlar Germany) 
equipped with a 63x oil immersion objective lens (N.A 1.4). 5 randomly selected Z-stacks were 
collected for each treatment group from the whole area of the coverslip for each treatment 
group. Maximum projections of these Z-stacks were then analysed by counting the number of 
red pixels and the number of nuclei using ImageJ. The number of red pixels was divided by the 
number of nuclei to give a ratio of the relative volume of ZO-1 signal per cell in each treatment 
group. 
 
2.2.6 Confirming PTx Activity 
To ensure these results can be attributed to PTx activity it was important to confirm that there 
was PTx activity within the cell. To achieve this, cells were exposed to PTx and PTd before being 
lysed in a solution of 2% Triton X-100. The lysates from untreated cells, PTx-treated cells and 
PTd-treated cells were normalised using the Pierce BCA protein assay (ThermoFisher, MA, USA) 
to ensure analysis was performed on comparable volumes of sample. Cyclic adenosine 
monophosphate (cAMP) was assayed using a commercial colorimetric kit (Abcam, Cambridge, 
UK) to ensure PTx was active within the cells. 
 
2.2.7 Statistical Analysis 
For determining statistical significance with respect to cell seeding densities and fibronectin 
coating, an ANOVA was performed. However, it was inappropriate to perform post hoc testing 
because of interaction between the “cell concentration” and “fibronectin coating” variables. 
Therefore, interaction analysis was used to analyse this data instead (Appendix 2). All data from 
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all permeability assays used to determine effects of DTaP-IPV-hib and PTx was pooled so to allow 
robust statistical analysis. The data was analysed using a generalised linear model fitting Log10 
response (dextran allowed to pass through the monolayer) against “cell” (the treatment groups) 
as fixed effect and “assay” as a random effect. A one-way ANOVA was performed to establish 
significant differences between treatment groups. Thus, Tukey’s multiple comparison test was 
performed to test for significant differences between treatments. For cytokine data, the data 
was modelled again using log response (TNFα secretion) with donors taken as random effect 
and treatment groups as fixed; one way-ANOVA followed by Tukey’s multiple comparison test 
was performed. “DTaP-IPV-Hib” and “DTaP-IPV-Hib + PTx” were tested both with and without 
HUVECs present. One-way ANOVA with Tukey’s post-test was performed on the image analysis 
data, the cAMP activity data and TEER data. 
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2.3 Results 
2.3.1 Development of Culture Conditions 
Early results showed that the HUVEC monolayer was extremely permeable to 10kDa dextran, 
reaching levels comparable to transwell inserts were no cells had been seeded. This made it vital 
to conduct experiments to establish the optimum culture conditions that would allow a 
confluent monolayer to be formed. Therefore, several experiments were conducted to 
determine the effect of attachment media, cell concentration and foetal calf serum 
concentration in the EBM-2 media used for the permeability assay. 
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Figure 2.2: Permeability of HUVEC monolayers to 10kDa dextran 
molecules. Three cell concentrations were used upon initial seeding: 
High: 5.5x103cells/cm2, Medium: 5.5x102cells/cm2 and Low: 
5.5x101cells/cm2. These cell densities were used in both transwells that 
had been coated with 10μg/cm2 fibronectin and those that had not. “No 
cells” indicates dextran transit in transwells that had not been seeded 
with cells and represents the maximum possible volume of dextran 
transported to the lower chamber of the transwell system. n=3 
duplicate experiments, error is SEM. 
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Figure 2.2 shows that when a high seeding density is used, pre-coating the transwell inserts with 
fibronectin resulted in the HUVECs forming a monolayer that was less permeable than the than 
the equivalent seeding density where transwells were not pre-coated. This trend also reflected 
in the comparison between the “medium” seeding densities, where addition of fibronectin 
results in a less permeable membrane, albeit to a lesser extent. To determine the statistical 
significance of this data, a one-way ANOVA was employed to assess the data set for significant 
differences. The results of this statistical analysis indicated that there were significant 
differences present within the dataset. However, it also showed that there was a statistical 
interaction between variables in the sample, therefore rendering one-way ANOVA an 
inappropriate means to test for statistical significance. Therefore, an interaction analysis of the 
variables (seeding density and fibronectin addition) being tested was performed to analyse this 
data (Figure 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High 
Medium 
Low 
+ Fib 
- Fib 
High Medium Low 
Figure 2.3: Interaction analysis of the influence of seeding density and 
fibronectin on HUVEC monolayer generation. Top right panel: Comparison of 
seeding densities and influence of fibronectin on HUVEC monolayer 
permeability; A – fibronectin coated inserts and B – without fibronectin. 
Bottom left panel: Comparison of fibronectin presence and influence of 
seeding density on HUVEC monolayer generation. Blue solid line - with 
fibronectin; red dashed line – without fibronectin. 
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The interaction analysis (Figure 2.3) showed that both pre-coating the transwells with 
fibronectin and increasing the seeding density results in improved performance of the 
monolayer as a barrier. The green and red dashed lines in the top right hand panel suggest that 
fibronectin decreases the permeability of the HUVEC monolayer to 10kDa dextran. The solid 
blue line suggests that increasing the seeding density above a given threshold drastically 
improves the performance of the monolayer as an impermeable barrier. Complementary 
analysis of the effects of seeding density (Figure, 2.3, Bottom left panel) confirm the results 
alluded to in the top right hand panel. Increasing the seeding density was shown to decrease 
the permeability of the HUVEC monolayer to the dextran tracer when the transwells had not 
been coated with fibronectin. Pre-coating the transwell inserts prior to seeding reduced the 
permeability by a similar magnitude in the wells seeded with the medium and low seeding 
densities, however, when the inserts were seeded with the high seeding density the reduction 
in permeability was magnified. The interaction analysis of the data confirmed that fibronectin 
decreases the permeability of a HUVEC monolayer to 10kDa dextran, but only if the cell seeding 
density is high enough, in this case 5.5x103cells/cm2. Therefore, the higher cell density and pre-
coating with fibronectin were used for subsequent experiments. 
Further development of the culture conditions was conducted with regard to supplementing the 
media used to generate the monolayers. This was important as the recommended media for 
culturing endothelial cells is Clonetics Endothelial Growth Media-2 (EGM-2, Lonza). This media 
contains many supplements intended to aid the development of endothelial cell cultures. 
However, as this model was intended to be a co culture model it was unknown how these 
supplements would influence the interaction of the HUVEC cells with the peripheral blood 
mononuclear cells (PBMCs) that would be added later on. How the EGM-2 media supplements 
influenced the PBMCs responses to treatments was also unknown. Therefore, experiments were 
carried out to determine a media formulation that would allow a HUVEC monolayer to be 
generated and that was compatible with PBMCs. Early experiments showed that RPMI + FCS + 
L-glutamine (Sigma) was not suitable for culturing HUVEC cells. Therefore, Clonetics Endothelial 
Basal Media (Lonza) was used and the growth supplements were not added. Instead, L-
glutamine and either 2% or 5% foetal calf serum were added to the media (Figure 2.4). 
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There was no obvious difference in the performance of monolayers that had been cultured in 
2% or 5% FCS in EBM-2 and this was confirmed by statistical analysis of the data by one-way 
ANOVA with Tukey’s multiple comparison test post hoc. The one-way ANOVA test did not 
indicate any synergistic interaction between seeding density and FCS content of the media, 
indicating that it is irrelevant whether the concentration of FCS in the EBM-2 is irrelevant. 
Therefore, 2% FCS EBM-2 + L-glutamine media was used from this point forward as this is the 
FCS concentration recommended by media manufacturers. 
 
2.3.2 Permeability Induced by DTaP5-Hib-IPV Vaccine 
After successful generation of a HUVEC monolayer, a pertussis-containing vaccine and PTx were 
compared in terms of their ability to induce permeability in the HUVEC monolayer. The 
pertussis-containing vaccine was prepared from individual stocks of bulk vaccine components 
from manufacturers of vaccines themselves. The pertussis antigens contained in the vaccine are: 
pertussis toxoid (PTd), filamentous haemagglutinin (FHA), pertactin (prn) and fimbriae (2/3). The 
Figure 2.4: Analysis of the effect of varying FCS content of the EBM-2. Two 
concentrations of FCS were used and these were tested against the same 
seeing densities as before. All transwells were coated with fibronectin prior 
to seeding. n = 3 duplicate experiments, error is SEM. *** = p≤0.001, ** = 
p≤0.01, * = p≤0.05. 
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non-pertussis antigens include diphtheria toxoid, tetanus toxoid, Hib polyribosyl ribitol 
phosphate and inactivated polio virus. These components are formulated together and form the 
DTaP5-Hib-IPV vaccine. The hypothesis was that PTx would increase the permeability of the 
HUVEC monolayers both as a single treatment and as a spike in the vaccine preparation.  
 
Permeability of HUVEC monolayer after
exposure to DTaP-Hib-IPV vaccine
N
o
 C
e
ll
s
U
n
tr
e
a
te
d
 c
e
ll
s
V
a
c
c
in
e
 
V
a
c
c
in
e
 +
 t
o
x
in
P
e
rt
u
s
s
is
 t
o
x
in
0
2
4
6 ***
***
***
***
Treatment
D
e
x
tr
a
n
 (

g
/m
l)
 
 
 
 
 
Assaying this vaccine using the permeability assay developed here (Figure 2.5) showed that 
while the vaccine induced some permeability compared to the untreated control, this was not 
of statistical significance. In contrast, the addition of 25ng/ml PTx induced a much larger increase 
in the concentration of dextran able to traverse the monolayer, which was shown to be 
significant by one-way ANOVA with Tukey’s test. Furthermore, significantly more permeability 
Figure 2.5: Permeability of HUVEC monolayer after treatment with 
formulation of DTaP-IPV-Hib and pertussis toxin. Tested by One-way ANOVA 
with Tukey’s multiple comparison test post hoc. n=9 triplicate experiments 
performed on different days. Whiskers are maximum and minimum values... 
*** = p≤0.001, ** = p≤0.01, * = p≤0.05. 
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was observed in the vaccine + PTx group as opposed to the vaccine alone group, indicating that 
this assay is able to distinguish between vaccine containing PTx and one that does not. 
I a further development of the assay, primary PBMCs were added to the permeability model to 
more closely match physiological conditions of the human body. These provided an opportunity 
to study how the PBMCs responded to treatment in terms of the cytokines that they produce 
and how they influence the permeability of the monolayer after treatment with a pertussis-
containing vaccine preparation (Figure 2.6). 
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Figure 2.6: Permeability of HUVEC monolayer after co-incubation with 
primary PBMCs and treatment with a formulation of DTaP-IPV-Hib and 
pertussis toxin. Tested by One-way ANOVA with Tukey’s multiple 
comparison test post hoc. n=23 triplicate experiments performed on 
different days. Whiskers are maximum and minimum values.  *** = p≤0.001, 
** = p≤0.01, * = p≤0.05. 
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Addition of the PBMCs to the permeability assay did not change the ability of the assay to detect 
untoxoided pertussis toxin when vaccine + PTx or PTx are compared to untreated cells. The 
trends that can be observed in the co-culture assay are very similar to the HUVEC only assay 
However, in the co-culture permeability assay, the vaccine induced significantly increased 
permeability compared to untreated cells and was no longer significantly different to the 
permeability induced by PTx (Figure 2.6). This indicates that PBMCs are complicating the use of 
this system as a means to detect pertussis toxin, if permeability is to be considered as the 
principle means by which to detect pertussis toxin. However, direct comparison between the 
vaccine treated groups in co-culture and with only HUVECs, there is no significant difference, 
this is also the case for all the other treatment groups (Figure 2.7). 
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Figure 2.7: Comparison of permeability of HUVEC monolayer only (green) 
and with co-incubation with primary PBMCs (red). Treatment with a 
formulation of DTaP-IPV-Hib and pertussis toxin. Tested by One-way ANOVA 
with Tukey’s multiple comparison test post hoc. n=23 triplicate experiments. 
Whiskers are maximum and minimum values. No differences between 
HUVEC only and co-culture treatment groups reached significance. 
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Comparative analysis of the co-culture and HUVEC only permeability assay showed that the 
permeability assay was perhaps more sensitive to PTx when run without PBMCs. Permeability is 
consistently increased in HUVEC/PBMC co-cultures compared to HUVEC only permeability 
assays (Figure 2.7), however these differences are merely a trend and none reached statistical 
significance. The HUVEC only assay is of course less akin to the physiological conditions found in 
a human and means that this model, while better for detecting PTx, means that no cytokine data 
can be generated. The in vitro nature of both these assays means it is difficult to translate the 
results here into mechanism behind vaccine related adverse events, perhaps an in vivo model 
for research purposes would better suited.  
 
2.3.3 Mechanism of PTx Induced Permeability 
Paracellular permeability in endothelial cells is normally to some extent controlled by the 
regulation of tight junction complexes between adjacent cells. Therefore, tight junction 
complexes between HUVEC cells were studied after treatment with either PTx or its chemically 
detoxified analogue pertussis toxoid (PTd). There were two approaches taken to study the 
effects of pertussis toxin upon tight junction complexes in HUVEC cells, analysis of 
transendothelial electrical resistance (TEER) and immunofluorescent staining. These approaches 
take into account the functionality of the tight junction complexes present between the HUVECs 
and immunostaining allows the distribution of these complexes to be discerned. 
Loading live cells cultured on transwell inserts with calcein AM live cell stain (Life technologies) 
showed that obvious gaps had opened between the cells after exposure to PTx (Figure 2.8). 
These gaps are indicative of a loss of the cells’ ability to associate with one another in a structural 
sense, therefore pointing towards dysregulation of junctional complexes between the cells.  
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Figure 2.8: Widefield fluorescent image of cells cultured on transwell 
inserts. Evenly distributed and confluent cells. Cells were alive at the 
time of imaging and TEER measurements had been collected. Cells are 
untreated (left) or treated with either PTx (centre) or PTd (right). 
Stained with Calcein AM (Life Technologies) and imaged using 
widefield fluorescence microscope (Leica Microsystems). The white 
circles in the images of untreated cells and PTd-treated cells show 
areas in each image where the cells are confluent and the white arrows 
in the image of cells treated with PTx show examples of voids that have 
opened up between the cells. 
Untreated cells 
Pertussis toxoid Pertussis toxin 
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To quantify the deleterious effect that PTx has upon junctional interactions between the cells, 
TEER measurements were taken. TEER is a measurement of the electrical resistance of a given 
cell monolayer cultured in a transwell insert. A monolayer’s resistance originates from the 
volume of functional tight junctions that are present between the cells. A functional tight 
junction will inhibit the movement of ions via the paracellular route and therefore increase the 
resistance of the monolayer as a whole. The units of TEER are given as ohm square centimetres 
(Ωcm2), reflecting the inverse relationship between resistance and the surface area of the cell 
monolayer.  
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Untreated HUVECs were found to have a mean TEER of 62.6Ωcm2 which was significantly 
different to the resistance measurements taken from cell monolayers that had been exposed to 
PTx, which were found to have a mean TEER of 48.6Ωcm2 (Figure 2.9). PTd-treated monolayers 
were found to have a mean of 58.8Ωcm2, which was not significantly different to that of the 
Figure 2.9: Transendothelial resistance measured using an EVOM 
voltohmmeter and ENDOHM-24 electrode (both WPI). Results are 
representative of five duplicate experiments performed on different 
days. Results were tested by one-way ANOVA with Tukey’s test to 
determine significance. Whiskers are maximum and minimum values. 
*** = p≤0.001, ** = p≤0.01, * = p≤0.05. 
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untreated HUVECs. Similarly, the PTd-treated cells offered significantly more resistance than the 
PTx-treated cells, but this difference was significant to a lesser extent than the difference 
between untreated cells and PTx-treated cells (Figure 2.9). These results are indicative of 
reduced tight junction functionality induced by the action of PTx and suggest that these 
complexes are under the control of pertussis toxin-sensitive G-proteins. 
Further investigation into the effect of PTx upon the tight junction complex was done by 
immunofluorescent staining of a protein marker of the tight junction complex, Zonula Ocludens-
1. ZO-1 was chosen as a marker for tight junction distribution because is an integral part of the 
tight junction. Its function is to interface the whole tight junction complex with the cells’ actin 
cytoskeleton, in effect anchoring the tight junction in place and enabling the cells to form strong 
associations with one another. Fluorescent staining of the ZO-1 in untreated HUVEC cells 
showed that the protein was regularly distributed around the perimeter of the cell with some 
diffuse signal originating from the cytoplasm (Figure 2.10). 
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A similar distribution was observed in the cells treated with PTd, although the ZO-1 appeared to 
be less evenly distributed. Both are in contrast to the PTx-treated HUVEC monolayer (Figure 
2.10) where there was little ZO-1 deposited around the plasma membrane and the gaps 
between the cells appeared even more pronounced than they had in Figure 2.9. Due to the 
apparent difference in the volume of Alexa Fluor 594 signal from the ZO-1, the volume of ZO-1 
signal was quantified in terms of red pixels per cell. This was done by using ImageJ to count the 
number of nuclei and the number of red pixels, these figures were divided together to produce 
a ratio of ZO-1 signal/cell. The analysis of the images shows that there is significantly more red 
Untreated cells 
Pertussis toxin Pertussis toxoid 
Figure 2.10: HUVEC monolayers cultured on glass coverslips and 
treated with PTx or PTd. Cells are immunostained with AF594 
conjugated monoclonal antibody (mouse anti-human ZO-1) (Life 
Technologies; 239914. Image is 512x512 pixels with 8-bit colour depth, 
taken using Leica SP8 equipped with a 63x 1.4 N.A. oil immersion lens. 
6 Z-projections of each treatment group were taken from 3 slides 
prepared on different days. 
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signal detected in untreated cells than in either PTx-treated cells and PTd-treated cells (Figure 
2.11).  The volume of signal detected in the PTd-treated cells was still significantly more than 
that detected in the PTx-treated cells. 
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Figure 2.11: Analysis of the number of red pixels (ZO-1 signal) per nucleus. 
The number of red pixels in the field of view was divided by the number of 
nuclei in the field of view for each maximum projection. The results were 
compared using a one-way ANOVA with Tukey’s test. n=6 images, taken on 
the same day form slides prepared on different days. Whiskers are maximum 
and minimum values. *** = p≤0.001, ** = p≤0.01, * = p≤0.05. 
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2.3.4 Confirming Intracellular PTx Activity 
Increased cAMP levels are a hallmark of PTx activity as PTx inhibits the action of G-proteins that 
are responsible for inhibiting cellular adenylate cyclase. Therefore, PTx activity will result in 
elevated cAMP levels. Results in this study showed that this was the case, cAMP levels were 
elevated in cells that had been treated with PTx, PTd-treated cells showed slightly elevated 
cAMP expression compared to controls, however this did not reach significance (Figure 2.12). 
Cells that had been treated with PTx were shown to have significantly elevated levels of cAMP 
(p≤0.001 vs. untreated cells and PTd-treated cells). These results show that PTx was active within 
the HUVEC cells and that the permeability and tight junction disruption can be attributed to PTx 
activity within the HUVECs. This assay was a commercial kit manufactured by Abcam in the UK. 
The minimum sensitivity is >0.02µM according to the datasheet. This assay was done to make 
sure that the PTx was acting as expected and not with use as a regulatory assay in mind. 
Therefore, it was not used to test the whole vaccine preparation. Although, it may be very suited 
for this purpose. 
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Figure 2.12: Analysis of cAMP levels in untreated cells and cells treated 
with PTx or PTd. Results are from 3 triplicate experiments performed 
on different days. The results were compared using a one-way ANOVA 
with Tukey’s test. Whiskers are maximum and minimum values. *** = 
p≤0.001, ** = p≤0.01, * = p≤0.05. 
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2.4 Discussion 
The ultimate aim of the experiments described here was to develop a permeability assay capable 
of detecting PTx activity in pertussis-containing vaccines. It is important that these types of 
quantitative in vitro assays are developed to address the ethical concerns surrounding the HIST 
assay, currently used as the safety test for pertussis-containing vaccines. The current HIST assay 
is based on the increased sensitivity to histamine experienced by mice following intraperitoneal 
injection of PTx (Isbrucker et al., 2014). There are several problems associated with this assay, 
from an ethical standpoint the large variation of responses observed requires large numbers of 
mice and that the endpoint of the assay is death by anaphylaxis. Furthermore, the cost of the 
animals and all the associated costs of the animal husbandry must be taken into consideration. 
Also, the exact mode of action of the assay is unknown. Furthermore, the current HIST assay is 
precisely the kind of assay that is targeted for replacement under the three Rs strategy, designed 
to reduce the number of animals used in scientific research. For these reasons several attempts 
have been made to develop an assay capable of detecting PTx in pertussis-containing vaccines 
(Isbrucker et al., 2014). The CHO cell assay is a good example of an in vitro bioassay that has 
been used to assess vaccines for active PTx content; however, this assay is highly subjective and 
is only semi-quantitative at best (Xing et al., 2002). Other approaches include carbohydrate 
binding assays (Yuen et al., 2002) which determines the affinity of the B-pentamer for 
carbohydrates after completion of the toxoiding process. In theory, this should be successful as 
it quantifies the binding capacity of the PTx B-pentamer, which has been cross-linked by 
glutaraldehyde or formaldehyde during the toxoiding process. The chemical treatment of the 
toxin lowers the affinity of the pertussis toxoid proteins to the carbohydrates (Rappuoli, 1994) 
and therefore, PTx should be differentiated thanks to its higher binding capacity. In practice, this 
was not successful as the PTd bound successfully to the selected carbohydrate substrate. An 
enzyme-linked HPLC assay has also been developed to quantify the enzymatic activity of the PTd 
molecule but does not account for B-pentamer binding, therefore, a carbohydrate binding assay 
was run concurrently (Yuen et al., 2010). This approach yielded promising results, however there 
are still issues that must be addressed. Such as significant variations in results of test samples 
originating from the same batch of vaccine, these variations are rarely seen in the HIST assay. 
Therefore, given the ethical problems surrounding the HIST assay and the ongoing practical 
issues with current in vitro alternatives, this project proposed to develop a cell-based bioassay 
capable of detecting unacceptable concentrations of PTx in pertussis containing vaccines.  
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The work presented here is the development of a permeability assay that could be used to 
detect active PTx in vaccine preparations. Furthermore, this study seeks to shed light on the 
mechanism behind permeability induced by PTx. It is already known that PTx inhibits G-proteins 
(Morgan et al., 1990) resulting in unregulated increases in cytoplasmic cAMP concentration, but 
how are the junctional complexes responsible for maintaining the endothelial barrier affected 
by this? Before this question could be answered, the cell culture model had to be developed. 
The first stage in this process was to develop a protocol that would allow the HUVEC cells to 
form a confluent monolayer upon transwell inserts. HUVECs have been used for similar purposes 
in many previous studies (de la Rosa et al., 2003, Hordijk et al., 1999 & Wittchen et al., 2005). 
HUVECs were chosen for this study as they are relatively easy to handle and express the key 
proteins of interest in terms of the junctional proteins that are key to the formation of an 
effective endothelial barrier (Lee et al., 2006), this complex functions in similar ways in brain 
microvascular cells (Verma et al., 2009). Transwell inserts were on a 24-well plate and the inserts 
themselves were manufactured from polystyrene and had a pore size of 0.4μm. This pore size 
ensured that the 10kDa dextran traced molecules could pass through the membrane but that 
the HUVECs would not be permitted to enter the lower chamber of the transwell system. Initial 
experiments demonstrated that the HUVECs would group around the edges of the insert, leaving 
large gaps near the centre. Two strategies were adopted to address this issue; firstly, the 
transwell inserts were coated with 10μg/cm2 fibronectin prior to seeding and secondly, the 
seeding density was altered to obtain a density that would allow confluence to be reached. 
Fibronectin binds to integrins present on the outside of the HUVEC plasma membrane and 
ensures that the HUVECS efficiently adhere to the surface (Keselowsky et al., 2003). Seeding 
density ensures that the cells have close enough proximity to one-another to send and receive 
the appropriate signals to stimulate cell growth and monolayer formation (Sipehia et al., 2009). 
The optimum seeding density was found to be 5.5x103cells/cm2 (Figure 2.4). This seeding density 
improved the performance of the cell monolayer when assayed with 10kDa FITC-dextran even 
in inserts that had not been coated with fibronectin. However, statistical analysis of the relative 
contribution of these factors (Figure 2.3) showed that this seeding density acted in combination 
with fibronectin to produce a monolayer that was an effective barrier to the dextran tracer. 
Total exclusion of dextran from the lower chamber is unrealistic given the inherently leaky 
nature of endothelial cells, therefore the performance of the monolayer under the optimum 
conditions (Figure 2.2) showed quantifiable and statistically different permeability rates with 
different treatments versus controls, and was therefore was deemed acceptable. The passing of 
dextran through the control HUVEC monolayer has been observed in other studies (Lal et al., 
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2001 & Talavera et al., 2004). To ensure FCS concentration was not a limiting factor in the 
generation of the cell monolayer, experiments were conducted to determine if EBM-2 
containing 2% or 5% FCS was optimum. It is important not to add too much FCS to the media as 
the readily available nutrients can alter the cells’ growth rate and can cause them to overgrow, 
which would confound the results of the assay. Here, no difference was found in the 
permeability of cells cultured in EBM-2 containing 2% or 5% FCS. This demonstrates that FCS is 
not limited in EBM-2 containing 2% FCS and confirmed that this was an appropriate 
concentration and suitable growth conditions for the study design.   
Following successful generation of a HUVEC monolayer, the permeability induced by a pertussis 
containing vaccine preparation was quantified. The HUVEC monolayers were cultured overnight 
and the following day an in-house preparation of DTaP-IPV-Hib was added to appropriate 
transwell inserts. Some of this vaccine preparation was spiked with 25ng/ml PTx to represent a 
batch of vaccine containing PTx. Results showed (Figure 2.5) that, fundamentally, this assay is 
capable of detecting pertussis toxin present in the vaccine preparation. The HUVEC monolayers 
treated with vaccine + PTx and PTx were both significantly more permeable than both the 
untreated cell monolayers and the cell monolayers treated with vaccine alone. Despite toxoiding 
of PTx, some adverse vaccine – associated effects are to be expected (Decker et al., 1995). In 
this study, the vaccine induced a slight elevation in the mean permeability of the HUVEC 
monolayers. Although this did not reach statistical significance versus the untreated cells, it 
indicates some residual activity which may explain some of the more common adverse events 
such as swelling and redness associated with pertussis-containing vaccines as these are likely 
due to increased permeability of endothelial barriers around the injection site (Anh et al., 2016). 
Furthermore, in the results presented here (Figure 2.5) HUVEC monolayers treated with vaccine 
alone were not statistically different to those treated with PTx alone. Rather than this being 
indicative of synergistic interaction between active PTx and vaccine components, the lack of 
statistical significance is more likely the result of a relatively large variation in the PTx treatment 
group. 
The HUVEC monolayer alone was demonstrated to be an effective means by which to detect 
PTx; however, this is not representative of the physiological environment in which HUVECs are 
found. Therefore, peripheral blood mononuclear cells were added to more closely match these 
conditions. The advantages of this are two-fold, firstly it is possible to discern the influence of 
the PBMCs upon permeability of the HUVEC monolayer and it is possible to determine if PTx 
induces inflammation originating from PBMCs. The PBMCs were prepared in the same EBM-2 + 
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2% FCS + 10mM L-glutamine that the HUVECs had been cultured in. The protocol was developed 
in such a way as to minimise the disturbance of the HUVEC monolayer which had been seeded 
on the previous day and allowed to reach confluence in the incubator overnight. The results of 
the permeability assay as a co-culture of HUVECs and PBMCs were broadly similar to the assay 
where HUVEC only monolayers were used. The PBMCs were expected to enhance the 
permeability induced by the PTx based on previous studies in this area (Seynhaeve et al., 2014). 
The main differences occurred in the vaccine only treatment group, which was shown to induce 
a greater degree of permeability than the baseline level determined by the untreated 
monolayers (p≤0.05) and was not significantly different to either the PTx only or vaccine + PTx 
treatment groups. Further analysis showed (Figure 2.7) that the permeability was clearly altered 
by the presence of PBMCs as the permeability is consistently increased in cells that had been co-
incubated with PBMCs regardless of treatment. It is possible that this increase in permeability is 
a result of some interaction between the PBMCs and the HUVECS, either via direct contact or 
via molecules secreted into the local environment. It is known that leukocytes and endothelial 
cells share a close relationship with one another, interacting via several molecules including 
cytokines, integrins and sphingosine molecules (Wang et al., 2013, Kawamoto et al., 2016 & 
Spampinato et al., 2016). It is also likely that the PBMCs themselves were serum shocked 
following isolation from whole blood. The transition from the blood stream of an organism to 
cell culture medium is a substantial alteration to the environment of the PBMCs and should not 
be underestimated. It was understood that this might be the case at the time that these 
experiments were conducted and as such care was taken to minimise the disturbance of these 
cells as they were isolated and processed. However, it cannot be guaranteed that the change in 
conditions had no effect on the behaviour of the PBMCs. Therefore, the addition of PBMCs to 
this assay represented some potential complications to the assay. However, the experimental 
design would be of benefit in terms of cellular physiological conditions. While this is interesting 
from a research point of view, it is not ideal if this assay is to be used to determine levels of 
active PTx present in samples of vaccine. Furthermore, PTx-induced permeability seen in the co-
culture assay was not significantly greater than when HUVECs were left treated alone (Figure 
2.7) but the, variance within the co-culture assay was greater, which may compromise sensitivity 
of the permeability assay and make discerning small changes in the concentration of PTx more 
difficult. Therefore, PBMCs were subsequently removed from this assay and the mechanism by 
which PTx induces permeability in the HUVECs alone was investigated. 
It was postulated that PTx induces permeability via the paracellular route by affecting the 
HUVECs’ ability to regulate tight junction organisation. As tight junctions are regulated by G-
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proteins (Chishiki et al., 2017), it was expected that PTx would induce changes to the 
organisation of the junctional complex. The dysregulation of tight junctions was investigated 
using both immunostaining to assess the distribution of the tight junctional complex and 
measurement of TEER to quantify the relative density of functional tight junction complexes 
present across the transwell insert as a whole. TEER is an effective means of quantifying tight 
junction functionality that has been used in several studies (Wang et al., 2016, Kuo et al., 2013). 
In the present study, the cells were treated with PTx or PTd to allow a direct comparison of PTx 
against its chemically toxoided analogue. The results of the TEER measurements indicated that 
PTx reduced the density of functional tight junctions present in the monolayer. The resistance 
of the monolayer significantly decreased after PTx treatment (p≤0.001 and p≤0.01 vs. untreated 
cells and PTd-treated cells respectively, Figure 2.9) and this is associated with a reduction in 
functional tight junctions. High densities of tight junctional complexes between the cells impede 
the passage of small molecules and even ions from the lateral face of the monolayer to the basal 
side (Suzuki et al., 2015). In this respect they act as electrical insulators and increase the 
electrical resistance of the monolayer. Therefore, the reduction in TEER that is induced by PTx 
is the direct result of loss of functional tight junctional complexes. To further investigate the role 
of tight junctional proteins in the PTx-induced permeability, immunostaining for tight junctions 
was carried out to determine any changes in the relative distribution of the junctional complexes 
within the cells. 
The tight junction is a complicated arrangement of many different proteins that determine the 
paracellular permeability of endothelial and epithelial cells (Gunzel & Yu., 2013). The tight 
junction complex is anchored to the actin cytoskeleton and transmembrane proteins interact 
with corresponding tight junction on adjacent cells in concert with signalling and regulatory 
proteins involved in assembly and modulation of junctional interactions (Liang & Weber., 2014). 
In this study, ZO-1 was selected as a marker of the tight junction complex. ZO-1 is an intracellular 
scaffolding protein responsible for anchoring the whole tight junction to the actin cytoskeleton. 
In concert with the other proteins that form the tight junction, the ZO-1/f-actin interaction 
provides structural integrity across the entire cell monolayer. The TEER measurements show 
that PTx disrupts the tight junction in terms of function but does not indicate how PTx may affect 
tight junction organisation. The immunostaining of untreated HUVECs showed that the ZO-1 
protein was localised to the plasma membrane as expected, likewise a similar distribution was 
observed in the PTd-treated HUVECs. Interestingly, the immunostaining of the PTx-treated 
HUVECs showed that not only was there a reduction in the localisation of ZO-1 to the plasma 
membrane, there appeared to be a reduction in the overall ZO-1 fluorescent signal. This was 
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confirmed by analysing the volume of ZO-1 fluorescence per cell from all the images collected 
which showed that there was a significant (p≤0.001 and 0.05 vs. untreated cells and PTd-treated 
cells respectively, Figure 2.10) reduction in ZO-1 signal. Interestingly there was also a significant 
difference between the untreated HUVECs and those treated with PTd (p≤0.01, Figure 2.10). A 
similar result was observed in the TEER measurements and in the vaccine only groups in the 
permeability assay and can be explained by the immunogenic nature of the PTd molecule. 
Production of vaccine antigens is a trade-off between immunogenicity and reactogenicity i.e. 
any given antigen must raise an immune response without eliciting potentially dangerous 
adverse events. In the case of PTd, this means that the molecule is only partially toxoided and 
retains some residual toxicity (Yuen et al., 2016), increasingly denatured toxin becomes less 
immunogenic (Thierry-Carstensen et al., 2013) meaning that the chemical toxoiding process 
compromises important epitopes. Overall, the initial hypothesis was shown to be correct, PTx 
induces permeability in HUVECs by impairing tight junction functionality, although it is likely the 
effects of PTx are more wide ranging than simply compromising the tight junctions. Besides G-
protein inhibition and ZO-1 downregulation, PTx is known to decrease p42/44 MAPK activity 
which can lead disorganised VE-cadherin and β-catenin deposition (Karassek et al., 2015).  This 
study has demonstrated that this permeability assay is a viable option in the search for an 
alternative to the HIST assay as a means for safety testing pertussis containing vaccines. 
Furthermore, it has shown that the permeability is the result of tight junctional dysfunction, 
showing that tight junctions are under the influence of G-proteins.  
G-proteins of the type sensitive to pertussis toxin are regulators of a multitude of cellular 
functions. Their primary means of effecting change within a cell is regulating adenylate cyclase. 
adenylate cyclase continually synthesises cAMP within the plasma membrane of the cell unless 
it is inhibited (Tsvetanova et al., 2015). adenylate cyclase is inhibited by G-proteins of the class 
Gi/o, which are also known as pertussis-sensitive G-proteins (Kang et al., 2014). This name was 
given to them as they were discovered after treatment of tissue with pertussis toxin lead to an 
increase in cAMP in the tissue. These G-proteins are associated with membrane receptors and 
are collectively known as G-protein coupled receptors or GCPRs and respond to extracellular 
stimuli. Therefore, disturbance of these G-proteins by PTx artificially raises the intracellular 
cAMP concentration (Nakashima et al., 2015) and results in increased paracellular transport of 
molecules across the cell monolayer. Potentially, this presents itself as a possible mechanism 
behind some of the rarer more severe adverse events documented following pertussis-
containing vaccine administration. Consistently, there was some toxic activity associated with 
the pertussis toxoid and as discussed earlier this is a balance that the toxoid is of immunological 
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value. However, in some patients who are more sensitive to the toxin, such as those with 
Dravet’s syndrome (Verbeek et al., 2015), they may be more susceptible to the residual toxic 
effects associated with PTd. This highlights the need for an assay capable of differentiating 
normal residual toxoid activity from unsafe concentrations of PTx. In this regard, the 
permeability assay shows some promise as it is able to detect residual vaccine toxicity and 
demonstrate the presence of untoxoided PTx in a vaccine preparation. Furthermore, compared 
to the HIST assay, the permeability assay described here has the potential to provide the same 
toxicity data using HUVECs cultured in several 24-well plates as opposed to large numbers of 
mice. 
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Chapter 3: 
TNF-α secretion by primary PBMCs in 
response to DTaP5-IPV-Hib and PTx 
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3.1 Introduction 
Permeability in endothelial cells is governed by intercellular signals received by the endothelium 
from cells in the local environment (Labus et al., 2014). These signals are particularly important 
in immune responses to pathogens and allow immune cells to translocate from the blood stream 
to infected tissue (Abadier et al., 2015). However, these mechanisms are tightly controlled to 
ensure that the endothelial layer remains largely impermeable when immune cell trafficking is 
not required. During an infection, multiple different types of immune cells are trafficked 
between blood and tissue as the immune system mobilises to contain invasive pathogens. 
Immune cells that traverse the blood/tissue interface do so by either transcellular or paracellular 
diapedesis and include the sub-types: monocytes (Calderon et al., 2017), granulocytes (Kumar 
et al., 2014) and some lymphocytes (Martinelli et al., 2014). Diapedesis is driven by cytokine 
release following recognition of molecular markers called pathogen associate molecular markers 
(PAMPs) by toll-like receptors (TLRs) present on antigen presenting cells (APCs) (Ravin & Loy., 
2016). The type of immune response elicited is dependent on the types of TLRs that are 
stimulated allowing differentiation between viral and bacterial infection and intracellular and 
extracellular pathogens. This ability to differentiate between pathogens is achieved by the 
locations of TLRs on the cell cell-surface (TLR1, 2, 4, 5, 6, 10, 11) or within endosomes (TLR3, 7, 
8, 9, 12, 13) (Lee et al., 2015 & O’Neill et al., 2013) 
In the case of Bordetella pertussis infection, TLR2 and TLR4 (Bernard et al., 2015) are activated 
resulting in an inflammatory immune response involving a mix of the Th1/Th17 type responses 
(Alvine et al 2016). This designation refers to the type of T-cell that responds to the B. pertussis 
bacterium. This type of response is characterised by type 1 T-helper cells and type 17 T-helper 
cells stimulating a cellular immune response to the presence of the pathogen. The subset of T-
cells that are activated are associated with specific cytokine markers that regulate the 
inflammatory response, such as: Il-2, Il-12p70, Il-27, IFN-γ and TNF-α; other cytokines like Il-4 
and Il-5 should be absent as these are characteristic of a Th2 type response (Raphael et al., 2015) 
The Th17 type T-cell is identified by secretion of Il-17A&F, Il-21, Il-22, Il-25, Il-26, GM-CSF, and 
TNF-α (Raphael et al., 2015). During the course of a B. pertussis infection, the adaptive immune 
response can be characterised by the Th1/Th17 response described above (Warfel & Merkel., 
2013). This response is also induced by the whole-cell pertussis vaccine (Ross et al., 2013), which 
has been phased out in developed countries in favour of acellular vaccines that have a lower 
rate of adverse events (Klein et al., 2013). However, the primary T-helper cells that respond 
following acellular vaccination is are typically from the Th2 subset (Ross et al 2013). This type of 
immune response is characterised by Il-3, Il-4, Il-5, Il-6, Il-10, Il-13 and Il-31 (Raphael et al., 2015). 
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The acellular pertussis vaccine a Th2 type immune response and not a Th1/17 response associated 
which has been associated with clearance B. pertussis infection (Bancroft et al. 2016. & Warfel 
& Edwards., 2015). Primarily, the immune memory cells generated by the Th2 type response 
(memory B-cells only) do not elicit as robust an immune response as those generated by the 
whole-cell vaccine (Grondahl-Yli-Hannuksela et al., 2016). The Th2 bias seen in aP vaccination is 
the result of the inclusion of an alum adjuvant in aP preparations (Holt et al., 2016) coupled with 
inadequate antigen content to skew the immune response back towards the protective Th1/Th17 
response (Cherry., 2015). The whole-cell vaccine is associated with more severe adverse events 
because the final vaccine still contains several bacterial components, such as LPS or active PTx, 
which induce in a more general inflammatory response (Geurtson et al., 2007), for example LPS 
is capable of inducing inflammation via mitogen activated protein kinas C which induces a strong 
TNF-α (MacKenzie et al., 2002). The aim of the acellular vaccine is to provide enough antigens 
for an immune response to be induced without any harmful adverse events. This was in part 
successful as the rate of serious adverse events was significantly reduced after the introduction 
of the acellular vaccine (Zhang et al., 2014). Some of more serious adverse events associated 
with pertussis vaccination can be explained by previously unknown underlying conditions like 
Dravet’s syndrome (a mutation in the sodium ion channel SCN1A) which increases the risk of 
seizure following pertussis vaccination via an as yet un elucidated mechanism (Wong et al., 
2016). Despite retrospective diagnosis of Dravet’s syndrome, the aetiology of some cases of 
seizure remain unknown but are suspected to be related to vaccination with pertussis-
containing acellular vaccines (Verbeek et al., 2014). 
3.1.1 Objectives 
Cytokine biomarkers have can be used as effective biomarkers of disease and are often used to 
determine vaccine efficacy in clinical trials. In this study, TNF-α was chosen as the primary 
analyte as it is a key indicator of a general inflammatory response. The purpose of the study was 
to determine in TNF-α could be used to determine the presence of high levels of PTx in a vaccine 
preparation. In this regard, it was hypothesised that PTx in combination with the antigens of the 
DTaP5-IPV-Hib vaccine would result in a TNF-α inflammatory response. This was based on 
previous data obtained by NIBSC showing that PTx administered to PBMCs concomitantly with 
LPS induced high levels of TNF-α secretion. In this study LPS was replaced with a DTaP5-IPV-Hib 
preparation. Furthermore, it was hypothesised that TNF-α secretion may contribute to the 
permeability of the endothelial cells observed in Chapter 2. TNF-α induced permeability may be 
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clinically relevant as it may begin to explain some of the rare seizure events seen post-
vaccination, if the permeabilization occurs in the BBB. 
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3.2 Materials and Methods 
3.2.1 Cell Culture 
HUVECs were cultured on transwell inserts as described in detail in an earlier chapter and fresh 
primary PBMCs were added to the transwell inserts after the HUVECs had been allowed to form 
a confluent monolayer. Before blood withdrawal took place, volunteer donors were sought, this 
entailed providing each donor with a consent form and project information sheet containing 
information how their cells would be used. Donors were selected according to strict criteria, 
donors must be healthy, can be male or female, have not been on NSAIDs during the previous 
week and are not pregnant. Donors were also informed of their right to withdraw consent at 
any time. The project was also approved by the NIBSC HuMAC ethics committee. Blood 
withdrawal was performed by trained phlebotomists by syringe. 30ml of blood was taken from 
each donor and transferred to a 50ml centrifuge tube containing heparin (10 units of heparin/ml 
whole blood). Upon withdrawal, blood samples were transferred to the falcon tubes 
immediately.  
3.2.2 PBMC Isolation 
15ml of histopaque (Sigma-Aldrich, Poole, UK) was pipetted into another 50ml Falcon tube and 
the blood sample was slowly and gently overlaid on to the histopaque. The tubes were then 
centrifuged at 320 x g at 22°C for 45 minutes. Centrifugation with the histopaque separated the 
blood into four constituent fractions, shown below in Figure 3.1: 
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Following centrifugation, the buffy coat was removed using a 10ml serological pipette and 
transferred to a new falcon tube. The volume was topped up to 50 ml using sterile PBS and the 
cells were centrifuged at 340 x g at 22°C for 15 minutes. The PBS was removed replaced with 
fresh PBS, before the tubes were returned to the centrifuge for ten minutes at the same 
temperature and speed. This step was repeated once more to ensure all of the serum had been 
washed out of the PBMC sample. Prior to enumeration, the PBMCs were re-suspended in EBM-
2 + 5mM L-glutamine and 2% FCS and incubated for 30 minutes at 37°C to reduce clumping. The 
cells were diluted 1 in 5 and manually counted using the trypan blue exclusion method and a 
haemocytometer. At this time, the transwell plates that had been seeded with HUVECs was 
removed from the incubator and the supernatant in the upper chamber was withdrawn and 
discarded. The PBMCs were then added at a concentration of 100,000 cells per well according 
to a plate layout. Subsequently, treatments of DTaP5-IPV-Hib (vaccine), DTaP5-IPV-Hib + PTx and 
PTx were prepared. These treatments were prepared and applied as described in Chapter 1.  The 
plates were then returned to the incubator for 24 hours. 
Erythrocytes 
Histopaque 
Plasma 
Buffy Coat 
Figure 3.1: Blood components following separation of whole blood using 
histopaque 1077. Blood separates into three components: erythrocytes, 
serum and the buffy coat. PBMCs are present in the buffy coat and 
granulocytes are present at the erythrocyte/histopaque interface. 
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3.2.3 Enzyme-Linked Immunosorbent Assay for detection of TNF-α 
Upon completion of the incubation period, the supernatants from the transwell plates were 
transferred to a 96-well plate and frozen in a -80°C freezer until it was possible to perform the 
analysis.  The plates were analysed for TNF-α using an enzyme-linked immunosorbent assay 
(ELISA). ELISA (NUNC maxisorp) plates were previously coated in-house using an in-house 
monoclonal anti-TNF-α coating antibody (NIBSC, South Mimms). 25µl of supernatant was added 
to each well of the ELISA plate and incubated for 4 hours at room temperature. The plates were 
washed three times in PBST (PBS + 2.5% Tween 20) before the secondary antibody was added 
(biotinylated anti-TNF-α IgG) (NIBSC, South Mimms), the plates were incubated at room 
temperature for 1 hours. TMB solution (Sigma-Aldrich, Poole, UK) was diluted and added to the 
ELISA plate after washing three times with PBST and the colour was allowed to develop for 15 
minutes before being stopped by the addition of 1M H2SO4. The optical density within each well 
was read using a plate reader equipped with a 450nm filter. The optical densities were 
interpolated from a standard curve (1 in 3 dilutions, starting from 3000pg/ml TNF-α) using 
GraphPad Prism 5. 
 
3.2.4 Statistical analysis 
Results from the PBMC only data from the five responsive donors (responsive: any donor where 
TNF-α) were pooled and statistical analysis was performed using GraphPad Prism 5. A One-way 
ANOVA with Tukey’s multiple comparison test was carried out to test for significance. Bartlett’s 
test was also carried out to determine that the sample data was of equal variance and therefore, 
that the one-way ANOVA was appropriate.  
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3.3 Results 
3.3.1 Cytokine Secretion by PBMCs in Response to DTaP5-IPV-Hib and PTx 
The supernatant was removed and either analysed immediately or frozen for future analysis. 
Upon removal from the freezer, the samples were analysed by ELISA for TNF-α. A total of 62 co-
culture assays were performed of which 8% (5 donors) of PBMC samples responded to the 
vaccine by secreting measureable TNF-α. Results of the TNF-α testing showed that inflammatory 
responses are highly variable between donors. Furthermore, the 5 donors that had previously 
responded to the vaccine treatment subsequently did not respond upon further 
experimentation. These results were not unexpected as the PBMCs used were used fresh after 
withdrawal from volunteers. The primary nature of these cells was expected to result in some 
variability in response between donors (Figure 3.2). 
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Figure 3.2: TNF-α secretion in co-culture model of PBMCs and 
HUVEC cultured in transwell inserts and incubated with either: 
culture medium, Vaccine, Vaccine + PTx or PTx alone. Four 
responsive donors are shown here. Donor numbers are assigned 
arbitrarily according to the order in which donors were recruited to 
the project and given in parenthesis. Error represents the SD of 
duplicate samples. Blue bars: HUVEC only, Green bars: PBMC only, 
Red bars: HUVEC/PBMC co-culture. 
  
HUVEC only PBMC only HUVEC/PBMC 
co-culture 
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In the donors that did respond to treatment, TNF-α responses were recorded when the PBMCs 
had been treated with either the vaccine formulation or the vaccine formulation spiked with 
PTx. PTx alone was insufficient to stimulate a TNF-α response from the PBMCs. It is also 
important to note that no TNF-α was secreted by the HUVECs, confirming that they do not 
secrete TNF-α under these conditions. The results showed that in responsive donors, the general 
trend was that PTx increased TNF-α secretion regardless of the presence of HUVECs. This pattern 
was repeated for two of the responsive donors (Figure 3.2, D008 & D039) in the co-culture assay 
where the influence of the HUVECs over PBMC cytokine secretion could be taken into account. 
The other two donors (Figure 3.2, D002 & D102), did not follow this pattern. D002 secreted 
similar concentrations of TNF-α regardless of the presence of PTx or HUVECs. Conversely, the 
TNF-α secretion from D102 reflected both D008 & D039 when PBMCs were treated in the 
absence of HUVECs. However, when HUVECs are introduced the highest TNF-α concentrations 
were observed when the co-culture was treated with only the vaccine. Furthermore, the TNF-α 
concentration in the supernatant from the co-culture was lower than that from the 
corresponding assay where PBMCs (D102) were treated in isolation. This was only observed 
once in a single donor, it is difficult to deduce the reasons why this donor responds so differently 
from the others, it may be the influence of the HUVECs or it could be inherent genetic 
polymorphisms of the PBMCs.  The variation observed in these results could explain some of the 
variation that was observed in the permeability results; however, it is too difficult to test this 
hypothesis given the inconsistency of the cytokine data. 
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Figure 3.3: Pooled data from responsive donors (n=5 individuals) showing 
TNF-α secretion. This data was pooled to allow statistical analysis to be 
carried out. The data was analysed using One-way ANOVA with Tukey’s test 
upon log TNF-α concentration. *p>0.05, **p>0.01, ***p≥0.001. 
 
To analyse this data, the responses from the responsive assays were pooled and statistical 
analysis was carried out. To reduce the variation present in the sample a logarithmic 
transformation was performed before a one-way ANOVA with Tukey’s multiple comparison test 
used to determine significance within the data. Analysis of the pooled TNF-α responses of the 
reactive donors showed that, when PBMCs were treated with the vaccine preparation and PTx 
simultaneously, there was a significant increase in TNF-α secretion (Figure 3.3). The observed 
increase in TNF-α secretion is suggestive of a synergistic action of PTx and other vaccine 
components. Additionally, the increase in TNF-α secretion reached a higher level of significance 
in samples that had been assayed without HUVEC cells, this discrepancy is most likely due to the 
higher variation in the co-culture samples, specifically the TNF-α secretion observed for D102. 
Furthermore, there was no significant difference between PBMCs treated in co-culture with 
HUVECs or alone regardless of the treatment used to stimulate the TNF-α response. To 
determine if there were any more suitable cytokine biomarkers a multiplex cytokine assay was 
performed. A luminex kit was purchased from Bio-Rad (M5000005L3) and was a 9-plex Th1/Th2 
kit that assayed supernatant samples for: GM-CSF, IFN-γ, Il-2, Il-4, Il-5, Il-10, Il-12(p70), Il-13 and 
TNF-α. Despite two attempts to produce results from the supernatants, these experiments were 
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not successful. This is probably due to the volume of supernatant leftover from the previous 
individual TNF-α ELISAs described above. Due to the volume of leftover supernatant from the 
previous ELISAs, the remainder had to be diluted to achieve the necessary volume required by 
the luminex assay kit. This dilution step likely diluted out any remaining cytokines to a level that 
was below the detection limit for the kit. 
 
3.3.2 Donor Recruitment 
Further issues encountered during this study included difficulty recruiting as wide a selection of 
donors. This was due to scheduling conflicts between times that blood could be taken and times 
that the donors themselves are available to have blood withdrawn. Furthermore, due to ethics 
constraints around multiple donations by the same donor, this study had to compete for the 
donors with other studies carried out at NIBSC and the blood bank. A maximum of 50ml of blood 
could be withdrawn per donor per month and a donor may not donate twice in one month. 
These restrictions are in place to ensure the health of the donors but placed further restrictions 
on the pool of available donors. Figure 3.4 is a breakdown of the number of times individual 
donors were available to donate blood to the study. 
Availability was one of the main practical issues during this study. Donors were selected at 
random in an attempt to assay PBMCs from as diverse a sample group as possible. Despite this, 
several donors were unavailable on several occasions and therefore, alternatives had to be 
sought. Donors whose schedule had a greater degree of flexibility allowed them to be available 
for donation more often. Hence, these donors were more likely to be used in an assay, likely 
introducing selection bias into the results. The breakdown of positive and negative assays shows 
in Figure 3.4, shows that of the reactive donors, two of them were assayed a total of five times 
and two of them were tested a total of four times. It is possible that the greater number on 
assays that were performed on these donors sufficiently shortened the odds on taking blood 
from them on a day which they were reactive to the vaccine in terms of TNF-α secretion. None 
of the donors assayed on a single occasion reacted to the vaccine by producing TNF-α and only 
one of the donors assayed twice reacted to the vaccine. These results show that it is possible 
that the more often a given donor is assayed, the more likely that they will react to the vaccine 
by secreting TNF-α. Therefore, it is possible that the donors that did not produce a TNF-α 
response to the vaccine would do so if assayed more often on different days. 
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Figure 3.4: Number of assays broken down by donor, showing the total 
number of assays performed using PBMCs from any given donor and how 
many positive (red) and negative (blue) assays were recorded. A positive 
assay is defined as an assay in which a detectable (by ELISA) concentration of 
TNF-α is produced by the PBMCs, a negative assay is defined as an assay 
where no TNF-α was detected. n=62 assays. 
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3.4 Discussion 
Results of this study were inconsistent in terms of the TNF-α secretion by the PBMCs so it is 
unlikely that TNF-α is the primary cause of permeability in the HUVECs. In the donors that were 
reactive to the vaccine formulation, secretion of TNF-α by PBMCs was independent of interaction 
with the HUVECs. Demonstrated by similar concentrations of TNF-α secretion in PBMC only 
experiments and co-culture experiments using the same PBMC source (means from the five 
responsive donors: 539pg/ml TNF-α and 594pg/ml for PBMC and co-culture respectively) (Figure 
3.3). A similar trend was observed, in PBMCs treated with the vaccine preparation which had 
been spiked with 25ng/ml PTx, this concentration was chosen as it simulates a batch of vaccine 
that would fail a regulatory test. In these treatment groups, significantly (p≥0.001, p>0.05 
respective of PBMCs only and in co-culture) more TNF-α was secreted (mean of 5 donors: 
1037pg/ml TNF-α PBMCs only and 1139pg/ml TNF-α in co-culture) when PTx was administered 
concomitantly as opposed to vaccine preparation alone. 
The differences between TNF-α responses to the vaccine and the vaccine with PTx are most likely 
explained by the differences between the PTx molecule and the PTd molecule present in the 
vaccine. During the manufacture of PTd, batches of PTx are produced and chemically detoxified. 
This entails adding glutaraldehyde and/or formaldehyde to the PTx and incubating for a length 
of time (Ellis., 2001). These chemical fixatives cross-link the PTx molecule and ultimately render 
it non-toxic as it is unable to perform its action upon the target cells. It is important to note that 
glutaraldehyde only cross-links the B-subunit of the PTx molecule, therefore, the enzymatic 
moiety (lacking in lysine residues) retains its activity (Worthington & Carbonetti, 2007 and 
Rossjohn et al., 1997). The B-subunit is responsible for binding to the target molecules on a cell 
surface and initiating retrograde transport (Beddoe et al., 2010), it is also where many of the PTd 
molecules protective epitopes are located (Arciniega et al., 1991). In the vaccine, the 
conformation of protective epitopes are altered meaning the PTd molecule is not recognised as 
well as the PTx molecule (Sutherland et al., 2011 & Ryan et al., 1998). It is possible that addition 
of un-detoxified PTx to the vaccine preparation effectively increases the number of PBMCs 
responding to the vaccine. PTx acts as a mitogen (Ryan et al., 1998) and causes massive clonal 
expansion of the PBMC population, therefore, increasing TNF-α secretion as more cells are 
available to respond. PTx alone does not induce an inflammatory response indicating that this 
molecule requires co-stimulation from other molecules present in the vaccine. It is well known 
that at least two TLRs must be activated before an inflammatory response is stimulated 
(Trinchieri & Sher et al., 2007). The components of the DTaP5-IPV-Hib vaccine components have 
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the potential to act in concert with one another to produce an inflammatory response via TLR 
co-stimulation. In the DTaP5-IPV-Hib vaccine, there are antigens from diphtheria, tetanus, polio 
and H. influenzae that could interact with PTx to produce the elevated TNF-α concentrations that 
were observed in this study. In future it would be useful to use the assay described here to 
determine if there are any interactions between PTx and individual vaccine components of the 
DTaP5-IPV-Hib vaccine. It was unfortunate that further investigation of the cytokine profile 
induced by PTx in combination with the vaccine by luminex assay was unsuccessful. This kind of 
study would have provided a better understanding of the inflammatory response induced by the 
vaccine and might possibly have provided a more reliable biomarker than TNF-α. Further 
investigation of the donor PBMCs would also be useful to show if any SNPs were influencing the 
results seen here. SNPs can have significant influence over the TLR mediated responses of 
different individuals to different diseases (Schroeder & Schumann., 2005).  
It was expected the results of this study would be variable due to the primary source of the 
PBMCs. It was hoped that there would be a consistent response across all of the donors that 
were tested that would allow a cytokine biomarker to be used as a method to detect PTx in the 
vaccine preparations. Unfortunately, the data presented here has shown that the inflammatory 
response by PTx is inconsistent between donors and even between PBMCs taken from the same 
donor on different days. This variation is best explained by the natural variation that is present 
within a given population which gives rise to large differences in the results in samples that have 
been treated in precisely the same way (Yagil-Kelmer et al., 2004). However, the observed 
response rate of 8% can be regarded as a success in the context of the number of assays that 
were run (62) but a much larger study analysing the responses of thousands of donors would 
allow a more comprehensive analysis of TNF-α secretion. This kind of study is far beyond the 
scope of the study presented here as the number of available donors is too small and there are 
several feasible alternative assays for detecting PTx besides cytokine biomarkers. Difficulty 
obtaining blood from a wide enough pool of donors is a further reason why this type o assay is 
not ideal in terms of use as a control assay. One possible solution may be to do experiments using 
leukocyte blood cones rather than performing experiments on fresh primary PBMCs (Tremblay 
et al., 2014). Leukocyte cones contain the mixed leukocytes of several donors and in this way 
may provide more consistent results provided that these processed PBMCs are capable of 
responding to DTaP-IPV-Hib vaccines and PTx.  
Besides inter-donor variation, variation in results between donors assayed on different days was 
also apparent. Care was taken to ensure that donors were fit, healthy and not on medication at 
 105 
 
the time of blood withdrawal. In this way, the influence of pathogens, such as the common cold, 
or medications, such as ibuprofen, which could skew the results of the study were minimised. 
Despite these measures, donors that had previously produced TNF-α in response to the vaccine 
did not reproduce this result in subsequent testing. Some studies have suggested that there is 
some seasonal variation in immune responses (Khoo et al., 2011) and this may explain some of 
the results seen in this study as the responses that were observed were seen in PBMCs isolated 
in winter. Like inter donor variability, this is a problem that may be overcome by the use of 
monocyte cell lines which may give more consistent results (Falco et al., 2004 and Wang et al., 
2011).  
Therefore, the initial hypothesis that TNF-α secretion may be an effective way by which to detect 
active levels of PTx present in pertussis-containing vaccines is false according to the results of 
the study presented in this chapter. As discussed, the variation in responses from the donors was 
too great. However, the variation displayed by the donor pool is perhaps reflective of the 
variation found in the wider public and it is possible that this may correlate with individuals that 
react badly to pertussis-containing vaccines via an immune system mediated mechanism. Due to 
this variation, it is also not possible to confirm the secondary hypothesis that enhanced TNF-α 
secretion would lead to increased permeability in the HUVECs as the results here do not support 
that hypothesis and it is more likely that the permeabilization of the HUVECs is the result of direct 
action by PTx. 
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Chapter 4: 
Microscopical examination of permeability 
induced by pertussis toxin 
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4.1 Introduction 
Visible light describes a relatively narrow band of frequencies within the electromagnetic 
spectrum that humans are able sense. Although we cannot sense the extremes of the 
electromagnetic spectrum of wavelengths longer than infra-red or shorter than violet visible 
light. However, short wavelength gamma rays, long wavelength radio waves and visible light all 
share the same properties. This study aims to apply techniques in fluorescence microscopy to 
the study of permeability in human umbilical vein endothelial cells (HUVEC). 
Fluorescence is a physical phenomenon that occurs when electrons return from an excited high 
energy state to their ground state. This property results from the absorption of incident photons 
which promotes an electron to an excited state. After a given time, the excited electron decays 
back to its ground state, i.e. unexcited state, and in doing so emits another photon. In 
fluorescence microscopy, this is exploited during the generation of fluorescent images. The light 
source used to promote the electrons of the fluorophore can be a high intensity lamp for 
epifluorescence or a laser light source for confocal and multiphoton imaging. For the purpose of 
this text, the focus will be on lasers as excitation sources (Lichtman & Conchello., 2005).  
 
4.1.1 The Basics of the Electromagnetic Spectrum and Visible Light 
To understand fluorescence, it is important to understand the properties of electromagnetic 
radiation. The visible portion of the electromagnetic spectrum is shown in Figure 4.1. 
 
 
 
 
 
Figure 4.1: The electromagnetic spectrum encompasses a large range of 
wavelengths and includes high frequency gamma rays, visible light and long 
frequency radio waves. For microscopy the portions of the spectrum of 
interest are the ultraviolet region, the visible light region and the infrared 
region. (Adapted from SPCImage handbook, Becker & Hickl GmbH, Berlin, 
Germany) 
 
8x1014 4x1014 
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In microscopy the portion of the spectrum that is of interest spans 1016Hz (UV) to around 1012Hz. 
The visible light spectrum can be found in the middle of this range spanning from 8x1014Hz to 
4x1014Hz. There are three key properties of the electromagnetic spectrum to consider: 
wavelength, frequency and the energy of waves (Atwater., 2007). These properties are related 
to one another through the following expressions:  
𝑐 = 𝜆𝑣 
Where: c=speed of light in a vacuum, λ=wavelength (nm) and v=frequency (Hz) 
This expression shows mathematically that as the wavelength of the light increases, its 
frequency must decrease, provided the light is passing through the same medium. Furthermore, 
the energy of the light must also decrease as the wavelength increases (Field., 2004). This is 
represented as: 
𝐸 = ℎ𝑣 
Where: E = energy in joules, h = Planck’s constant (6.626 x 10-34 J s-1) and v = frequency (Hz) 
The relationship between wavelength, frequency and energy describes the basic principles of 
the electromagnetic spectrum and it is particularly important when trying to understand 
fluorescence. 
 
4.1.2 Introduction to Fluorescence 
Fluorescence occurs when a molecule absorbs energy from an incident photon which culminates 
in the emission of another photon of a longer wavelength. In the context of fluorescence 
microscopy; a light source is used to excite fluorophores, a laser in confocal microscopes 
(Carlsson et al., 1985), in a sample and the emitted light is subsequently captured by the 
detectors, usually a camera or a photomultiplier tube (Zucker & Price 1999). There are many 
different fluorophores to choose from and each one has a distinct excitation and emission 
spectrum. In essence, this means that every fluorophore is optimally excited by a different range 
of incident light frequencies and likewise, the emission spectrum of each fluorophore, is also 
distinct. It is important to note, however, that there can be significant overlap between these 
spectra between some fluorophores (Jameson et al., 2003). The excitation wavelength is always 
shorter than the emission wavelength and therefore is also higher energy, this is because energy 
from the incident photons is expended during the excitation process. For example, FITC is 
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typically excited by a 488nm laser and the emitted light is a spectrum of wavelengths around 
550nm. This then must also mean that the process of fluorescence expends energy as the 550nm 
emitted photons possess less energy than the 488nm incident photons. This holds true for 
confocal imaging where single photon excitation is employed, here, one incident photon excites 
one electron which results in the emission of one photon. Alternative excitation techniques exist 
and this text will focus on multi-photon excitation. 
Multi-photon excitation works on a similar principle to confocal where a laser beam is raster 
scanned across a sample but with a few key differences. In its simplest form, a pulsed infrared 
laser provides the photons that excite electrons in fluorophores that emit light in the visible 
spectrum. At first glance, this does not appear to make sense as the excitation wavelength is 
longer than the emission wavelength. Here, instead of one photon exciting one electron 
resulting in emission of one photon of a longer wavelength, two photons arriving simultaneously 
to excite an electron resulting in emission of one photon approximately half the wavelength of 
the two incident photons (Xu et al., 1996) (Figure 4.2). It is crucial that enough photons reach 
the sample simultaneously to increase the chance of a rare two-photon event taking place and 
this is achieved by using an ultrafast femtosecond infra-red laser. This type of laser ensures that 
enough photons arrive at the focal plane to allow two photon events to take place and 
fluorophore excitement. 
 
 
 
 
 
 
 
 
 
 
  
Two photon 
excitation 
S0 Ground state 
Excited state 
S1 
Emission 
Figure 4.2: Jablonski diagram of excitation and emission during fluorescence 
during multi-photon excitation. Two incident photons “combine” to provide 
enough energy to promote an electron to its excited state which results in 
the emission of a photon of approximately half the wavelength of the 
excitation photons. Solid arrows show movement of electrons and dashed 
arrows show movement of photons. (Adapted from Svaboda & Yasuda., 
2006) 
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In confocal microscopy one photon has enough energy to promote an electron, where in two-
photon excitation two are required, each providing half of the energy needed (Figure 4.2). The 
probability of two photons arriving at exactly the correct co-ordinates in space and time under 
normal circumstances is infinitesimally small. However, it is made possible by the repetition 
(pulse) rate of the laser used to generate the incident photons (Periasamy et al., 1999). Modern 
infrared lasers operate between wavelengths of around 680nm to 1080nm and are capable of 
producing 80 million pulses per second. These lasers are known as ultrafast femtosecond lasers 
because the pulses themselves last for only 100 femtoseconds. This pulse rate significantly 
increases the probability of two photons arriving simultaneously at a fluorophore, such that 
enough energy is supplied for an electron to be promoted (Konig., 2000). This mode of excitation 
can be applied to advanced techniques such as fluorescence lifetime imaging (FLIM) and is 
especially useful for imaging thick tissue sections because longer wavelengths have much 
greater potential for penetrating deep tissue (Brown et al 2009, Helchman & Denk., 2005 & 
Kobat et al., 2009). In addition, because the chances of 2 photons arriving simultaneously at the 
same space is extremely rare, the only place this can happen (statically) is where the density of 
photons is at its maximum; this is at the focus point of the imaging objective. Any position above 
or below the focus point of the objective will not have sufficient photons for a 2-photon event 
to take place. Consequently, any emitted photons from the sample are confocal in their own 
right and no confocal pinhole is required to remove out-of-focus light from the collected image, 
this increase the sensitivity of method as all photons can be collect in the detector and results 
in less photobleaching above and below the plane of focus than single photon excitation. 
 
4.1.3 Basic Principles of Fluorescence Lifetime Imaging (FLIM) 
The fluorescence lifetime is a property of every fluorophore and can be measured to separate 
different sources of fluorescence in a heterogeneous mix. It is important to note that multi-
photon excitation does not have to be used; single photon excitation i.e. confocal excitation can 
be used as well as long as the laser is pulsed. This is because the laser pulse is used as a reference 
point for measuring the length of time taken for the emission of a photon (Dunsby et al., 2004). 
This is shown in Figure 4.2, where a two distinct lifetime are being detected. 
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The measurement of a particular fluorophore’s lifetime depends on the detection of one photon 
between each laser pulse. The laser pulse is used as a reference point and detection of a single 
photon defines the end of the measurement until the next laser pulse, i.e. following excitation, 
how long does it take for a photon to be emitted? The time taken between excitation and 
emission is the fluorescence lifetime. The fluorescence lifetime is different for every 
fluorophore; hence, its measurement can be used to define individual fluorophores from a 
heterogeneous mix (Becker et al., 2004). 
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Figure 4.3: Schematic diagram of the basic principles of 
fluorescence lifetime imaging, here two lifetimes are being 
analysed. Laser pulses are represented as peaks and the emitted 
photons are represented by the blue circles. Both are blue to 
demonstrate that two photons with similar emission spectra can 
have very different fluorescent lifetimes. “fl” refers to 
fluorescence lifetime, which is the time taken for an emitted 
photon to be detected following a laser excitation pulse. 
100fs 
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4.1.4 FLIM, NADH & Cellular Metabolism 
The differences in fluorescence lifetime exhibited by fluorophores with similar emission spectra 
can be used to the advantage of scientific research. The metabolic co-factor NADH possesses 
similar excitation and emission spectra to the common nuclear stain DAPI. NADH exists as two 
fluorescent species within the cell, both are excited by the same wavelength and emit the same 
wavelength. However, they can be separated using FLIM, NADH free in the cell cytoplasm has a 
short fluorescent lifetime of around 800ps and the protein bound form (NAD(P)H) has a lifetime 
of above 2500ps (Wakita et al., 1995). The lifetime of NAD(P)H fluorescence can vary depending 
on which protein it is bound to at the time of analysis (Lakowicz et al., 1992). This property has 
been used successfully to determine healthy cells from malignant cancer cells by profiling the 
ratios of NADH to NAD(P)H which indicates the type of respiration the cell is utilising to produce 
ATP (Skala et al., 2007). The differences between each type of respiration relevant to this report 
are shown in Figure 4.4. 
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Figure 4.4: Different forms of cellular respiration. A: Normal aerobic 
respiration in the presence of oxygen, where oxidative phosphorylation is 
allowed to proceed. B: Anaerobic respiration characterised by the 
production of lactate as opposed to pyruvate that is produced in aerobic 
respiration due to the lack of oxygen as the final electron acceptor. C: 
Aerobic glycolysis is characterised by the production of lactate despite the 
presence of oxygen. This is seen often in cancers and in this context is called 
the Warburg effect (Heiden et al., 2009). 
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These metabolic states can be characterised by the ratios of NADH to NAD(P)H present in the 
cell. Normal aerobic respiration is characterised by a ratio of NADH to NAD(P)H, typically 10-20% 
NAD(P)H and 90-80% NADH (Bird et al., 2005). In the case of aerobic glycolysis, the ratio 
indicates that there is more NAD(P)H than in aerobic respiration. This shift is known as the 
Warburg effect and shows the differences in metabolism between malignant cancer cells and 
normal cells. NADH is a necessary co-factor in the catalytic activity of pertussis toxin and it is a 
reasonable hypothesis that the NADH:NAD(P)H ratio is more akin to aerobic glycolysis and 
results in disrupted cellular metabolism (Stringari et al., 2012). This study seeks to understand if 
PTx perturbs cellular metabolism and if so, the consequences of this on the ability of the cells to 
maintain junctional complexes and barrier function. 
 
4.1.5 Relevance of Metabolism with Respect to PTx Mediated HUVEC Permeability 
The action of pertussis toxin requires NADH as a cofactor. Therefore, the toxin must use the 
cell’s supply of free NADH present in the cytoplasm. It is possible that this re-appropriation of 
cellular resources may result in an altered metabolic state, which means that the cell’s ability to 
produce energy may be impaired. This alteration of respiration may have drastic effects on the 
cells’ ability to form an effective barrier as the individual cells must continually turnover 
junctional complexes to ensure that the barrier remains tight. As this is a dynamic process, the 
cells must consume ATP, thus, perturbance of respiration may be detrimental to the cells ability 
to carry out this function. This is a question that can be answered in part by carrying out FLIM 
experiments. 
 
4.1.6 Introduction to Fluorescence Recovery After Photobleaching (FRAP) 
Fluorescence recovery after photobleaching (FRAP) was used to quantify gap junctional 
communication between HUVEC cells in a monolayer following PTx treatment. FRAP is a versatile 
technique that can be used to characterise molecular kinetics and interactions within cells 
(Takeshi et al., 2016). The change in the density of functional gap junctions in treated cells is 
used here as a proxy measurement of how closely associated the HUVECs are in a physical sense 
when exposed to PTx. By bleaching a whole cell and measuring both how quickly recovery occurs 
and to what extent the cell recovers fluorescence, the effect of PTx on the associations between 
the cells can be measured. The principle of this is shown schematically in Figure 4.5. There are 
two fractions that can be analysed during a FRAP experiment, the mobile fraction and the 
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immobile fraction. The mobile fraction is free to move and this fraction accounts for the 
fluorescence recovery demonstrated by the increasing fluorescence intensity curve. The 
immobile fraction is also bleached but cannot be replenished like the mobile fraction as these 
molecules are prevented from freely moving as they are sequestered in some way. Therefore, 
the immobile fraction explains why the fluorescence recovery curve cannot reach 100% of the 
pre-bleach intensity  
  
 
 
 
 
 
In previous experiments it was shown that the HUVECs are unable to maintain their tight 
(Chapter 1) and adherens junctions after PTx treatment and therefore, become more loosely 
associated with each other. Further consequences of decreased interaction between structural 
junctional complexes include loss of the ability to pass small molecules through gap junctions 
(Blatter and Wier., 1990). Gap junctions are formed of connexin monomers, arranged in 
Figure 4.5: The principle behind the FRAP experiments that are presented 
here. Left: a whole cell is bleached, represented by one green box in t0 and 
the fluorescence recovery is monitored by taking an image at pre-determined 
time points. Right: The time trace generated at each time point from which 
the fluorescence recovery time (given as τ1/2) and the immobile fraction can 
be determined. 
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hemichannels that span the plasma membrane and align with connexin hemichannels on 
adjacent cells. Without close association, the cells are not able to pass molecules through gap 
junctions as efficiently. This can be exploited as a means of measuring how closely associated 
the cells are and may offer a sensitive method of quantifying how the cell monolayer has been 
affected by the presence of PTx. To develop gap junctional communication as a potential assay, 
the HUVEC cells were loaded with Calcein AM and FRAP was utilised to quantify the time taken 
for PTx-treated cells to recover, compared to untreated cells. Calcein AM is a live cell stain that 
stains intracellular calcium and can be transported through gap junction channels, allowing 
intracellular calcium trafficking to be studied.  
 
4.1.7 The principles of fluorescence loss in photobleaching (FLIP) 
Fluorescence loss on photobleaching (FLIP) is a similar technique to FRAP, except the rate of 
fluorescence loss during bleaching is measured as opposed to the rate of fluorescence recovery 
in the bleached region as is done in FRAP. In the experiments reported here, a small region of 
interest (ROI) within a cell is selected and high intensity laser light is scanned across this ROI. 
During bleaching, a second laser scans the whole field of view and collects fluorescence in the 
bleaching ROI and the remaining field of view. This data can be used to characterise the kinetics 
of intracellular movement of a particular target molecule during bleaching and has previously 
been used to characterise protein dynamics in live cells, usually using GFP fusion proteins 
(Wustner et al., 2012). In this study, FLIP was used to characterise the mobility of intracellular 
calcium ions (stained with Calcein) following FRAP experiments where fluorescence recovery did 
not reach expected levels, thereby suggesting a large immobile calcium store present within the 
cells. FLIP was carried out to confirm that these ions were sequestered within the cell. 
 
4.1.8 Objectives and Hypothesis 
The primary objective of this study was to dynamically characterise the effects of PTx upon 
HUVECs. The study took two directions to achieve this aim: firstly to non-destructively 
demonstrate PTx activity within the HUVECs using FLIM and secondly, to determine gap junction 
function as this could be used as a proxy for the relative proximity of adjacent HUVECs and can 
be used to indirectly demonstrate wider effects of tight junction functions. It was expected that 
PTx would result in an increase in NAD(P)H lifetimes and change the lifetime distribution of the 
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NAD(P)H population itself (investigated using FLIM) because PTx uses NADH during its 
mechanism of action. This is in lieu of a PTx-GFP fusion molecule. Additionally, it was expected 
that PTx would compromise exchange of calcium molecules between adjacent cells as impaired 
tight junctional functionality (Chapter 2, Figure 2.10, 2.11 and 2.12) could reduce the number of 
functional gap junctions. Therefore, the fluorescence recovery of PTx-treated cells was 
anticipated to be slower than that of the control cells.  
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4.2 Materials & Methods 
4.2.1 Cell Culture for FRAP and FLIM 
HUVECs were cultured in EGM-2 (Lonza, Slough, UK) and seeded at a density of 2x104 cells/cm2 
in two 35mm polystyrene Petri dishes. The cultures were incubated for 24 hours to allow them 
to form a monolayer before 1 dish was treated with 25ng/ml PTx (supplied by NIBSC) in EGM-2, 
the media in the other was replaced with fresh EGM-2. Both cultures were then incubated 
overnight. The cells were loaded with Calcein AM (Life Technologies, Eugene, OR, USA) (ex/em: 
495/520), using a solution of 5μg/ml which they were bathed in for 30 minutes before the 
Calcein AM solution was removed and the cells washed twice before replacing with EGM-2 
containing 20μg/ml propidium iodide (ex/em: 535/617). NADH/NAD(P)H fluorescence lifetime 
measurements were taken before loading the cells with Calcein AM. 
 
4.2.2 Capturing Fluorescence Lifetime Images of Live HUVECs 
The microscope used to image the cells was an upright Leica SP2 (Leica GmbH, Wetzlar, 
Germany) confocal system with a Tsunami multi-photon femtosecond laser (SpectraPhysics, 
Santa Clara, CA, USA). The data was collected using “bh spcm” software (Becker & Hickl GmbH, 
Berlin, Germany). Cells were placed on the microscope stage which is enclosed in an 
environmental chamber set to 37°C. CO2 was supplied from a gas cylinder (BOC, London, UK) 
containing compressed air with 5% CO2. Cells remained in EGM-2 cell culture media for imaging, 
despite the drawbacks associated with phenol red during infrared imaging (Phenol red absorbs 
some of the fluorescent signal before it reaches the objective). All images were taken using a 
40x water-dipping objective lens with a numerical aperture of 0.8. The aspect ratio of each image 
was set to 256x256. Each photon collection cycle was 4 seconds in duration and 30 cycles were 
done for each image. 10 images were taken per sample per experiment, 4 experiments were 
done on different days. 
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4.2.3 Calculating Fluorescence Lifetime 
Analysis of the fluorescence lifetime images was done using “bh spcmImage” software (Becker 
& Hickl GmbH, Berlin, Germany). All equations listed below can be found in the Becker & Hickl 
SPCImage handbook. The data was processed in a number of ways to ensure the lifetime 
calculations reflect the metabolic state of the cell. Each image is collected and analysed later. 
First, a region of pixels was selected on the basis that there were enough photons available to 
fit the decay curve and that the signal originated from the imaged cells. Secondly, the software 
was set to perform biexponential curve fitting, as two lifetimes are being analysed here. Thirdly, 
pixel binning was done to improve the fit of the curve. Binning was done to bring the χr2 value 
to as close to one as possible, the minimum possible binning was done on each image to avoid 
over-fitting of the decay curves. The average lifetimes present in each pixel were calculated by 
the software using the equation:  

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τm – weighted average lifetime, aI – amplitude of lifetime, τi – fluorescence lifetime, i – lifetime 
component 
The lifetime of each component and the relative contribution of these components were 
calculated using a biexponential function shown below:  
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a0 – offset correction, a1 – proportion of lifetime 1, a2 – proportion of lifetime 2, τ1 – fluorescence 
lifetime 1, τ2 – fluorescence lifetime 2. 
The fluorescence lifetime values are also corrected for “pile-up” during the 
excitation/emission/detection process by the following equation 
)4/1( Pp   
P is a constant calculated from the total measurement time, the laser repetition rate and the 
dead time of the detector. Pile-up describes photons lost during the detectors ‘dead time’. The 
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dead time is a brief period of time after the detector his detected a photon where it is unable to 
detect further photons. 
Images and distribution histograms of the fluorescence lifetime images were collected and these 
were used to determine the average fluorescence lifetime present in the cells. The fluorescence 
lifetime value of the untreated cells was used to set a threshold to determine if PTx affected the 
ratio of NADH/NAD(P)H.  
 
4.2.4 Determining the Effect of PTx upon Fluorescence Lifetime of NAD(P)H 
The distribution histograms of 40 images were used to determine the average fluorescence 
lifetime of HUVECs from each of the treatment groups. To determine if PTx caused a significant 
change in the lifetime of NAD(P)H from that observed in untreated and PTd-treated cells, the 
frequency distribution histograms of fluorescence lifetimes were fitted to a Gaussian 
distribution and the maximum values of these curves were compared by one-way ANOVA with 
Tukey’s multiple comparison test.  
 
4.2.5 Determining the Effect of PTx Upon NADH/NAD(P)H Ratio 
To determine if the PTx induced a change in the ratio of NADH:NAD(P)H frequency distribution 
histograms of NAD(P)H were analysed. These are a graphical representation of the images 
produced by the software showing the relative contribution to each pixel made by NAD(P)H, the 
inverse showing NADH is also available. First the distribution histograms of the untreated cells 
were taken and the mean NAD(P)H contribution in these cells was calculated (19.95% of 
fluorescence per pixel originated from NAD(P)H). A threshold of mean + 2 standard deviations 
from the mean was then set (20.18%). Each set of images (showing %NAD(P)H) were then false 
coloured according to this threshold to show the pixels above the threshold in blue and those 
below in green. These new images show the number of pixels below and above the threshold 
thereby determining if PTx caused a greater or lesser number of pixels to be representative of 
NAD(P)H as opposed to NADH. The number of pixels above the threshold were counted using 
ImageJ (NIH, Bethesda, MD, USA) and the mean number of pixels were calculated from 40 
images per treatment group. This data was tested for significance by using a one-way ANOVA 
with Tukey’s test upon the number of pixels present above the threshold value. 
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4.2.6 Lactate Assay 
A lactate assay was carried out to determine if the cells were exhibiting aerobic respiration. This 
was a colorimetric kit purchased from Abcam, Cambridge, UK (ab65331). The assay was 
performed using supernatant samples taken from cells that were untreated or had been treated 
with PTx of PTd. This assay, in conjunction with the FLIM results, was carried out to confirm 
which type of respiratory pathway was used by the HUVECs during PTx intoxication. 
 
4.2.7 Fluorescence Recovery After Photobleaching (FRAP) 
HUVEC monolayers were stained with Calcein AM, an intracellular calcium stain that marks 
calcium but does not inhibit its transit through gap junctions. A Leica SP2 confocal microscope 
(Leica GmbH, Wetzlar, Germany) was used to collect this data. The microscope’s environmental 
chamber was heated to 37°C and the cells were supplied with 5% CO2 from a mixed air/CO2 gas 
cylinder (BOC, London, UK) for the duration of the experiment. For imaging, the pinhole was 
opened to 2 Airy units and a 488nm argon laser was used as the excitation source. For imaging 
the laser power was set to 5% of the limited laser power but for bleaching the laser power was 
increased to 80% of the laser’s maximum output. Images were detected using two 
photomultiplier tubes (PMT), one set to detect emission between 500nm and 600nm, and the 
other to detect emission between 600nm and 700nm. These PMTs detect calcein and propidium 
iodide emission respectively. PMT gain was adjusted based on the volume of signal emitted from 
the sample at any given time. The parameters for collecting FRAP data are as follows: 5 pre-
bleach images taken with the minimum possible interval between images, 20 bleach frames 
taken with the minimum possible interval between images and 40 post bleach images taken 10 
seconds apart, resulting in a 400 second (6 minute) time course. Each frame was scanned 
bidirectionally. 10 time courses were collected from each treatment group per experiment, 
resulting in 30 FRAP experiments per treatment from 3 experiments. The Leica TCS software 
calculates the recovery times automatically using the equation below: 
))()((Pr)(
)/(
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21 CeAeAtI
tt     
Pr – intensity prior to bleaching, A1 – amplitude of exponential term 1, A2 – amplitude of 
exponential term 2, τ1 – time constant of exponential term 1, τ2 – time constant of exponential 
time 2, C – Pr-(t  →∞) 
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4.2.8 Statistical Analysis of FRAP 
Statistical analysis was carried out using GraphPad Prism 5 software. A log transformation was 
carried out on the data before statistical analysis was performed. A one-way ANOVA followed 
by Tukey’s multiple comparison test was performed to test this data for significant differences. 
 
4.2.9 Fluorescence Loss in Photobleaching (FLIP) - Cell culture 
HUVECs were seeded using the same seeding densities as before into fluorodishes (WPI, 
Sarasota, FL, USA) which are compatible with live imaging using an inverted microscope. The 
cells were incubated for 24 hours post seeding and treated with the same treatments detailed 
above. The cells were incubated for a further 24 hours before the media was changed and the 
cells were loaded with calcein, outlined in above. 
 
4.2.10 FLIP Microscope Setup 
An Olympus FV1000 microscope (Olympus KeyMed, Southend-on-Sea, UK) was used to perform 
these experiments. The microscope was equipped with a Sim scanner to allow bleaching and 
imaging scans to be carried out simultaneously. All experiments were carried out using a 
coverslip-corrected 40x UPLSAPO objective lens with an N.A. of 0.95 and the pinhole was opened 
to 2 airy units. A 488nm laser set to 3% power output was used to image the samples during 
bleaching and a 405nm laser set to 70% was used to bleach the samples. The bleaching area was 
defined by a small Region of Interest (ROI) within the target cell, placed away from the nucleus. 
The tornado scan function was selected in the SIM scanner menu, to allow the fastest possible 
bleaching to occur in each frame. Live data acquisition mode was active to allow monitoring of 
the fluorescence intensity within the bleach ROI to ensure the experiment was running as 
expected. Before the bleaching laser was activated the, initial fluorescence intensity was 
established by scanning the sample for approximately 10 seconds. The experiment was 
terminated when the live data trace showed the fluorescence intensity had reached its nadir 
and therefore could not bleach any further. 
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4.2.11 Analysing Bleaching Dynamics of HUVECs Treated with PTx 
Following termination of the experiment, the time series was used to determine the bleaching 
dynamic within the cell. 4 ROIs were drawn on the image series and were distributed away from 
the bleaching ROI. The time traces from these ROIs were collected and the mean fluorescence 
intensity for each time point was calculated. This was done for all images (10 per treatment 
group). The average intensities were used to construct an average time trace that describes the 
fluorescence decay during bleaching in the whole cell. These decay curves were plotted using 
GraphPad Prism 5 and the rate constant (K) and the half-life of the decay curves were calculated. 
Statistical analysis was performed on the rate constant data and the half-life data using the 
GraphPad in-built statistical analysis. A log transformation was performed and a one-way 
ANOVA followed by Tukey’s multiple comparison test was run to identify statistical significance 
between the treatment groups. 10 time courses were taken from each experiment and 3 
experiments were performed on different days. 
 
4.2.12 Connexin immunostaining 
HUVECs were cultured on glass cover slips (seeding density 5.5x103 cells/cm2) and allowed to 
reach confluence before being treated with PTx or PTd. After treatment, the cells were fixed 
with 4% paraformaldehyde, permeabilised with 0.3% Triton X-100 in PBS and incubated with 
rabbit anti human Cx43 monoclonal antibodies (Sigma, C6219, Gillingham, UK) A secondary 
antibody (goat anti-rabbit) conjugated to Alexa Fluor 594 (Life technologies, R37117, Eugene 
OR, USA) was used to visualise the location of the Cx43 distribution. The primary antibody was 
incubated overnight at 4°C, followed by the secondary incubation for 2 hours at room 
temperature. The cells were then stained with Hoechst 33342/33258 and mounted on a 
microscope slide using Citifluor AF1 (Citifluor, Hatfield, PA, USA) anti-fadant mounting media. 
The coverslips were glued in place using nail varnish.  The slides were imaged using a Leica SP8 
confocal microscope, 5 randomly distributed z-stacks were taken for each sample to ensure a 
representative sample was taken. Unstained control slides were also prepared to ensure 
endogenous autofluorescence was not confounding the results of the imaging and a control slide 
stained with only secondary antibody was prepared to ensure there was no non-specific 
staining. 
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4.3 Results 
4.3.1 Determining the Effect of PTx on NADH:NAD(P)H Using FLIM 
Raw data gathered using B&H spcm (Becker & Hickl, Germany) software was processed using 
B&H spcmImage (Becker & Hickl, Germany) software was analysed and the lifetimes of NADH 
and NAD(P)H were elucidated as were the relative proportions of each lifetime. To obtain this 
data, a small reference sample within each image was selected and the requisite pixel binning 
was performed to achieve a χr2 value as close to 1 as possible (Figure 4.6).  
 
 
Figure 4.6: Biexponential decay curve of a fluorescence lifetime image of 
HUVEC cells. The number of photons used to construct the curve is plotted 
on the left-hand axis and the IRF function is plotted on the right-hand axis. 
The fit of the curve was improved by binning adjacent pixels. Binning was 
done to reduce the χ2 value of the fitted curve, but it is important to keep 
binning to a minimum to minimise the risk of introducing artefacts into the 
analysis. 
 
The fit curves were then used to calculate a decay matrix which the b&h spcmImage software 
uses to calculate average lifetime present in each pixel. This results in images where the colour 
of each pixel is relative to the lifetime that was calculated from the decay matrix (Figure 4.6). The 
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software concurrently constructs a frequency distribution histogram from these images also and 
this was used to determine the most common fluorescence lifetimes present within the sample. 
To elucidate this data a Gaussian fit was carried out on the lifetime distribution curves (Figure 
4.7). Cursory analysis of the distribution curves did not suggest that there was a change in the 
lifetime of NAD(P)H induced by PTx. The Gaussian curves appeared to overlap one another with 
little variation between treatment groups suggesting that PTx presence within the cell does not 
affect the lifetime of NAD(P)H.  
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Figure 4.7: Top: Fluorescence lifetime images of HUVEC cells coloured 
according to a continuous scale showing the average lifetime contribution 
(NAD(P)H) from each pixel, given in picoseconds. Red indicates shorter 
lifetimes and blue indicates longer lifetimes. Bottom: Gaussian fit of 
frequency distributions of fluorescence lifetimes detected in untreated cells 
(red), PTx-treated cells (green) and PTd-treated cells (blue). Shown above are 
the Gaussian fits of three histograms derived from single images, Gaussian 
fits were carried out on all fluorescence images and these were used to 
determine the average fluorescence lifetime present in the samples. The 
above figure represents one image of Untreated cells, PTx-treated cells and 
toxoid treated cells.  
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Despite the apparent similarity of the lifetime distributions seen when fitting curves to the 
lifetime frequencey distribution, further analysis was carried out to determine the mean 
fluorescence lifetime within each group of fluorescence lifetime images. The maximum value of 
each Gaussian curve was taken from each distribution histogram and the mean value of these 
maximum values were calculated for each treatment group (Figure 4.8). 
 
Lifetime of NAD(P)H in HUVEC
cells treated with PTx
U
n
tr
e
a
te
d
 c
e
ll
s
P
e
rt
u
s
s
is
 t
o
x
in
P
e
rt
u
s
s
is
 t
o
x
o
id
3200
3400
3600
3800
4000
L
if
e
ti
m
e
 (
p
s
)
  
Figure 4.8: Average Lifetime detected in HUVECs following treatment with 
PTx. Average lifetimes are calculated from fitting a Gaussian curve to the 
lifetime distribution histogram given by the B&H TCSPC software. The data 
was tested for significance by One-way ANOVA; p≤0.05. n=4 experiments, 10 
images per treatment group per experiment, done on different days. 
  
Analysis of the average lifetime maxima showed that there was no significant difference between 
the most common fluorescence lifetimes present in each of the different treatment groups 
(Figure 4.8). The data was tested by one-way ANOVA which showed that there was no 
significance present within the samples. There was some variation between the means of each 
treatment group. The untreated PTx-treated cells most frequent mean lifetime was 3666ps, 
longer than both the untreated cells and pertussis toxoid treated cells, where the mean 
maximum fluorescence lifetimes were 3584ps and 3510ps respectively.  These values are well 
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within the expected range of lifetime values that have been previously attributed to NAD(P)H 
(1500-5500ps) and the differences between them were inconsequential and did not represent a 
change in the fluorescence lifetime of the NAD(P)H fraction.  
The next stage of the analysis of the FLIM data was to ascertain the effect of PTx upon the relative 
proportions of NADH and NAD(P)H within the HUVECs. The ratio of free and bound NADH further 
characterises the metabolic state and general health of the cell when it is exposed to PTx. The 
analysis of this aspect of the FLIM data is similar to that of the lifetime data. First, the 
fluorescence lifetime images are false coloured to represent the proportion of NAD(P)H present 
in each pixel, termed a2 in the biexponential FLIM expression (Figure 9A). 
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Figure 4.9:  A: Fluorescence lifetime images of HUVEC cells coloured 
according to a continuous scale showing the a2 lifetime contribution 
(NAD(P)H) in each pixel, as a percentage of total lifetime (a1+a2) 
contributions for that pixel. Red indicates smaller NAD(P)H lifetime 
contributions and blue indicates greater NAD(P)H lifetime contributions. B: 
Comparative example of frequency distribution histograms from images of 
cells treated with PTx, PTd or left untreated. These traces were used to define 
a threshold for false colouring the images to determine the effect of PTx on 
NAD(P)H distribution. The mean of the maxima from the histograms was 
taken of the untreated cells and the standard deviation was calculated. The 
threshold was then defined as two standard deviations from the mean of the 
untreated cell maxima. 
 
A 
B 
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The mean proportion of bound NADH was determined in the untreated HUVECs and was found 
to make up 19.96% of the total lifetime signal. The images of each of the three treatment groups 
suggested that there was a similar proportion of bound NADH contributing to the overall 
fluorescence of the HUVEC cells (Figure 4.9B). The mean of a2 values were calculated for the 
untreated cells, PTx-treated cells and PTd-treated cells which respectively showed that in the 
PTx-treated cells there was a greater contribution form NAD(P)H at 19.94% as opposed to 
19.96% in both the untreated cells and PTd-treated cells. However, superficial analysis of the 
NAD(P)H distribution histograms suggested that the cells that had been treated with PTx had a 
larger number of pixels where the contribution of NAD(P)H lifetimes was greater than 19.96. 
This difference was not in the maximum values of the histograms, but appeared in the tails, 
therefore, analysis was carried out to determine any significance.  
The greater diversity of values observed in the PTx-treated HUVECs NAD(P)H distribution 
histogram made it necessary to seek an alternative method of analysis, to account for 
differences in the tails rather than the peaks of the histograms. To determine if this apparent 
effect was of any significance, a threshold was set to differentiate the pixels in each treatment 
group where the contribution NAD(P)H fluorescence is greater than 19.96. This threshold was 
calculated from analysis of the distribution histograms of the untreated cells (the mean 
maximum value of all the histograms of the untreated cells). This threshold is shown in Figure 
4.9B, here pixels that are accounted for on the right-hand side of the dashed black line are those 
where the NAD(P)H fluorescent contribution was more than 20.18.  The threshold of 20.18 was 
calculated by adding two standard deviations to 19.96 (the mean of the NAD(P)H contribution 
from the untreated cells). All pixels with a proportion of NAD(P)H fluorescence less than 20.17 
were coloured green and all pixels contributing more than 20.17 NAD(P)H fluorescence were 
coloured blue. The discretely coloured images (Figure 4.10) showed that more blue pixels were 
present in PTx-treated cells than in either untreated HUVECs or PTd-treated cells. The images 
were split into two channels and the number of pixels in each channel was determined by 
counting the number of pixels using ImageJ. The blue and green values for each image were 
divided to get a ratio of green to blue pixels. 
The images appeared to show that there were more blue pixels present in PTx-treated cells but 
this was not immediately obvious by simple observation alone and analysis of the difference 
between the ratio of blue and green was required. This analysis showed that a significantly 
greater number of blue pixels were present in the PTx-treated cells relative to the number of 
green pixels. The differences in the ratio of green to blue pixels were significant when tested by 
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one-way ANOVA (p≤0.05). The increase in blue pixels corresponds to an increase of NADH bound 
to protein when PTx is present in the cell and may indicate disturbance of normal metabolic 
function within the cells, however a lactate assay confirmed the aerobic respiration was taking 
place (Figure 4.10C).  
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Figure 4.10: A: Thresholded analysis of a2 (NAD(P)H). The cells were false 
coloured to differentiate pixels where there was a relative increase in the 
contribution of NAD(P)H, this increase was defined as any pixel where the 
relative contribution was greater than 20.18%, which is the mean NAD(P)H 
contribution to the lifetime signals in untreated cells plus two standard 
deviations. Green: <20.18; Blue:  >20.18. B: The blue and green pixels were 
counted and the ratio between the two was calculated, this is represented by 
the box and whisker plot. The ratios were tested using One-way ANOVA with 
Tukey’s multiple comparison test; *** = p≥0.001, ** = p≥0.01, * = p≥0.05. C: 
lactate concentration in supernatant of HUVECs treated with PTx. n=4 
duplicate experiments, 10 images per experiment per treatment group, done 
on different days. 
A 
B C 
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 4.3.2 Functional Gap Junction Communication Between HUVECs Exposed to PTx 
To build upon the previous work done upon the influence exerted by PTx upon junctional 
interactions in HUVEC monolayers a more dynamic means of analysis was sought. In this section, 
analysis of gap junctional (connexins) communication in HUVECs exposed to PTx is presented as 
an alternative method of determining PTx activity in HUVECs. Conveniently, gap junctional 
activity can be quantified using FRAP on cells that have been loaded with calcein. Hypothetically, 
as PTx acts upon the cells they are no longer able to maintain tight junctions and therefore 
cannot maintain the non-structural gap junctions, leading to an increased length of time 
required for fluorescence recovery in the bleached cells from neighbouring unbleached cells that 
are in direct gap junction communication with each other. 
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Figure 4.11: Example of single time traces from HUVECs during FRAP 
experiment. The solid green line shows a bleached HUVEC and its subsequent 
recovery. The solid red and blue lines are time traces from cells adjacent to, but 
not directly communicating with, the cell represented by the green line.  The 
colours of the lines correspond to the ROIs in the images above which 
represent a frame from the pre-bleach series and the first and last frames of 
the post-bleach series. For comparison the dashed purple line shows the time 
trace of a single cell that has been treated with PTx prior to bleaching (to be 
compared to the recovery of the green line). 
 
To quantify the dynamics of gap junctional activity in HUVECs, one whole cell was outlined and 
bleached using a 488nm laser. During analysis, ROIs were drawn in adjacent cells to ensure that 
any observed fluorescence recovery was indeed the result of gap junctional communication as 
opposed to calcein re-uptake by some other mechanism (Figure 4.11). The results consistently 
Pre-bleach Post-bleach frame 1 Post-bleach frame 40 
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showed that this is a viable method by which to analyse connexin functionality in the HUVECs as 
the cells are able to recover their fluorescence from neighbouring cells. However, the cells did 
not recover to the same fluorescence intensity that they had displayed prior to bleaching. Only 
around 50% of the previous fluorescence was recovered post-bleaching indicating that there is 
a large immobile calcium store located within the HUVECs regardless of treatment. 
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Figure 4.12: Mean half recovery time of HUVECs in their normal state or 
treated with PTx or PTd. Mean values were calculated from raw figures in 
GraphPad Prism 5, raw figures were calculated by the Leica TCS confocal 
software for each time course. *** = p≤0.001, ** = p≤0.01, * = p≤0.05 n=3 
duplicate experiments, 10 time traces per experiment per treatment group, 
done on different days. 
 
Despite failure to recover fully the fluorescent signal to the previous fluorescence intensity, the 
cells did recover sufficiently so that the half fluorescence recovery time could be elucidated. The 
recovery time of the untreated cells and PTd-treated cells was approximately 35 seconds, which 
was shorter than the 42 seconds taken by the pertussis toxin treated cells. When tested by one-
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way ANOVA with Tukey’s multiple comparison test post hoc, the recovery time of the PTx-
treated cells was significantly different to both the untreated cells and the PTd-treated cells; 
p≤0.01 and p≤0.05 respectively (Figure 4.12). These results suggest that PTx impairs the cells 
ability to maintain gap junction channels, possibly as a result of the reduced intercellular stability 
induced by tight junction but also, possibly due to a more direct action upon the organisation of 
connexins themselves. 
To investigate the effect of PTx upon connexin organisation, immunostaining was carried out.  
Connexin 43 was chosen as a biomarker, this species of connexin was chosen because of 
previous studies that had shown the primary anti-Cx43 antibody to have a high affinity for Cx43 
while exhibiting low background and no binding to other molecules (Sutcliffe et al., 2014 & Wang 
et al., 2007). Control slides were produced to determine that fluorescence was not exhibited by 
any of the reagents and that the secondary antibody was not cross reacting with any proteins 
within the cells, all of these were negative.  
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Figure 4.13:  Cx43 secondary immunostaining of HUVECs, 
untreated, PTx-treated or PTd-treated respectively. White arrows 
point to Cx43 deposition in untreated cells and PTd-treated cells at 
the plasma membrane, Cx43 deposition at the plasma membrane 
is difficult to differentiate in the PTx-treated cells. Cells are stained 
with Hoechst 33342/33258 and Alexa Fluor 594. Images are 
512x512 pixels with 8-bit colour depth taken with a 63x 1.4 N.A. 
objective lens.  
 
The Cx43 immunostaining showed that, in untreated HUVECs, the Cx43 molecules have two 
distinct populations within the cell. One is distributed evenly around the plasma membrane of 
the cell and a second population sequestered near the nucleus of the cell (Figure 4.13, left). The 
population found around the edge of the cell is likely to be the constituent parts of functional 
Untreated Cells 
PTx-treated 
 Untreated cells 
PTd-treated 
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Cx43 hemi-channels; the other sequestered Cx43 population is most likely to be newly 
synthesised protein awaiting transport to the plasma membrane (Gaietta et al., 2002). This 
distribution was also present in cells that had been treated with PTd (Figure 4.13, right) 
although; these two Cx43 distributions were not as well defined, indicating that the PTd retains 
some capacity to disturb the HUVECs typical function. Most notably, however, is the distribution 
of Cx43 following treatment with PTx (Figure 4.13, centre). In this case, there are no distinct 
populations of Cx43 and the protein appears to be distributed somewhat randomly throughout 
the cell. The erratic distribution of Cx43 observed in these experiments shows that the increased 
fluorescence recovery time is in part due to loss of coherent connexin expression possibly in 
addition to loss of tight junctional functionality.  
 
4.3.3 Investigating the Immobile Calcium Fraction in HUVECs Treated with PTx 
During the course of the FRAP experiments, the time traces suggested that there was a large 
immobile fraction present within the HUVEC cells. This was investigated further by analysing 
Fluorescence Loss In Photobleaching (FLIP). During the FRAP experiments, the whole cell was 
bleached rendering visual confirmation of large immobile calcium stores impossible. Therefore, 
FLIP was employed as this technique allowed visual confirmation of calcium sequestration and 
further characterisation of the calcium dynamics within the cell. This is achieved by using a 
scanning confocal microscope equipped with a SIM scanner, which allows a whole field of view 
and a region of interest to be scanned with different lasers simultaneously. In FLIP, the intensity 
of the laser used to scan the ROI is turned up and all the molecules in this region of interested 
are bleached while the rest of the field is scanned using a lower intensity for capturing the 
fluorescence intensity in the rest of the cell. As bleaching proceeds, mobile (by Brownian motion 
of by an active process) molecules pass through the bleaching ROI and are bleached until no 
more mobile fluorescent molecules remain, leaving only the immobile fraction. The FRAP and 
FLIP experiments were both conducted using calcein as a marker of intracellular calcium. The 
Calcein chelates calcium ions and allows their movements to be tracked within a cell of between 
adjacent cells. 
Upon completion of the first FLIP experiments, it became immediately obvious that there was a 
large volume of sequestered calcium (the immobile fraction) within the cell. In these cells, the 
calcium store took the form of punctate vesicle-like structures and some more filamentous 
structures that were easily observable following bleaching of the free-moving cytoplasmic 
fraction (Figure 4.14). 
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Figure 4.14: Calcein loaded HUVECs before (left) and after (right) bleaching 
with a 405nm laser. The bleaching ROI (red circle) was positioned away from 
the nucleus to prevent unnecessary damage to the cell during the 
experiment. Red arrows point to the sequestered calcium store in both 
before and after bleaching images, showing the extent to which the immobile 
calcein signal was masked by the mobile fraction. 
 
This result explains the lack of complete recovery that was seen in the earlier FRAP experiments. 
As the whole cell was bleached, the immobile fraction was not replenished and therefore the 
fluorescence recovery was not to the expected extent. Furthermore, the application of FLIP in 
this context allows calcium flux between the cells to be further characterised.  
Collection of the bleaching time traces showed that cells that had been intoxicated with pertussis 
toxin bleached at a slower rate than the untreated HUVECs and those that had been treated with 
PTd (Figure 4.15).  This decreased rate of bleaching lead to an increased time before the cells 
reached their minimum fluorescence intensity. 
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Figure 4.15: Time traces from cells during bleaching. Untreated cells are 
shown in green, PTx-treated in red and PTd in blue. Control over the start end 
of the bleaching phase of the experiments was manual, resulting in small 
variations between samples in terms of bleach start and end time between 
experiments.  
 
While the PTx-treated cells differed from untreated cells and PTd-treated cells, there was no 
obvious disparity between the bleaching rates of the untreated cells and the PTd-treated cells 
(Figure 4.16). These results were collated and the mean bleaching rate for the untreated cells, 
the PTx-treated cells and PTd-treated cells respectively were 0.24, 0.15 and 0.25 fluorescence 
units/s. The mean bleaching half-life for each of the treatment groups was 3.59, 5.95 and 3.36s 
for untreated, PTx-treated, and PTd-treated cells respectively. Statistical analysis of these data 
sets showed that the differences between PTx and the other treatment groups were significant 
(both tested by one-way ANOVA with Tukey’s multiple comparison test, p≤0.05) (Figure 4.16). 
 144 
 
Bleaching time of HUVEC cells
 collated averages
U
n
tr
e
a
te
d
 c
e
ll
s
P
e
rt
u
s
s
is
 t
o
x
in
P
e
rt
u
s
s
is
 t
o
x
o
id
0
5
10
15
20
*
*
ns
B
le
a
c
h
in
g
 h
a
lf
 l
if
e
 (
s
)
Rate constants of bleaching curves of
HUVECs treated with PTx
U
n
tr
e
a
te
d
 c
e
ll
s
P
e
rt
u
s
s
is
 t
o
x
in
P
e
rt
u
s
s
is
 t
o
x
o
id
0.0
0.2
0.4
0.6
*
*
ns
K
 (
F
lu
o
re
s
c
e
n
c
e
 u
n
it
s
/s
)
 
Figure 4.16: Half bleaching time (left) and bleaching rate (right) of HUVECs 
that have been treated with PTx. Both the bleaching half-life and the 
bleaching rate were calculated by fitting a curve to the raw data in GraphPad 
Prism 5. Data was tested using one-way ANOVA with Tukey’s multiple 
comparison test, * = p≤0.05. n = 3 experiments done on different days, 6 time 
traces per experiment per treatment group. 
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4.4 Discussion 
Fluorescence lifetime imaging is a powerful tool that can be used in a variety of contexts, in this 
study it was used to determine the effects of PTx upon NADH fluorescence lifetime and the 
proportion of the NADH molecules bound to protein. This type of study allowed the health of the 
cells to be characterised by analysing their metabolic state during intoxication by PTx. Use of 
FLIM as a tool to detect pertussis toxin in living cells is possible, because PTx binds NADH 
molecules and uses them as the source of ADP-ribosyl required to ribosylate the G-protein target 
(Mangmool & Kurose., 2011). Furthermore, NADH is autofluorescent when excited by 
wavelengths of light between 740-780nm (Balu et al., 2013). Therefore, FLIM of the NADH 
molecules allowed the activity of PTx within the HUVECs to be characterised in a unique way. 
The results from the FLIM experiments were expected to show a change in the fluorescence 
lifetime of the protein bound NADH and an increase in the proportion of the bound NADH 
relative to free NADH. A change in fluorescence lifetime was expected because several variables 
affect the fluorescence lifetime of a given molecule. The fluorescence lifetime can vary 
depending on, amongst several other factors, the protein that the NADH is bound to (Blacker et 
al, 2014). In terms of NADH autofluorescence, there are two lifetimes associated with the free 
and bound NADH species, 800-900ps and 1500-5000ps respectively. The wide range of lifetime 
values associated with bound NADH is due to this molecule being bound to a wide variety of 
molecules within the cell, each of which lengthens the fluorescence lifetime to a greater or lesser 
extent relative to the free NADH species (Conklin et al., 2009). In the case of the HUVEC cells the 
fluorescence lifetimes for each of these species was as expected, indicating that NADH and 
NAD(P)H autofluorescence had been successfully detected. Addition of PTx to the culture media 
was expected to alter the fluorescence lifetime of the bound NADH in some way, either by 
increasing the contribution of the longer or shorter lifetimes to the total fluorescent signal 
detected in the cells. Results showed that this was not the case as the lifetime frequency 
distribution histograms (Figure 4.7) of the untreated HUVECs overlapped almost perfectly with 
their equivalents generated from images of HUVECs that had been treated with PTx. Analysis of 
these lifetime distributions showed that there was no difference in the fluorescence lifetime 
induced by pertussis toxin in terms of where the modal fluorescence lifetime appears (Figure 
4.8). Therefore, PTx does not affect the fluorescence lifetime of the bound NADH in HUVEC cells. 
When performing biexponential FLIM experiments, the lifetime values of the cells are not the 
only metric that provides useful data about the biological state of the cells, the relative 
proportions of the two lifetimes can also be elucidated. In NADH imaging, this is particularly 
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useful because even small changes in the ratio between free and bound NADH can be biologically 
significant (Conklin et al., 2009). An increase in the proportion of bound NADH was expected 
because of the requirement of NADH binding by PTx for the action of the toxin against its G-
protein target. Cursory analysis of the images showing the proportion of NAD(P)H within the cells 
suggested that there was a greater proportion of bound NADH present in cells that were 
intoxicated by PTx (Figure 4.9B), but that this difference was observed in the tails of the 
histogram. The maximum values for untreated cells and PTx-treated cells, 19.96% and 19.94% 
respectively, did not significantly change However, the tails of the frequency distribution 
histograms of these images suggested that there was a slight increase in the contribution of the 
longer NAD(P)H lifetimes to the overall fluorescence detected in cells that had been treated with 
PTx. The increase in NAD(P)H fluorescence is represented by the right-hand tail of the frequency 
distribution histogram shown in Figure 4.9.  To analyse this difference and determine if it was of 
any significance a threshold was set. The analysis of the frequency distributions of proportional 
NAD(P)H fluorescence showed that there was a significantly greater fluorescent contribution 
made by NAD(P)H in HUVECs that had been treated with PTx.  
The increase in NAD(P)H versus free NADH in PTx-treated cells, shown in Figure 4.10A/B, may be 
explained by three possible reasons: (i) there has been a shift in the type of metabolism towards 
an aerobic glycolysis-like respiratory pathway which is characterised by an increase of NAD(P)H 
fluorescence contribution, (ii) PTx is directly binding to NADH, which is represented by an 
increase in NAD(P)H signal or (iii) PTx is inducing a general increase in enzymatic activity and 
NADH is binding to other enzymes. In certain cancers, increased NAD(P)H is accompanied by 
increased output of d-lactate in the presence of oxygen, indicating an aerobic glycolysis type 
respiratory pathway (Heiden et al., 2009). A lactate assay was carried out on the supernatants of 
HUVECs to determine the metabolic state of the cells. Treatment of the HUVECs with PTx did not 
induce secretion of lactate levels that were above that of the baseline established by the 
untreated HUVECs (Figure 4.10C). This showed that the PTx did not alter the normal aerobic 
respiratory pathway of the HUVEC cells. It is likely that PTx increases volume of bound NADH 
within the cell by binding directly to the protein rather than increasing binding to other 
molecules. This is the more likely scenario because the change in the free:bound ratio in favour 
of bound NADH is small and suggests that the NADH fluorescence is lost soon after binding to 
the PTx molecule. This would be consistent with the known action of PTx, where the ADP-ribose 
moiety that is added to the G-protein is derived from NADH and not ATP (Jobling., 2016). The 
NADH molecule is hydrolysed by PTx during G-protein inhibition and, therefore, the fluorescent 
signal from this molecule would be transient, resulting in a small increase in bound NADH in PTx-
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treated cells, as observed in this study. If PTx was inducing binding to endogenous proteins, the 
proportion of NAD(P)H would be expected to be higher than the results obtained here because 
the bound NADH molecules would not necessarily be hydrolysed resulting in increased 
fluorescent contribution of the bound NADH.  
When using untreated cells as a baseline measurement, the sensitivity of this technique is such 
that small differences may be detected when assaying cells where PTx has been administered. 
The sensitivity means that it has some potential as a means of detecting PTx as part of a bioassay 
itself. In this case, the proportion of NAD(P)H fluorescence per pixel was the most useful measure 
of PTx activity within the cell. With the advancement of FLIM and single photon correlative 
technology, the rate at which the NAD(P)H lifetimes appear and disappear could be measured. 
This is a technique called fluorescence lifetime correlation spectroscopy (FLCS) and allows the 
tracking of the appearance and disappearance of discrete lifetimes (Ishii & Tahara., 2013). This 
would allow further characterisation of NAD(P)H in the presence of PTx. In particular, the rate at 
which NAD(P)H lifetimes are recycled, this would be of particular use as, hypothetically, PTx 
would simultaneously decrease and increase the NAD(P)H fluorescence as discussed earlier. 
Furthermore, high throughput FLIM-based systems are in development (Guzman et al., 2016 & 
Zhao et al., 2013), these would be suitable for a screening type of bioassay where several batches 
of vaccine products could be screened in one experiment where the sensitivity is high ensuring 
confidence that the screened product is safe for use.  
Therefore, FLIM of HUVEC cells showed that PTx did not influence the lifetime of NAD(P)H. 
However, there was an increase in the proportion of NAD(P)H within the PTx-treated HUVEC 
populations. This increase is likely to be at least partly explained by direct binding of NADH to 
PTx but it is also possible that the free NADH molecules are induced to bind to other cellular 
proteins. A conclusion on what the NADH is binding to cannot be drawn from this data. 
Additionally, using a metabolic inhibitor as a control, such as cyanide, to alter the NADH/NAD(P)H 
balance would have been useful to further characterise the redox state of the HUVECs and 
understand the effects of PTx upon metabolism. Use of a metabolic inhibitor would have 
determined the maximum dynamic range of NADH/NAD(P)H within the cell (Blacker and 
Duchen., 2016). However, it can be stated that the initial hypothesis was partially correct 
because PTx did increase the abundance of NAD(P)H signal, but it did not significantly alter the 
lifetimes associated with NAD(P)H. 
Immediately after collection of the FLIM data, the cells were loaded with calcein and FRAP 
experiments were performed. The FRAP data was used to determine how closely associated the 
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HUVECs were. This measurement was intended to be a simple metric that could be used to assay 
for active PTx. In previous experiments it was shown that PTx induces permeability via the 
paracellular route by perturbing tight junctional complexes. The tight junctional complexes are 
responsible for holding the cells that make up the monolayer closely and ensuring minimum 
transit of material across the membrane (Tornavaca et al., 2015). PTx interferes with the 
organisation of the tight junction complexes and when this happens the close associations that 
the cells have is lost. The consequences of this are that permeability via the paracellular route is 
increased (Chapter 2, Figure 2.5). Further ramifications of the breakdown of tight junctional 
complexes were shown to be breakdown of the gap junction complexes. As the structural 
junctional complexes are no longer functional, the non-structural gap junctions also lose function 
as adjacent cells’ plasma membranes begin to dissociate. Furthermore, PTx also induced a high 
degree of disorganisation in the distribution of connexin 43, likely to be a major contributing 
factor, besides tight junction dysregulation, in the loss of gap junction function. The gap 
junctional channels are a means by which neighbouring cells can pass small molecules, ions and 
secondary messengers between each other (Iyyathurai et al., 2016). Gap junctional dysfunction 
was assayed in this work by loading the cells with calcein AM, a calcium stain (Thuringer et al., 
2015), and bleaching a whole cell to allow fluorescence recovery of that cell to be monitored 
over time. As the whole cell is bleached, the only means of fluorescence recovery is via functional 
gap junctional channels between the cells. Calcein flux through gap junctions only and not 
reabsorption from the culture media is ensured by washing absorbed calcein off the cells before 
the assay begins and the charged nature of the calcein dye itself. The charge is masked by 
esterification of the calcein molecule which allows the cell to absorb the dye. Upon absorption 
of the calcein, the ester moieties are cleaved off and the calcein molecule becomes fluorescent. 
A proportion of this fluorescent calcein leaches out of the cells into the surrounding medium, 
however the charge of the molecule has been unmasked, and the dye cannot be reabsorbed by 
the bleached cell. 
The results of the FRAP studies showed that PTx-treated cells recovered their fluorescence at a 
significantly slower rate than their untreated counterparts. This showed that pertussis toxin 
decreased net gap junctional communication between the cells. The reason for this decrease is 
discussed above where loss of the structural tight junctional associations between the cells 
means non-structural molecular relationships, like gap junctions, cannot be maintained. 
Furthermore, the time traces generated from these experiments indicated that the cells were 
not recovering fluorescence to the expected extent. The apparent lack of recovery indicates that 
as the whole cell is bleached there is a large immobile calcium store present. The lack of recovery 
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was notable in all treatment groups, but appeared more pronounced in PTx-treated cells. 
Therefore, proving the initial hypothesis that PTx would impair gap junctional functionality was 
proven correct because the recovery times of PTx-treated HUVECs was longer than their control 
cell counterparts. However, the recovery was not as great as expected and FLIP was carried out 
characterise the dynamics of calcium flux between the cells. 
The FLIP experiments allowed the immobile fraction that was observed in the FRAP experiments 
to be visually confirmed and was used to characterise the bleaching dynamic in the HUVECs. 
Analysis of the FLIP data showed that the PTx-treated cells took longer to bleach than untreated 
cells or cells that had been administered PTd. This decelerated bleaching was the opposite of the 
expected result. The results were expected to show that with PTx treatment would result in  less 
functional gap junction molecules and therefore the bleaching would be relatively fast as the cell 
cannot replace the bleached dye with dye from another cell as easily. The opposite of this was 
observed, suggesting that PTx treatment results in membrane destabilisation, either of the 
plasma membrane or of the membranes of the organelles responsible for sequestering calcium. 
Therefore, two mechanisms behind the increased bleaching rate are possible: either i) partial 
loss of plasma membrane integrity allows dye to leach back into the cell or ii) partial 
destabilisation of the organelle membranes allows sequestered calcium to leach into the 
cytoplasm. It is not possible to determine which hypothesis best describes the biology from these 
FLIP experiments alone, but this effect directly correlates with PTx activity within the cell. Some 
loss of plasma membrane stability offers, at least in part, an explanation why PTx-treated cells 
were unable to recover to the same extent as the untreated cells during the FRAP experiments.  
The source of PTd originated from NIBSC and was passed as “safe” as it had passed the industry 
standard HIST assay. Throughout both the FRAP and FLIP experiments, there was consistently a 
difference in bleaching and recovery time observed in PTd-treated cells. While this difference did 
not reach significance, it does indicate that the PTd possesses some limited capacity to act upon 
the HUVEC cells. This was expected because during manufacture of PTd, large batches of PTx are 
purified and treated with formaldehyde and/or glutaraldehyde (Klein 2014). The cross-linking is 
random, although glutaraldehyde primarily cross-links lysine residues (Migneault et al., 2004), 
and cannot guarantee complete neutralisation of toxic activity. The enzymatic A-subunit contains 
no lysine residues to avoid ubiquitination and proteasomal degradation (Worthington et al., 
2007), meaning that after glutaraldehyde treatment only the B-pentamer has been cross linked. 
Complete neutralisation of toxin activity by chemical means is undesirable in any case as this is 
deleterious in terms of the ability to provoke an immune response (Palazzo et al., 2016). Other 
 150 
 
variants of the acellular pertussis vaccines have been proposed including a genetically modified 
toxoid lacking an active enzymatic moiety (Seubert et al., 2014), but none have been 
commercially accepted. 
Therefore, PTx can be detected by either FLIM, FRAP or FLIP and is characterised by an increase 
in protein bound NADH, increased recovery time and also increased bleaching time. The single 
photon counting of FLIM means that this is theoretically the most sensitive of the three 
techniques but requires the most specialised equipment, whereas FRAP produced similar 
sensitivity in terms of the results. In light of the results presented here the FRAP experiments are 
the most promising in terms of easily detecting pertussis toxin. However, if this technique was 
to be taken forward as a potential replacement for the HIST assay the hypothesis suggested by 
the FLIP data regarding membrane instability would need to be further explored to fully 
characterise the effects of PTx upon the HUVEC monolayer.  
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Chapter 5: 
General Discussion and Conclusions 
  
 157 
 
Vaccination against paediatric infectious diseases remains a vital component of public health 
strategies across the world. Safety testing of those vaccines is of paramount importance to 
ensure that the vaccine’s risk of causing harm is reduced to as low a level as possible. Every 
vaccine carries some risk of adverse events, in the case of pertussis-containing vaccines these 
can include soreness, redness and swelling at the injection site (Rennels et al., 2000). Historical 
associations between pertussis vaccinations and more serious adverse reactions such as seizure 
persist and warnings are given in the package inserts of the vaccine products themselves. These 
events are extremely rare and are stated by manufacturers to occur at a rate of less than 0.01% 
(VAXELIS®, Sanofi Pasteur & Infanrix-hexa®, GSK package inserts). There is continuing debate as 
to whether a causal link between administration of pertussis-containing vaccines and severe 
neurological complications exists as several cases of seizure have been linked to underlying 
conditions such as Dravet’s disease (Reyes et al., 2011) There are two types of pertussis vaccines 
currently licenced, the whole-cell and the acellular vaccines. The latter was introduced as a less 
reactogenic alternative to the whole-cell vaccine and has been associated with a lower rate of 
adverse events (Rosenthal et al., 1996). PTx provides important seroprotective antibodies 
against B. pertussis (Taranger et al., 2000), In this study, vaccine-induced anti-PTx antibodies 
were correlated with the prevention of development of whooping cough in children that were 
vaccinated and subsequently exposed to B. pertussis. Additionally, Kapil et al., 2018 
demonstrated that maternal vaccination of baboons using a monocomponent PTd vaccine 
accelerated convalescence compared to infants born to unvaccinated mothers, which failed to 
recover and were euthanised due to the severity of disease.  Furthermore, Nguyen et al., 2015 
administered humanised murine IgG1 to baboons and found that these antibodies resulted in 
reduced signs of disease and enhanced clearance of B. pertussis in infected individuals and 
reduced, but did not prevent, bacterial colonisation, when given prophylactically. PTx is too toxic 
to add to a vaccine in its native form (Podda et al., 1992), therefore, pertussis toxoid (PTd) is 
included instead. PTd is manufactured by treating PTx with formaldehyde and/or glutaraldehyde 
or hydrogen peroxide to attenuate the toxin’s biological effect (Seubert et al., 2014). Whelan et 
al., 2012 found that Infanrix hexa (GSK) induces a seroprotective response of 25 ELISA Units/ml 
of anti-PTx antibodies in 98.9 % of 92 children between the ages of 2, 3, 4 and 11 months of age 
during the national immunisation program in the Netherlands. There must be rigorous safety 
testing in place to ensure that residual PTx activity in pertussis-containing vaccines is at a level 
comparable to batches that were used in clinical trials with no adverse effects.  
Current safety testing of pertussis-containing vaccines is carried out using the Histamine 
Sensitisation Assay (HIST assay). In this assay, mice are administered an intraperitoneal injection 
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of pertussis-containing vaccine, followed by a dose of histamine. Where the vaccines contain 
PTx, the histamine injection results in an anaphylactic reaction and death. There are several 
practical and ethical problems with this assay. The mechanism behind the sensitisation of the 
mice by PTx is poorly understood, despite the relationship between PTx and histamine 
sensitisation in mice having been first described in 1948 (Parfentjev & Goodline., 1948). Studies 
unrelated to vaccination have induced experimental autoimmune encephalopathy in mice by 
injecting large doses of PTx to compromise the blood-brain barrier (Choi et al., 2011 & Webb et 
al., 2004) suggesting an influence of PTx upon brain endothelial cells. It has been shown that PTx 
upregulates the endothelial histamine receptor H1 in the blood-brain barrier, thereby increasing 
permeability (Lu et al., 2010), but this only partly explains histamine sensitisation and more 
research is required. Furthermore, the HIST assay exhibits poor reproducibility (Bache et al., 
2012) and therefore requires large numbers of mice, which is an ethical concern 
notwithstanding the nature of the assay as a lethal endpoint assay (Ochiai et al., 2007). 
Therefore, efforts have been made to develop an alternative assay that may replace the HIST 
assay altogether.  
To date there have been two main strategies that have been developed as alternatives to the 
HIST assay. One is the Chinese hamster ovary (CHO) cell assay and the other is a biochemical 
system which includes a carbohydrate binding assay and an enzyme-linked HPLC assay. In the 
CHO cell assay, CHO cells are cultured in petri dishes and vaccine or PTx is introduced to the 
culture medium. The action of PTx causes the CHO cells to round. The rounding of the cells is 
scored on a scale of 0-3 by the technician performing the assay (Wagner et al., 2016). The 
subjective and semi-quantitative nature of this assay make it less than ideal for a safety test for 
pertussis containing-vaccines along with the fact that adjuvants used in acellular vaccines are 
toxic to CHO cells. The other strategy that has been developed involves a carbohydrate binding 
assay to quantify the binding capacity of the PTx or PTd molecules B-pentamer and an enzyme-
linked HPLC (eHPLC) assay to quantify the enzymatic activity of the A-subunit. This work showed 
that the sialyated N-glycan polysaccharides could be used to differentiate preparations of PTx 
and PTd (Yuen et al., 2002 & 2010). This work was expanded by including an assay for 
determining A-subunit activity by using an enzyme-linked HPLC assay, both this and the 
carbohydrate binding assay displayed higher sensitivity than the HIST assay, evidenced by the 
higher rate of variation between test samples found in the biochemical assays (Yuen et al., 
2010). These assays were able to show that different means of preparing PTd can lead to 
molecules with different biochemical properties, i.e. some might bind very efficiently but the A-
subunit is compromised by the treatment or equally the A-subunit may be left intact but the 
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affinity of the B-pentamer for carbohydrates has been attenuated to a greater extent. These 
differences in the biochemistry of the PTx molecules were not distinguished in the HIST assay 
but may be significant (Oh et al., 2013 & Yuen et al., 2010). While this assay is sensitive to 
differences in the biochemistry of the PTd molecules it does require the alum adjuvant present 
in the vaccine batches to be desorbed as this interferes with the ELISA assay used as the basis 
for the carbohydrate binding assay. The common aims of these studies are that such an assay i) 
should not involve experimental animals and ii) the mechanism of action of these new assays 
should be understood before any is adopted as a new safety test.  
This study seeks to further investigate the mode of action of pertussis toxin and as a result 
develop a possible alternative for testing vaccine batches for active PTx. In this work, a 
permeability assay was designed to quantify the effect of PTx upon the passive paracellular 
permeability of a Human Vein Endothelial Cell (HUVEC) to large dextran molecules 
(permeability, Chapter 1). The assay initially included PBMCs to mimic more closely the 
physiological environment that HUVECs are found in and to allow cytokine data (Chapter 2) to 
be included as part of the analysis as it was hypothesised that cytokines could be an important 
determinant of permeability in the HUVECs. It has been shown that cytokine secretion can 
influence the permeability of endothelial cells layers (Seyenhaeve et al., 2006). During the 
development of this assay, work was also carried out to determine the mechanism behind the 
demonstrated permeability and imaging experiments were done to try to refine the 
permeability assay (FRAP, Chapter 3) and to quantify the activity of the PTx molecule itself in 
live cells non-destructively (FLIM, Chapter 3). The initial evaluation of the assay analysed the 
permeability induced by preparations of a DTaP5-IPV-Hib vaccine, prepared in-house at NIBSC, 
that was either administered alone or after having been spiked with 25ng/ml of PTx (NIBSC 
designation: 10/158). Data obtained from these experiments, showed that the vaccine alone 
increased the permeability of the cell monolayer above that of experimental background, but 
also that a preparation of PTx-spiked vaccine could be differentiated from permeability induced 
by the vaccine alone (Chapter 2, Figure 2.5). This result is significant because recent CHO cell 
assays carried out at NIBSC on PTx lot: 10/158 suggest that 25ng/ml of PTx 10/158 equates to 
0.64 IU/ml, though HIST assays must be performed to confirm this. Xing et al., 2010, defined the 
maximum acceptable PTx activity in pertussis containing vaccines as 2 IU/single human dose 
(SHD). One SHD is 0.5ml, therefore the maximum acceptable threshold of PTx activity is 4 IU/ml, 
therefore, this assay is suitable for testing pertussis containing vaccines as it is capable of 
detecting 0.64 IU/ml PTx, far below the 4 IU/ml threshold. No dose response was demonstrated 
here and this of the highest priority if this assay is to be developed further. 
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As a simple model, the assay worked well in terms of its ability to distinguish a vaccine with and 
without PTx, it is not necessarily representative of the physiological environment of the blood-
brain barrier, where it is known that PTx is capable of acting (Karassek et al., 2015). The model 
was developed further to better mimic the blood-brain barrier by adding Peripheral Blood 
Mononuclear cells (PBMCs). The PBMCs were primary cells that were withdrawn from 
volunteers at NIBSC. The addition of the PBMCs resulted in similar results to the permeability 
assay where HUVECs alone were assayed (Chapter 2, Figure 2.6). Comparison of the 
corresponding treatments showed that the PBMCs did not significantly influence the 
permeability of the HUVECs. Therefore, direct action of PTx upon the HUVECs is likely to be the 
cause of the increased in permeability rather than via an indirect mechanism involving PBMCs. 
The cytokine data obtained from these experiments would seem to corroborate this conclusion. 
However, not enough donors responded to treatment to allow analysis for significant trends to 
be carried out. The main analyte of the cytokine analysis was TNF-α, this cytokine was chosen 
because previous work done at NIBSC (not published) showed that stimulating PBMCs with LPS 
and PTx secreted more TNF-α than when the PBMCs were stimulated with LPS alone. In the 
DTaP5-IPV-Hib vaccines antigens such as Hib polysaccharide and filamentous haemagglutinin 
(FHA) also stimulate toll-like receptors (TLRs) (Latz et al., 2004 & Asgarian-Omran et al., 2014) 
and may co-stimulate the PBMCs in concert with PTx, therefore it was hypothesised that there 
would be a TNF-α mediated inflammatory response that would complement an increase in 
permeability. However, in only 12% of assays (Chapter 3, Figure 3.2) TNF-α secretion was 
detected, contrasting with the permeability assay where PTx reliably increased the permeability 
of the HUVEC cells in all assays. The rate of response to the vaccine and the vaccine and PTx, 
may be reflective of the rate of adverse reactions to pertussis vaccines seen in the wider 
community, it is important to take note of this but, also to acknowledge that the sample size is 
too small draw stronger conclusions. Other cytokines may also play an important role and may 
be better markers in this system, therefore a luminex cytoscreen was carried out on some of the 
reactive donors and unreactive to try to determine if there were more suitable markers present, 
however, this was unsuccessful. 
To investigate the mechanism behind the permeability demonstrated in the permeability assay, 
the PBMCs were removed from the system and focus was placed upon the effects of PTx on the 
HUVECs on a cellular level. The hypothesis was that PTx disrupts the structural junctional 
proteins, tight and adherens junctions, which anchor adjacent HUVECs to one another and in 
doing so increase the paracellular permeability of the HUVEC monolayer. This hypothesis was 
investigated in two ways, immunofluorescence was performed to determine the effect of PTx 
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upon the distribution of the junctional complexes (Chapter 2, Figure 2.10) and measurements 
of the of transendothelial electrical resistance (TEER) (Chapter 2, Figure 2.9), which quantifies 
density of functional tight junction complexes across the whole monolayer. The marker chosen 
for immunofluorescence was Zonula Occludens-1 (ZO-1), ZO-1 anchors the tight junction 
complex to the actin cytoskeleton and has been used before as a marker of tight junction 
stability (Van Itallie et al., 2017). Immunofluorescence of the ZO-1 showed it was distributed 
around the periphery of the cell when not treated. Introduction of PTx changed this distribution 
and very little ZO-1 deposition was observed around the plasma membranes of the HUVECs. This 
data was quantified (Chapter 2, Figure 2.11) and showed that there was significantly less signal 
originating from HUVECs treated with PTx, meaning that PTx has induced a drop in the 
expression of ZO-1. The observance of a decrease in ZO-1 staining in the HUVECs suggested that 
few viable tight junctions would be able to form. This hypothesis was confirmed by the TEER 
data which showed decreased resistance to electric current across monolayers that had been 
treated with PTx. B-catenin staining to take in to account the role of the adherens junction, was 
inconclusive, perhaps indicating this junctional complex is less susceptible to interference by 
PTx. Therefore, inhibition of G-proteins by PTx in HUVECs induces permeability by interfering 
with the cells’ ability express the tight junctional protein ZO-1 and without this protein functional 
tight junctions cannot be formed and therefore paracellular permeability is increased when the 
cell monolayer is exposed to PTx.  
Further understanding of the relationship between PTx activity and permeability was sought by 
conducting an imaging study. This work focused upon fluorescence lifetime imaging (FLIM) to 
determine PTx enzymatic activity in live cells and the fluorescence recovery after 
photobleaching (FRAP) to quantify the density of functional gap junction channels. The FRAP 
assay showed that the HUVECs were unable to maintain functional gap junctions after treatment 
with PTx, shown by their failure to recover fluorescence at the same rate as the untreated cells 
or those treated with PTd (Chapter 4, Figure 4.12). These results suggested that the cells were 
not able to form close enough associations to maintain gap junctions. The reduction in gap 
junction functionality corroborates the evidence of tight junctional dysfunction presented in 
chapter 2 as the tight junctions are required to hold the cells together so that the non-structural 
gap junctions can form along the membrane. However, immunostaining of connexin 43 (Cx43) 
showed that PTx directly affected the distribution of the Cx43 protein (Chapter 4, Figure 4.13). 
The disorganised nature of the Cx43 in PTx-treated cells will partially have contributed to the 
reduced fluorescence recovery seen in the FRAP experiments along with the decreased 
expression of ZO-1. Confirmation of PTx activity in the cells came from the FLIM data which was 
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performed upon the same cells that were used in the FRAP experiments. This data showed that 
PTx resulted in a small but significant increase in protein-bound NADH within the HUVEC cells. 
This result agrees with the data from a cAMP assay carried out on cell lysates (Chapter 2, Figure 
2.12) and confirms that PTx is active within the cells at the time that the observed effects are 
taking place. Therefore, the FRAP assay and the FLIM experiments corroborate the results seen 
in the permeability assay and the proposed mechanism of PTx induced tight junction 
dysfunction. 
Throughout the experiments, it was observed that the vaccine without PTx and cells that had 
been treated with PTd exhibited some of the effects that were associated with PTx treatment. 
This included: increased permeability, more tight junctional disorganisation, decreased TEER, 
reduced fluorescence recovery time, more gap junctional disorganisation and a slight increase 
in protein-bound NADH. None of these observations reached statistical significance, but they 
were indicative of some residual enzymatic activity that could be associated with the PTd that 
was used in these experiments. These observations show that the some PTd molecules must 
retain some minimal capacity to bind to the cells and translocate the enzymatic A-subunit into 
the cytoplasm. This should not be taken as cause for alarm as some biological activity of the PTd 
molecule must be accepted, as a completely inert PTd preparation would likely not produce a 
protective immune response (Arciniega et al., 2011). Furthermore, this study would not be able 
to differentiate between different biochemical profiles of PTd molecules like the carbohydrate 
binding assay coupled with the eHPLC assay discussed earlier. However, the permeability assay 
developed in this work shows some promise and is worth developing further, it’s main 
advantage over the CHO cell assay is that it is not subjective. In common with the other assays 
discussed here, a strategy to overcome adjuvant induced cellular toxicity would have to be 
devised as has been done for the CHO cells (Isbrucker et al., 2014). Therefore, there is a need to 
develop protocols to desorb the adjuvant from the vaccine before the vaccine could be tested 
using the permeability assay developed here. Several methods exist to desorb alum adjuvants 
from vaccines and it would be logical to develop one of these for the permeability assay.  Zhang 
et al., 2015 developed several desorption protocols based on incubating Hepatitis vaccines with 
a citrate/phosphate dissolution buffer. This study found that it was possible to desorb the alum 
adjuvant from the vaccine without compromising the antigen structure and epitope recognition 
by mAbs, indicating that the antigens were stable following desorption. Applying these 
techniques to the DTaP5-IPV-Hib vaccine would mean that this assay could be used to test 
pertussis-containing vaccines but the conditions would have to be modified to suit the test 
vaccine. Tleugabulova et al., 1998 used similar methods to that of Zhang et al., 2015 but the 
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structure of the antigen molecules was compromised by the desorption process, highlighting 
the need to refine the desorption protocol for the any given vaccine that is to be tested. In the 
long term, a protocol could be developed for the automation of this assay. The permeability of 
the assay was developed using Corning Costar HTS-multiwell transwell inserts. HTS stands for 
high-throughput and these transwell plates are designed for use with robots so this would seem 
the most logical long term goal.  
As mentioned previously, replacement assays for the HIST assay have been sought for many 
years due to the fact it has a number of disadvantages such as being an in vivo assay, it is highly 
variable and the mechanism is poorly understood. Ideally, a replacement assay would address 
these three shortcomings. The aim of this study was to develop an assay that may act as a 
replacement for the in vivo HIST test. Over the course of the study a number of different 
techniques were utilised to monitor changes in cultured cells when exposed to PTx. Considering 
they all identified a signal in the presence of PTx they all have the potential as alternative assays. 
However, there are a number of criteria that should be considered for any alternative assay in 
the control of biological medicines and these include reproducibility, sensitivity, ease of use and 
an understanding of the mechanism of the assay. To determine the reproducibility of these 
assays full validation studies would have to be performed and these can be considered as the 
next steps in advancing this study. Dose-response studies to confirm that the signals from each 
assay correlate with increasing PTx concentrations are also required. The permeability assay was 
designed with these criteria in mind and was originally conceived of as the most likely assay that 
would be put forward as an alternative to the HIST assay. During the course of this study several 
of the other assays that were done in the course of this work to investigate the mechanisms of 
permeability could also be developed into regulatory assays. The permeability assay developed 
here satisfies the 3Rs criteria because it is in vitro and laboratory animals are not involved at any 
stage, the results are sensitive and can detect levels of PTx at the limit of detection of HIST. The 
mechanism has been partially described here, although further work must be done to fully 
understand mechanism behind PTx induced permeability. Furthermore, the permeability assay 
does not require any specialist equipment or expertise, only an understanding of how to culture 
HUVECs. Additionally, using PBMCs in this assay did not significantly affect permeability or yield 
promising results in terms of TNF-α secretion. This was not entirely unexpected as the PBMCs 
were a primary culture withdrawn from donors on the days of the experiments and more 
variation was anticipated, but it was too great for TNF-α to be considered as a marker in a control 
assay. It is possible that TNF-α was not the best analyte to use as inconsistent responses were 
observed and it is unfortunate that the Luminex cytoscreens were unsuccessful as these may 
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have identified a more consistent biomarker. The permeability assay and cytokine studies were 
carried out with designing a control assay in mind, however some techniques used to investigate 
the mechanism may also be useful for this purpose. 
The FRAP and FLIM experiments that were described in chapter 4 were done mainly to 
investigate the mechanism of action of PTx that relates to permeability, however, these assays 
should also be discussed in terms of their potential as control assays. FLIM is the least suited to 
control work as it requires highly specialised equipment and expertise to successfully carry out 
experiments. Furthermore, it is not easily scaled up to match the throughput necessary for a 
regulatory assay. It is, however, sensitive to subtle changes in the NAD(P)H population within 
the cell and the variability between experiments is small, making it a useful research tool, but 
these advantages do not outweigh the disadvantages when considering the requirements of a 
control assay. The other microscopical technique, FRAP, is more promising as a control assay as 
it requires less specialist equipment and expertise. All that is required is a standard confocal 
microscope, the four major microscope manufacturers (Leica Microsystems GmbH, Nikon 
Instruments Europe B.V., Olympus KeyMed Ltd. and Carl Zeiss AG) provide FRAP modules and 
analysis tools to interpret the data. The results of this study showed that the reproducibility of 
this technique was good as significant differences were detected following three experiments. 
The HUVECs, were stained with Calcein, which does not require any special skills and the FRAP 
experiment is relatively easy to set up on a confocal microscope. Therefore, a technician would 
not need to have extensive experience in microscopy to carry out and analyse this data. The 
major disadvantage of FRAP is that single cells must be identified and drawn around manually, 
this introduces a possible source of human error and means that the experiment cannot 
currently be automated. This means that it is a laborious technique in terms of the time needed 
to gather the required number of replicates per experiment. In this study only three treatment 
groups were assayed, this would be need to be increased before this technique could be 
adopted as a control assay, however, doing so would likely extend the time required to complete 
the assay to an impractical extent. A cAMP assay was also carried during this study to confirm 
the biological activity of PTx in the HUVECs. The results of this assay were unambiguous, PTx-
treated cells had significantly larger concentrations of cAMP than either untreated cells or PTd-
treated cells. The assay carried out here was a commercial kit manufactured by Abcam (product 
no. ab65355) and its ability to detect the dose of PTx used here suggests that it would be 
sensitive enough to be used as a control assay. Again only three treatments were assayed, 
however it would be easier scale up this assay to the required number of groups than it would 
be either the permeability assay or the FLIM and FRAP assays. The cell culture required for the 
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cAMP assay could very easily be performed in a 96-well plate which is not possible in any of the 
other assays. The permeability assay without PBMCs is the most likely assay to be taken forward 
of the assays described here because it satisfies the aim of replacing animals, it is reproducible, 
it is relatively easy to carry out and requires only basic tissue culture skills and it can be readily 
scaled up to include the necessary number of treatment groups. The cAMP assay, should not be 
overlooked as it’s reproducibility is good, the variability is low, lower than that of the 
permeability assay; no advanced skills are necessary to carry it out and it is easy to scale it up to 
include the necessary number of treatment groups, however it was not thoroughly investigated 
for this purpose in this study. In either case, the dose dependence of the effects of PTx must be 
established. 25ng/ml PTx was determined to be an appropriate dose of PTx to use during this 
study based on morphological changes to HUVEC monolayers exposed to a dose of 100ng/ml, 
50ng/ml, 25ng/ml, 12.5ng/ml or 6.25ng/ml PTx assessed by phase contrast microscopy. These 
or similar doses should be used to determine dose dependency in the permeability assay and 
the cAMP assay.  
Besides development of the assay into a regulatory tool, more work should be carried out on 
the mechanism behind PTx induced permeability, particularly focussing on the effects of PTx on 
other junctional proteins. The format of this assay is relatively well suited so scaling up to the 
throughput necessary for testing large batches of commercial vaccines. The Corning HTS 
multiwell transwell plates that the assay was developed in were developed with high throughput 
cell-based assays in mind. This work has demonstrated that PTx interferes with the ability of 
HUVECs to form a monolayer barrier by reducing the number of functional tight junctions by 
reducing the expression of ZO-1 (Chapter 2, Figure 2.11). Therefore, it would be useful to carry 
out a proteomic and transcriptomic study targeting the proteins of the tight junction (ZO-1/2/3, 
claudin 1-23, occludin and junctional adherence molecule A/B/C) to understand the effects of 
PTx upon tight junctional protein expression and translation. Further immunostaining would be 
useful to target claudin-5 and occludin as ZO-1 is required to incorporate these into the tight 
junction complex (Limonciel et al., 2012). Depending on these results, transmission electron 
microscopy (TEM) may also be useful to the extent that PTx causes ultrastructural changes to 
the tight junction complex. The transcriptomic and proteomic approach would also be useful to 
determine the effect of PTx upon the connexin (gap junction) family of proteins.  
The overall hypothesis of this thesis was that PTx increases the permeability of HUVECs by two 
mechanisms. Firstly, by interfering with the HUVECs ability to maintain the junctional complexes 
that physically bind the cells together and secondly, permeability would be enhanced by 
secretion of TNF-α by PBMCs in response to PTx. The results of the study showed that the 
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hypothesis was partially correct, direct action of PTx upon the HUVECs did interfere with tight 
junction deposition and this explains the increase in permeability observed in chapter 2. The 
results of the FRAP experiments in Chapter 4 confirmed this result. The hypothesis was shown 
to be incorrect in terms of TNF-α secretion. PTx did not reliably increase TNF-α secretion in 
PBMCs and therefore high TNF-α concentration cannot explain the increase in HUVEC 
permeability, which is likely due to PTx acting upon the HUVECs alone. Therefore, it is not 
possible to draw conclusions on clinical implications of PTx and TNF-α secretion however, the 
permeability assay has the potential to become a viable alternative to the current HIST assay for 
testing pertussis-containing vaccines for untoxoided PTx. The permeability assay that has been 
developed here could be used to replace the HIST assay as a control assay for testing pertussis-
containing vaccines for PTx content. This assay is does not require animals, it is objective and 
not subjective, it accounts for all three processes of PTx binding, translocation and enzymatic 
activity and the mechanism of permeability has been investigated and partially explained. 
Therefore, this assay has been successful in its aim of developing a safety test for pertussis-
contain vaccines, however, some further work such as establishing dose responses must be done 
before it can be taken forward as a candidate to replace the HIST assay. 
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Appendix 1 
The buffers and reagents listed in this appendix were prepared by NIBSC Scientific Support 
Services 
Table 3: Phosphate buffered saline 
Material Volume Supplier 
Sodium chloride 10g Fisher Scientific S/3160/53 
Potassium chloride 0.25g Merck 10198 4L 
Disodium hydrogen orthophosphate 1.44g Merck 10249 4C 
Potassium dihydrogen orthophosphate 0.25g Merck 10203 
Ultra Pure Water 1000ml Barnstead 
To sterilise, bottles were autoclaved for 15 min at 122°C, 1.05 bar. 
 
Table 4: Coating buffer for ELISA 
Material Volume Supplier 
Sodium dihydrogen orthophosphate 
dihydrate 
5g Fisher Scientific S/3160/53 
Disodium hydrogen orthophosphate 2.9g VWR 102494C 
Ultra Pure Water 1000ml Barnstead 
After mixing to dissolve the solids, the pH was adjusted to 7.5 using 1 M sodium hydroxide 
prior to making the volume up to 500 ml with Ultra Pure Water. Stored between 2 - 8°C. 
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Table 5: Blocking Buffer for ELISA 
Material Volume Supplier 
Tris (hydroxymethyl) aminomethane 12.1g VWR 103156x 
Ultra Pure Water 400ml Barnstead 
Albumin from bovine serum 5g Millipore 82-100-1 
After mixing to dissolve the solids, the pH was adjusted to 7.5 using 4 M hydrochloric acid prior 
to making the volume up to 500 ml with Ultra Pure Water. Stored between 2 – 8°C. 
 
Table 6: Detection antibody buffer for ELISA 
Material Volume Supplier 
Tris (hydroxymethyl) aminomethane 2.1g VWR 103156x 
Ultra Pure Water 400ml Barnstead 
Phenol 0.5g Sigma P5566 
Heat-inactivated (30 minutes at +56°C) FCS 25ml Sera Laboratories Int. Ltd EU-000FI 
After mixing to dissolve the solids, the pH was adjusted to 7.5 using 4 M hydrochloric acid prior 
to making the volume up to 500 ml with Ultra Pure Water. Stored between 2 - 8°C. 
 
Table 7: TMB substrate buffer 
Material Volume Supplier 
Citric acid 7.3g Sigma C-2404 
Disodium hydrogen orthophosphate 9.47g VWR 102494C 
Ultra Pure Water 800ml Barnstead 
After mixing to dissolve the solids, the pH was adjusted to 5.0 with 1 M sodium hydroxide prior 
to making the volume up to 1000 ml with Ultra Pure Water. Stored between 2 - 8°C. 
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Table 8: TMB substrate solution 
Material Volume Supplier 
3,3',5,5'Tetramethylbenzidine (TMB)1 240 mg Sigma T2885 
Acetone  5 ml VWR 20065.327 
Ethanol  45 ml Hayman Speciality Products F200238 
Hydrogen peroxide solution  0.3 ml Sigma H-1009 
1The TMB was dissolved in acetone prior to addition of the remaining materials. Stored 
between 15 – 25 °C protected from light. 
 
 
 
 
